Development and application of NMR methods for challenges in drug discovery by Pilger, Jens
Development and application of
NMR methods for challenges
in drug discovery
Dissertation










• Prof. Dr. Christian Griesinger, NMR-based Structural Biology, MPI
for Biophysical Chemistry
• Prof. Dr. Ulf Diederichsen, Organische und Biomolekulare Chemie,
Georg-August Universität Göttingen
Mitglieder der Prüfungskommision
• Referent: Prof. Dr. Christian Griesinger, NMR-based Structural
Biology, MPI for Biophysical Chemistry
• Korreferent: Prof. Dr. Ulf Diederichsen, Organische und
Biomolekulare Chemie, Georg-August Universität Göttingen
Weitere Mitglieder der Prüfungskommission:
• Prof. Dr. Henning Urlaub, Bioanalytical Mass Spectrometry, MPI for
Biophysical Chemistry
• Prof. Dr. Bert de Groot, Computational Biomolecular Dynamics,
MPI for Biophysical Chemistry
• Dr. Lars Kuhn, Biomolecular NMR Spectroscopy, European
Neuroscience Institute Göttingen
• PD. Dr. Thomas Exner, Theoretische Pharmazeutische Chemie,
Eberhard Karls Universität Tübingen
Tag der mündlichen Prüfung: 2.April 2013
Eidesstattliche Erklärung
Hiermit versichere ich, dass ich die vorliegende Arbeit selbstständig verfasst






The work presented in this thesis is published or will be published as follows:
1. J. Pilger*, A. Mazur*, P. Monecke , H. Schrader T. Langer, A. Schif-
fer, M. Wegstroth, D. Lee, G. Hessler, K. U. Wendt, S. Becker and C.
Griesinger:
A Spin Diffusion Based NMR Method to Determine Protein-Ligand
Complex Structures Demonstrated on Three Enzymes of Pharmazeu-
tical Interest.
-in final preparation-
2. A. Lange*, H. Sun*, J. Pilger*, U. Reinscheid and H. Gross:
Predicting the Structure of Cyclic Lipopeptides by Bioinformatics: Struc-
ture Revision of Arthrofactin.
ChemBioChem, 2012, 13: 2671-2675
3. J.Wagner*, S. Ryazanov*, A. Leonov*, J. Levin*, S. Shi, F. Schmidt,
C. Prix, F. Pan-Montojo, U. Bertsch, G. Mitteregger-Kretzschmar, M.
Geissen, M. Eiden, F. Leidel, T. Hirschberger, P. Tavan, J. Pilger, M.
Zweckstetter, T. Frank, M. Bähr, J. Weishaupt, M. Uhr, H. Urlaub, U.
Teichmann, M. Samwer, K. Bötzel, M. Groschup, H. Kretzschmar, C.
Griesinger and A. Giese:
Anle138b: A Novel Oligomer Modulator for the Treatment of Prion
and Parkinson Disease.







ADMET Absorption, distribution, metabolism, excretion, toxicity properties
ATP/AMP Adenosine triphosphate/monophosphate
Bac Baccatin
BSE Bovine spongiform encephalopathy
CDK Cyclin-dependent kinase










EC50 Effective concentration 50
ECL Extra-cellular loop
EDTA Ethylene diamine tetraacetic acid
e.g. Exempli gratia
EGTA Ethylene glycol tetraacetic acid
EM Energy minimization
Epo Epothilone
ESI Electron spray ionization
FA Fluorescence anisotropy
FBDD Fragment-based drug design
FFAR Free fatty acid receptor
FL Fluorescence lifetime
FT Fourier transformation
GAFF General amber force field
GBSA Generalized Born surface area
GPCR G-protein coupled receptor
HDX Hydrogen deuterium exchange
HMBC Heteronuclear multiple bond correlation
HPLC High-performance liquid chromatography
HSA Human serum albumin
HSQC Heteronuclear single quantum coherence
i.e. Id est
INPHARMA Inter-ligand NOEs for pharmacophore mapping
ITC Isothermal titration calorimetry
LC Liquid chromatography





MSM Markov state model
MT Microtubule
NS Number of scans
NOE Nuclear Overhauser effect
NOESY Nuclear Overhauser effect spectroscopy
NRPS Non-ribosomal peptide synthetase
PD Parkinson‘s disease
PDB Protein data base
PIPES Piperazine-N,N-bis(2-ethanesulfonic acid)
PKA Protein kinase A






SIFT Scanning for intensely fluorescent targets
SPE Solid phase extraction
SPR Surface plasmon resonance
STD Saturation transfer difference







TOCSY Total correlation spectroscopy
trNOE Transferred NOE
Summary
NMR spectroscopy plays an important role in all stages of the drug discovery
process. Namely in the structure elucidation of natural products, synthetic
ligands and metabolites, as well as a high-throughput screening technique.
Yet, the application of NMR in structure-based drug design, e.g. in finding
the binding mode of a small molecule drug to a macromolecular protein re-
ceptor is far from making the most from the opportunities available to it.
Structure-based drug design is a powerful and widely used tool for the op-
timization of low molecular weight compounds that should be turned into
highly efficient drugs. The method mainly relies on high-resolution crystal
structures of the receptor-ligand complex to obtain the required information
for optimizing target binding of small molecules. However, obtaining crys-
tals and structures of sufficient quality cannot be achieved for nearly the
half of pharmaceutically relevant protein targets. For those target proteins
that cannot be crystallized, NMR spectroscopy is an alternative and struc-
tures of protein-ligand complexes can be determined, provided the protein
can be labelled with stable isotopes such as 13C or 15N. However, pharma-
ceutically relevant non-crystallizable target proteins are often non-tractable
by NMR, because they are too large and result in overcrowded spectra or
they cannot be expressed in bacteria and therefore cannot be labelled with
stable isotopes enabling heteronuclear NMR. In such cases one can employ
INPHARMA (Inter-Ligand NOEs for PHARmacophore MApping). It uti-
lizes two ligands that bind competitively to the same binding pocket of a
protein. INPHARMA peaks in a NOESY spectrum emerge from the magne-
tization transfer from the protons of one ligand to the protons of the other
ligand via the protein protons, provided the ligands dissociate from the pro-
tein several times during the NOESY mixing time. The method is further
developed and it is investigated whether the methodology can be improved by
inclusion of Saturation Transfer Difference (STD) restraints and transferred
NOE (trNOE) restraints in addition to the INPHARMA restraints. STD is
a frequently used technique in NMR spectroscopy and NMR-based screening
for protein binders. The technique is developed and tested on protein kinase
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A, where crystal structures of the protein/ligand complexes are known. The
results show that the combination of the NMR methods INPHARMA, tr-
NOE and STD results in a precise scoring function for docking modes and
therefore the determination of ligand binding modes. It is demonstrated
that the method is superior to docking scoring functions alone and can lead
to the correct result by using a molecular dynamics simulation driven re-
finement, even if the initial conformation of the protein side chains is not
correct. Multiplexing of several ligands improves the reliability of the scor-
ing function further. Then the technique is extended the G-protein coupled
receptor GPR40, a membrane protein, for which only homology models exist
and which is an interesting drug target in on-going research. For this sys-
tem, the ligand binding mode found is supported by SAR data. The binding
mode of epothilone to tubulin, an important interaction for cancer therapy
is reinvestigated using STD data. The binding mode found by INPHARMA
is confirmed and further optimized, while the electron crystallography de-
rived structure does not fit to the experimental NMR data. The NMR-based
ligand binding mode determination method is presented to derive binding
modes of ligands based on simple NMR experiments (NOESY and STD). It
is demonstrated on the examples of PKA, GPR40 and the tubulin-epothilone
complex, that based on a crystal structure or homology model of the pro-
tein, binding modes can be determined that can be used for pharmacophore
mapping and drug optimization.
In the second part the drug metabolism of anle138b, a modulator of toxic
protein oligomers in prion and Parkinson’s disease is investigated. A method-
ology is developed to extract the drug from organs and to determine its con-
centration in the brain. It was confirmed that anle138b is the only active
compound in the brain, while metabolites are only formed in liver and kid-
ney. With combined HPLC, mass spectrometry and NMR techniques, the
structures of the metabolites were determined and the drug metabolism of
anle138b in the mice and rat model was revealed.
In the last part NMR spectroscopy is applied to reinvestigate the structural
and stereochemical features of arthrofactin, a potentially antibiotic natural
product. Arthrofactin was initially reported in 1993 as a bioactive cyclic
lipopeptide from the bacterium Pseudomonas sp. The structure of arthro-
factin and its derivatives was reassigned on the basis of extensive NMR exper-
iments and chiral HPLC analysis. A new approach of phylogenetic structure
prediction is tested and was successfully approved with NMR data.
In conclusion, NMR spectroscopy is applied and further developed in this
thesis to several challenges of the drug discovery process.
Zusammenfassung
NMR Spektroskopie spielt eine wichtige Rolle in allen Arbeitsschritten der
pharmazeutischen Wirkstoffentwicklung. Genauer gesagt in der Strukturbes-
timmung von Naturstoffen, synthetischen Liganden und Metaboliten, ebenso
wie als Hochdurchsatz Screening Technik. Im Moment jedoch liegt die NMR
Anwendung im Bereich der strukturbasierten Wirkstoffentwicklung, also im
Bestimmen des Bindungsmodus eines kleinen Wirkstoffmoleküls an einen
makromolekularen Rezeptor, weit hinter ihren Möglichkeiten. Die struktur-
basierte Wirkstoffentwicklung ist ein mächtiges und weit verbreitetes Werk-
zeug für die Optimierung niedermolekularer Stoffe, welche zu effizientenWirk-
stoffen verbessert werden sollen. Die Methode basiert hauptsächlich auf
hochauflösenden Kristallstrukturen des Rezeptor/Ligand Komplexes um die
Bindung des kleines Moleküles an seinen Ziel-Rezeptor zu optimieren. Den-
noch können Kristalle und dementsprechend Kristallstrukturen für fast die
Hälfte aller pharmazeutisch interessanten Zielproteine nicht realisiert werden.
Für diejenigen Zielproteine die nicht kristallisiert werden können stellt NMR
Spektroskopie eine Alternative dar um die Protein/Ligand Komplexstruk-
tur zu erhalten, insofern das Protein mit stabilen Isotopen wie 13C oder
15N markiert werden kann. Dennoch sind pharmazeutisch relevante, nicht
kristallisierbare Zielproteine oft nicht mit NMR messbar, da sie zu gross
sind und zu überfüllten Spektren führen würden. Oder sie können nicht in
Bakterien exprimiert werden, und damit nicht mit den für heteronukleare
NMR notwendigen stabilen Isotopen markiert werden. In solchen Fällen
empfiehlt sich die Verwendung der INPHARMA (Inter-Ligand NOEs für
PHARmacophore MApping) Methode, welche zwei Liganden benötigt die
um dieselbe Bindungsstelle eines Proteins konkurrieren. INPHARMA Sig-
nale innerhalb eines NOESY Spektrums entstehen durch den Transfer von
Magnetisierung von den Protonen des Liganden über die Proteinprotonen
zu den Protonen des anderen Liganden, wenn gegeben ist, dass die Ligan-
den während der NOESY Mischzeit mehrmals die Bindungstelle verlassen.
Die Methodik wird nun weiterentwickelt und es wird untersucht ob sich
die Technik verbessern lässt, wenn zusätzlich Sättigungstransfer Differenz
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(STD) Beschränkungen und transferierter NOE (trNOE) Beschränkungen zu
den INPHARMA Beschränkungen verwendet werden. STD ist eine häufig
verwendete Technik in der NMR Spektroskopie, speziell wenn es um NMR
basiertes Screening von Proteinbindern geht. Die Methode wird entwick-
elt und getestet an Protein Kinase A; hier sind Kristallstrukturen der Pro-
tein/Ligand Komplexe bekannt. Die Ergebnisse zeigen, dass die Kombina-
tion der NMR Methoden INPHARMA, trNOE und STD in einer präzisen
Bewertungsfunktion für Dockingmodelle resultiert und daher die Bestim-
mung des Liganden Bindungsmodus ermöglichen. Es wird gezeigt, dass die
Methodik den rein theoretischen Docking-Bewertungsfunktionen überlegen
ist. Weiterhin kann das korrekte Ergebnis auch durch eine Optimierung mit-
tels molekulardynamischen Simulationen erhalten werden, selbst wenn die
initiale Konformation der Aminosäure Reste nicht richtig ist. Eine weitere
Verbesserung entsteht durch die Anwendung mehrer verschiedener Ligand-
kombinationen, genannt Multiplexing. Danach wird die Methode auf den
G-Protein gekoppelten Rezeptor GPR40, einem Membranprotein, übertra-
gen, von welchem nur Homologie Modelle existieren und welches in der ak-
tuellen pharmazeutischen Forschung eine wichtige Rolle spielt. Für dieses
System wird ein Bindungsmodus gefunden, der den SAR Daten der Lit-
eratur entspricht. Der Bindungsmodus von Epothilon an Tubulin, einer
wichtigen Interaktion in der Krebsforschung, wird mittels STD Daten neu
untersucht. Der Bindungsmodus der einst mit INPHARMA gefunden wurde
wird bestätigt und weiter optimiert, während der Bindungsmodus der mittels
Elektronen-Kristallographie gefunden wurde sich nicht mit den NMR Daten
vereinigen lässt. Die Methodik zur NMR-basierten Wirkstoffbindungsmodus
Bestimmung wird vorgestellt, um Bindungs-modi von Liganden mittels ein-
facher NMR Experimente (NOESY und STD) zu erhalten. An den Beispie-
len PKA, GPR40 und dem Tubulin-Epothilon Komplex wird gezeigt, dass
basierend auf einer Kristallstruktur oder einem Homologie Modell des Pro-
teins Bindungsmodi bestimmt werden können, welche dann zur Wirkstoffop-
timierung genutzt werden können.
Im zweiten Teil wird der Metabolismus des Wirkstoffs Anle138b untersucht,
einem Modulator von toxischen Protein Oligomeren der Prionen und Parkin-
son Krankheit. Eine Methode wurde entwickelt um Anle138b aus Organen
zu extrahieren und seine Konzentration im Gehirn zu bestimmen. Es wird
bestätigt, dass Anle138b der einzig aktive Wirkstoff im Gehirn ist, während
Metabolite in den Organen Leber und Niere gefunden wurden. Mit einer
Kombination von HPLC, Massenspektrometrie und NMR gelingt die Struk-
turbestimmung der Metaboliten und der Metabolismus von Anle138b im
Maus und Ratten Modell wird erklärt.
Im letzten Teil wird NMR Spektroskopie angewandt, um die strukturellen
v
und stereochemischen Eigenschaften von Arthrofactin, einem potenziell an-
tibiotisch wirksamen Naturstoff neu zu untersuchen. Arthrofactin wurde
zuerst 1993 als bioaktives, cyclisches Lipopeptid des Bakteriums Pseudomonas
sp. beschrieben. Die Struktur des Arthrofactins und seiner Abkömmlinge
wurde neu bestimmt auf der Basis ausführlicher NMR und chiraler HPLC An-
alytik. Ein neuer Ansatz der phylogenetischen Strukturbestimmung wurde
getestet und mittels NMR Daten verifiziert.
Zusammengefasst wird NMR Spektroskopie in dieser Dissertation auf einige
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Chapter 1
Introduction
1.1 Structure-based drug design
1.1.1 The drug discovery process
Health is one of the most important aspects of life. Therefore a main aspect
of science is to provide the knowledge of medicine, therapies and drugs to cure
sick persons and restore their health and quality of life. Natural products
that can be used as drugs are known during the whole history of mankind.
Still, it is only a century ago, that is was possible to develop drugs in a ra-
tional way. This methodology is called drug discovery and aims to identify
and modify molecules chemically to fit best the designation of a drug, being
able to cure a disease. The first thoughts about a rational drug develop-
ment process came up at the end of the 19th century, when Paul Ehrlich
postulated the existence of chemoreceptors [Ehrlich, 1900]. The structure of
suitable molecules have to be modified and optimized to best fit these recep-
tors. This was expressed in the phrase: ’we have to learn to aim chemically’.
Indeed, in his laboratories the first screening was done by using hundreds of
new synthesized organic arsenic compounds to discover arsphenamine to cure
syphilis [Ehrlich, 1910]. This ground-breaking study influenced the following
generations and led to the discovery of many drugs, e.g. penicillin [Fleming,
1929] and the establishment of chemotherapy [Strebhardt and Ullrich, 2008].
In 1905 the concept of receptors was refined by describing them as switches
that can be activated (agonists) and blocked (antagonists) [Langley, 1905].
But it took until the early fifties that this finding could be exploited, when
the different forms of adrenergic receptors were described [Ahlquist, 1948]
and drugs like adrenalin (β-adrenoreceptor agonist), β-blockers or benzodi-
azepines were discovered and further developed [Drews, 2000].
The driving force of drug discovery is still high-throughput screening
1






























































































Figure 1.1: Overview of the drug discovery process from target identification to
approval for market. Indicated are the topics investigated in this thesis.
[Macarron et al., 2011, Lahana, 1999] which is nowadays fully automated
and provides the ’hits’, which are binding scaffolds that are then optimized
to lead structures.
Hand in hand with the improvements in structural biology, more 3-D
structures of proteins became available and the medicinal chemist can now
optimize compounds in a more rational and faster manner. These structural
informations also provide the opportunity to screen molecules in a virtual
manner, which is obviously less resource-expensive [Kitchen et al., 2004] and
still provides a good selection [Clark, 2006]. Additionally the properties of
drugs have been understood more profoundly today. Especially with the
appliance of the Lipinski rules of five, which states that: a drug molecule
should have a i) lipophilicity of logP below 5, ii) weight less than 500 Da
and has iii) less than 5 hydrogen bond donors and 10 acceptors [Lipinski
et al., 2001]. Implementation of such rules helps to identify drugs at an early
stage, that would fail in later stages due to toxicity or too low bioavailability
[Kubinyi, 2003]. Besides the developments in screening, the application and
optimizations by the addition of functional groups to natural products as
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drugs has again come into the focus [Koehn and Carter, 2005].
The overall drug discovery process (Fig. 1.1) is very long and very cost
intensive [Lombardino and Lowe, 2004]. The estimations of time and money
that are spent differ a lot, but all are in an average range of 10 years and 1
billion dollar [Adams and Brantner, 2006]. To save resources in the devel-










Enzymes 47% GPCRs 25%
Figure 1.2: Marketed small-molecules drug targets by biochemical classes [Hopkins
and Groom, 2002].
An interesting questions arising from the drug discovery process is: how
many drug targets are there in the end? The human genome comprises
around 30.000 genes which encode for a much higher number of proteins,
if alternative splicing, post-translational modifications and protein complex
formations are also considered. Still, predicting a number of how many of
these proteins can be targeted by drugs is not possible. The number of
approved drug targets is approximately 324 [Overington et al., 2006] and
an estimation of 600-1500 possible drug targets is proposed in the literature
[Hopkins and Groom, 2002]. As seen in Fig. 1.2 most of the approved drugs
are enzymes like protein kinases, but more than 40% are membrane proteins
like G-protein coupled receptors, ion channels and transporters. Interestingly
the membrane proteins are very difficult to crystallize and therefore for most
of these important targets no 3-D crystal structures are available.
1.1.2 3-D protein structures
The starting point of structure-based drug design is a 3-dimensional model
of the macromolecular receptor with atomic resolution. Such a model can
4 CHAPTER 1. INTRODUCTION
be provided by the free apo-form of the protein or the holo-form, when a
ligand is bound. The latter provides even more information, especially when
dealing with an induced-fit situation. But the holo-form also comprises the
side chain conformations of the bound ligand, which might change when
using another binder. 3-D protein structures are open to the public, due
to the RCSB Protein Data Bank (PDB, www.rcsb.org/pdb/) [Berman et al.,
2000], where these data can be deposited. In 2012 the PDB contained around
80.000 structures, many of them with a bound ligand.
The standard technique to obtain a 3-D structure of a molecule is X-ray
crystallography, which was applied for 90% of the structures found in the
PDB. The technique is well established and documented with its benefits
and limitations [Davis et al., 2003]. Initially X-ray crystallography was used
only for the structure elucidation of small molecules. This is done since a
century and the world repository, the Cambridge Structural Database (CSD,
www.ccdc.cam.ac.uk), comprises around half a million deposited structures.
The scattering pattern of protein crystals was obtained already for pepsin in
1934 [Bernal and Crowfoot, 1934]. Structure calculation was possible at that
time for small molecules but due to the lack of highly efficient computational
resources, protein structures were not solved. The landmark event of protein
X-ray crystallography happened in 1958, when the structure of myoglobin
[Kendrew et al., 1958] was solved. The technique is based on the observation
that an X-ray photon can be scattered by an electron by producing secondary,
spherical waves that can be detected. In practice, X-ray crystallography
relies on a crystal of the protein, which is often only obtained in a time
consuming process. Especially in the case of membrane proteins it is often
not possible. Given that a crystal exists, it is exposed to an X-ray beam
and investigated from all orientations, by rotating the crystal. Hereby the
crystal must be of sufficient quality to remain stable. During this process,
the X-ray diffraction is detected and results in a distinct diffraction pattern.
Hereby every spot of the diffraction pattern represents one lattice plane and
depends on i) the unit cell, ii) wavelength and iii) crystal orientation in the
beam. The unit cell is the imaginary smallest unit inside the crystal, which is
normally around 50 Å3 in size. A second challenging task, after obtaining the
crystal, is to solve the phase problem. Only the amplitudes can be directly
derived from the measured intensities, but not the phases. The technique
most frequently used to solve this problem nowadays is multiple wavelength
anomalous dispersion (MAD). Therefore anomalous diffraction is recorded
at different wavelength, created by a special atom like selenium which can
be brought into the protein during the expression by the modified amino
acid selenomethionine. Another method is isomorphous displacement, which
relies on the soaking of heavy atoms into the crystal structure. This has
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the disadvantage that several crystals with different heavy atoms have to be
grown, largely increasing the amount of necessary protein. When the phase
problem is solved, which has to be done only once for a specific protein, an
electron density map is obtained and the crystallographer can fit the protein
coordinates into the electron density. This task becomes easier with better
resolution of the density map, which is normally around 2 Å. The structure
obtained by X-ray crystallography is not a photograph in atomic detail, but
is a model supported by strong experimental data [Podjarny et al., 2011].
Once the structure of a protein is solved, complexes with many different
ligands can be obtained very fast. For the approach of fragment based drug
design, it is even common to do a high-throughput crystallography [Blundell
et al., 2002].
Figure 1.3: 3-D structure of ubiquitin, derived as a single model by X-ray crystal-
lography (left) and as a structure ensemble by NMR spectroscopy (right).
The second important method to reveal 3-D structures of proteins is NMR
spectroscopy and it accounts for approximately 10% of the structures in the
PDB. The advantage in comparison to X-ray crystallography is, that no
crystal is needed and the sample can be measured in solution, which also
excludes the problem of crystal contact sides. The limitation on NMR is first
the size of the protein, being typically less than 40 kDa, even though much
larger structures have also been solved or were investigated, e.g. the 82 kDa
protein malate synthase [Grishaev et al., 2008]. The second limitation of
NMR is the possibility to express the protein in bacteria and label it with
heteronuclear NMR-enabling stable isotopes like 13C or 15N. Protein struc-
tures can be calculated based on the experimental NMR data of i) NOESY
spectra that yield distances and ii) chemical shifts, that provide chemical en-
vironments. Additional informations like residual dipolar couplings (RDC)
or pseudo-contact shifts (PSD) are frequently used. The application of these
experimental restraints requires an assignment of most of the protein signals
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in the NMR spectrum, which can be a very time consuming task, hampering
the industrial workflow. The NMR methodology is described in detail in
chapter 1.2.
1.1.3 Molecular docking
Given that a model with atomic resolution exists for a protein target, the
binding of small molecules can be simulated with an approach termed molec-
ular docking. This structure-based approach starts from a model of the apo-
protein (uncomplexed conformation) or the holo-protein (complexed confor-
mation). The ligand is now computationally placed into the binding pocket
of the protein structure to propose a suitable binding mode. Molecular dock-
ing is done in two steps called posing and scoring. The quality of posing
decides if the ligand can be docked correctly. Furthermore the quality of
the scoring functions decides, if the correct binding mode is really identified.
Posing refers to the actual docking, the placement of the ligand, and scoring
to an energetic evaluation of the ligand binding pose. Posing can be done
in a systematic or random manner. Systematic algorithms explore all de-
grees of freedom in the molecule and often grow the ligand incrementally in
the binding site and is implemented in the programs FlexX, Dock or Glide.
Random search approaches are Monte Carlo simulations like in AutoDock or
genetic algorithms as in GOLD.
The quality of a docked ligand pose can be evaluated with a scoring function,
based on i) a force field, ii) empirical or iii) knowledge-based manner [Kitchen
et al., 2004]. Force fields like Amber or Tripos can be used to calculate the en-
ergy of the protein-ligand interaction, as well as the energy inside the ligand.
This approach is accurate, but time consuming. Much faster is the empiri-
cal approach, that applies potentials obtained by experimental data sets to
score the binding energies in a fast manner. As these potentials represent
a simplification of the force fields they are not as accurate as the further.
Knowledge-based scoring functions like Astex Statistical Potential (ASP) or
DrugScore rely on empirical data more than on binding energies.
The state-of-the-art program GOLD [Jones et al., 1995] applies a genetic
algorithm for posing and an empirical (ChemScore) or a force field based
scoring function (GOLDscore). It was shown that the best scoring results
can be obtained, when consensus scoring is done, which means that the dock-
ing structures are rescored by different scoring functions, e.g. ChemScore,
GOLDScore and ASP [O’Boyle et al., 2009]. Comparable with GOLD is the
new docking program PLANTS [Korb et al., 2006], which uses an ant colony
algorithm for posing and the empirical scoring function ChemPLP [Korb
et al., 2009a]. It is a consensus in the drug design community that a docked
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structure is considered correct, if the RMSD to the crystal structure is less
than 2 Å, as can be seen in the comparisons and tests of docking pro-
grams, e.g. [Meiler and Baker, 2006, Moitessier et al., 2008, Cross et al.,
2009,Cortés Cabrera et al., 2012]. In modern approaches the small molecule
is kept flexible during the docking and the protein rigid, or partially flexible
with specific rotatable amino acid residues. If a ligand binds to the surface
of the protein, it is advisable to use algorithms for protein-protein docking
(e.g. HADDOCK [Dominguez et al., 2003]), which are specifically developed
for the purpose that interaction of proteins take place on their surfaces. Here
the protocols start with rigid molecule docking, which is then refined with
semi-flexible side chains, flexible backbone and refinement in a water solvent
environment. Docking results can be improved by the inclusion of experi-
mental NMR data in the programs HADDOCK and PLANTS [Korb et al.,
2010b].
The docking approach relies on a protein model of high quality from X-ray
crystallography or NMR spectroscopy. If no model is available, a homology
model can be used, but results have to be treated very carefully [Hillisch et al.,
2004]. Studies in the field of GPCR modeling have shown the difficulty of the
approach. Failure is often due to wrong amino acid conformations [Michino
et al., 2009,Kufareva et al., 2011], that block the correct orientation of the
ligand.
1.1.4 Pharmacophore mapping
The pharmacophore concept is a very useful technique for the identification
of hit molecules. Additionally it can be used for binding site mapping or
virtual screening, if no structure of the receptor is available or the docking
approach would be too time-consuming. The method is ligand-based and
focusses on the assignment of chemical features of the ligand to find other
molecules with similar properties by ligand alignment. The IUPAC defini-
tion of a pharmacophore is the ensemble of steric and electronic features
that is necessary to ensure the optimal supra-molecular interactions with a
specific biological target structure and to trigger or to block its biological
response [Wermuth et al., 1998].
In principle, the approach could be started with one binder that has to be
superimposed to all molecules in a library, in order to find similar structure
elements and identify new binders. This concept can be strongly improved
by screening not for a ligand structure but for the pharmacophore, including
the necessary structure-activity-relationship informations of donors, accep-
tors or aromatic moieties. The more known binding ligands are taken into
account, the preciser the information of the pharmacophore will be. Such
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a pharmacophore alone gives already a map of the binding site, even if the
structure of the binding site is not known. The chemical features of the phar-
macophore are then screened through a compound library and often result
in specific binding ligands [Langer and Hoffmann, 2006].
Figure 1.4: Pharmacophore of staurosporine (left) derived from the crystal struc-
ture of the complexes (pdb structures 1STU). Green arrows indicate hydro-
gen donors, red arrows indicate hydrogen acceptors and spheres illustrate the
aromatic features and methyl groups. On the right a pharmacophore derived
from the alignment of multiple ligands that bind CDK2 (image taken from
http://macinchem.org/reviews/ligandscout-update.php). Hereby the orange cir-
cles indicate common pharmacophore features. The protein structures were omit-
ted for clarity.
If several molecules are to be taken into account for deriving the pharma-
cophore, they have to be superimposed. This 3-D alignment is a challenge,
as it incorporates the problem of conformational flexibility [Wolber et al.,
2006]. Normally this problem is solved by the creation of many 3-D confor-
mations of each molecule, which are then aligned pairwise. A scoring function
chooses then the best fitting pair. Still, this process of alignment and assign-
ment of the chemical features has to be inspected visually and is often driven
by experience. The chemical features can be assigned in the most effective
manner, if a 3-D structure of the ligand-protein complex is available and the
donor/acceptor interactions are visible [Steindl et al., 2006]. This is exem-
plary shown in Fig. 1.4, where the pharmacophore of staurosporine bound
to PKA was automatically derived. If the crystal structure of the complex is
available, the pharmacophore can be assigned in the most efficient manner.
Obviously the methodology can only work, if the ligand binding mode to
the protein is correct. Besides the staurosporine figure, a figure is shown of
multiple aligned crystal structures of ligands that bind CDK2. This multiple
alignment gives a more robust pharmacophore and illustrates the necessity to
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correctly align ligands. These can be very similar in shape as in the example
or completely different.
When a 3-D structure of the protein is available, one can apply virtual screen-
ing using molecular docking, but the pharmacophore approach is orders of
magnitudes faster. The state-of-the-art program for aligning molecules, as-
signing pharmacophores and perform virtual screening is Catalyst [Kurogi
and Güner, 2001]. LigandScout [Wolber and Langer, 2005] displayed a com-
parable performance [Wolber et al., 2008]. Recently the program pharmA-
COphore [Korb et al., 2010a] for molecule alignment was implemented in the
docking program PLANTS and follows a new ant colony optimization based
algorithm.
1.1.5 Molecular dynamics simulations
3-D structures of a molecule represent a static view, which is of course not
the reality. Molecules with rotatable bonds are often highly dynamic and this
has to be taken into account, when they are investigated at the molecular
level. The movement at an atomic resolution can be efficiently described with
the molecular dynamics (MD) simulation approach. The basic equation for
the dynamics of a quantum system and is evolution in time (wave function)
is the Schrödinger equation:
ih̄∂tψ(r, R) = Hψ(r, R) (1.1)
Where i is the imaginary unit, ψ the wave function and H the Hamilton
operator, indicating that the motion is based on energy. The calculation
effort that has to be full-filled in order to run such a calculation for a whole
protein is too high to be accomplished. Therefore the atoms are described by
the classic Newton mechanics. The electrons are ignored and only the nuclei





~Ri = −~∇iE(~R1) (1.2)
Two different interactions between nuclei are distinguished: those nuclei
i) connected by a bond and those ii) close in space. The interactions are
described as physical springs that undergo attraction and repulsion. Bond
parameters are bond-length, bond angle, dihedral bond angle and extra-
planar bond angle. Nuclei close in space which are not connected by a bond
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are described by the Lennard-Jones potential in the case of Van-der-Waals
interaction and with an electrostatic potential in the case of a charged in-
teraction. Bond length, angles and charges of the specific atom types are
described by the force field and have to be parametrized. These parameters
result from empirical and quantum chemical investigations. Several different
force fields are available, for example Amber, CHARMM, Gromos or Tripos.
When the atoms of the molecule are parametrized, the integration of the
Newtonian equation of motion is done numerically via the leapfrog scheme.
Therefore, the equation is solved for all atoms in the system, followed by a
step where the atoms move and then a second step of integration. Attraction
and repulsion of the mechanically treated nuclei produce the movement of
the whole biopolymer. A more detailed description of the system, if needed,
is obtained when the environment is also simulated, i.e. the solvent, ions or
the lipid bilayer in the case of a membrane protein.
The limitation of MD is the amount of computer time that is necessary. To-
day protein-water simulations in the ns range are standard, extendable to
µs. MD simulations in the millisecond range were so far only achieved by
the super-computer Anton [Shaw et al., 2010] or the distributed-computing
project Foldingathome [Voelz et al., 2010]. MD simulations start from a
crystal structure, a homology model, a de novo protein model or an NMR
structure, whereas NMR data can also restrain an MD trajectory. MD simu-
lations are a great help for the understanding of very different kinds of protein
motions [Henzler-Wildman and Kern, 2007]. For example the function of the
aquaporin water channel was explained by an MD simulation [de Groot and
Grubmüller, 2001].
Recently it was possible for the first time to simulate the way of a charged
ligand into its binding pocket during an MD simulation and to completely
reconstruct the ligand binding process in terms of energy and kinetics [Buch
et al., 2011]. Therefore 495 MD simulations of 100 ns each were obtained from
the enzyme-inhibitor complex trypsin-benzamidine and showed the binding
event with an RMSD less than 2 Å from the crystal structure in 187 cases.
A Markov state model (MSM) was produced and the obtained potential of
mean force (PMF) is show in Fig. 1.5 and reveals several metastable states.
It is interesting to see how often the ligand resides at other binding sites and
gives an idea about the unspecific binding events of a ligand. Simulating the
binding event of a ligand to a protein is very interesting but often not possi-
ble, as the simulation time is not long enough for an occurrence of a binding
event or too high energy barriers that have to be crossed. An alternative to
the latter can be metadynamics, that have shown to reproduce correct bind-
ing modes by the combination of MD and a new methodology to cross the
energy barriers [Gervasio et al., 2005]. Besides its functionality in describing
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protein mechanisms and ligand movements in the binding site, MD is very
useful to sample a wide conformational space, especially in the case of small
molecules. If described accurately by the force field, the conformational anal-






Figure 1.5: PMF in the xz plane identifies five different metastable states (S0-S4)
of the ligand benzamidine binding to trypsin. The states are represented on the
right site and illustrate specific and unspecific binding events of the ligand [Buch
et al., 2011].
1.1.6 Drug metabolism
The discovery and optimization of a drug molecule to inhibit a specific macro-
molecule is just one side of the medal. It is essential to understand more than
the action of the drug to the organism, which is termed pharmacodynamics.
Equally important is pharmacokinetics, which is the action that the organism
takes on the drug, also called drug metabolism. Five questions have to be
answered to understand the pharmacokinetics: i) absorption (A), is the drug
bioavailable? ii) distribution (D), does the drug reach the supposed location
of action, e.g the brain? iii) metabolism (M), how is the drug biotransformed?
iv) excretion (E), does the drug leave the organism after a certain time and
how? and v) toxicity (T), is the drug or one of the metabolites toxic? These
characteristics of the drug are summarized as the ADMET properties and
need to be determined for every potential drug candidate. The reason for
withdrawal of a drug, besides the lack of efficacy, is most often toxicity and
side effects [Schuster et al., 2005]. Therefore ADMET properties are often
the most difficult part of the drug discovery process. Given that no toxic
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metabolites are produced, every new drug is regularly tested for inhibition
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Figure 1.6: Schematic metabolism and elimination of ethanol.
A common example for drug metabolism and ADMET properties is ethanol
(Fig. 1.6). Ethanol has a very good bioavailability and as it passes through
all membranes it is distribution everywhere in the organism. Ethanol is oxi-
dated by the enzyme alcohol-dehydrogenase to ethanal. This substance gets
further oxidized by aldehyde-dehydrogenase to acetic acid, which can enter
the citric acid cycle or be stored in fatty acid chains. Thus, ethanol can be
completely eliminated during metabolism. If ethanol is not pure and for ex-
ample contaminated with methanol, the drug metabolism is very dangerous.
Methanol follows the same metabolic pathway, but the metabolic products
methanal (formaldehyde) and formic acid are highly toxic.
Normally drugs are not completely metabolized as it is the case for
ethanol. Elimination takes also place over the kidneys (urine) and the liver
(bile). The biotransformation is normally done by the cytochrome P450
(CYP450) enzyme superfamily 1.7. All members of the CYP450 family are
attached to membranes, most often in liver cells, and possess a heme group
in the reactive center. Differences in the size of the binding pocket make
them suitable to oxidize or reduce most xenobiotic substances that enter
the organism. Examples for the reactions are demethylenation, demethyla-
tion, N-dealkylation and hydroxylation. The reaction mechanisms, which are
often coupled with NADPH-P450-reductase, are rather complicated and doc-
umented in the literature [Zhang et al., 2008]. These oxidative and reductive
reactions are termed the phase I reactions of the metabolism. Additionally
to the CYP450 enzymes, the actions of alcohol-dehydrogenase, aldehyde-
dehydrogenase, monoamine oxidase (MAO) or different esterases belong to
the phase I group.
In contrast, phase II reactions comprise the addition of a functional group to
the drug in the cytosol. These phase II reactions often follow directly a phase
I reaction, for example the opening or addition of a hydroxy group. The most
important functional group added is glucose (glykosylation) by the enzyme
UDP-transferase. Very common is also a sulfate (sulfurylation) group, done































Figure 1.7: Routes of elimination of the top 200 most prescribed drugs in 2002.
Most drugs are eliminated by biotransformation during metabolism. More than
three quarters of the drugs are metabolized by the cytochrome P450 superfamily.
The majority of reactions is carried out by CYP3A, CYP2C9 and CYP2D6 (from
[Wienkers and Heath, 2005]).
by the SULT family, especially SULT1A3. Further functional groups com-
prise i) methyl-groups, which are transferred by catechol-O-methyltransferase
(COMT), ii) gluthatione, transferred by gluthathione-S-transferase and iii)
acetate, transferred by acetyl-CoA.
Investigation of drug metabolism in the pharmaceutical industry is an estab-
lished procedure. Due to the very complicated issue of drug-drug interac-
tions, it is often not possible to predict the metabolites of a drug correctly in
advance. Urine or blood samples from humans or animals are taken at differ-
ent time points to measure the concentration of the drug to understand the
absorption and elimination behavior. In the case of animals, organ samples
can be taken as well to investigate the distribution in the body and check
for example if a compound passes the blood-brain-barrier. After extraction,
the compound can by separated and quantified with HPLC. The standard
procedure for the investigation of biotransformations and identifications of
metabolites is LC/MS [Clarke et al., 2001]. There are many softwares, e.g.
MetaSite [Cruciani et al., 2005] that predict metabolic sites in small molecules
and can speed up the metabolite identification. For structure elucidation of
the metabolites the LC/MS and MS/MS approach is often sufficient, as there
is only a limited number of functional groups (see above) that can be attached
to the compound during drug metabolism. Even though, it is often not pos-
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sible to predict the exact metabolic site, e.g. in which position a hydroxy
group is added to a phenyl ring. In this case the metabolite structure can be
elucidated with NMR, given that the metabolite can be concentrated high
enough to enable 2-dimensional NMR.
When the crystal structure of CYP2C9 was solved [Williams et al., 2003],
it revealed the complexity of the drug transformation. In Fig. 1.8 the drug
warfarin is bound to CYP2C9, but in a position with the closest distance 10
Å away from the catalytic heme site iron. Still, the metabolic site of war-
farin [Kaminsky and Zhang, 1997] is closest to the catalytic site and it was
shown, e.g. on the cytochrome bc1 complex [Bartoschek et al., 2001], that
electron transfers can take place between distances like 10 Å. The binding
pocket is large enough to accommodate a second ligand, which could be an
explanation for complex drug-drug interactions.
Heme
S-warfarin
Figure 1.8: Crystal structure (PDB entry code: 1OG5) of CYP2C9 with bound
ligand S-warfarin. Indicated is the heme group, which is the catalytic side.
1.2 Nuclear Magnetic Resonance
1.2.1 NMR applied to drug discovery
The whole drug discovery and development process is accompanied by NMR
spectroscopy at certain stages. The most important NMR application is
the analytical identification and structure elucidation of small molecules.
These comprise newly discovered natural products, chemically synthesized
compounds or extracted metabolites. In the first stage of the drug discovery
process, which is basic research, NMR can be used to determine protein struc-
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tures and investigate the dynamics and interactions with drug candidates and
other molecules. While the protein structure determination of NMR is less
and less done in pharmaceutical industries, the studies especially of weak
interactions in the early phase of drug development is a growing field. In
the final stage of drug development, the clinical trials, NMR (than termed
MRI) can be used to monitor patients organs and even the distribution of
labeled compounds. NMR gets a growing importance as a screening tool to
investigate large compound libraries for their binding behavior to a target
protein [Pellecchia et al., 2008], [Lepre et al., 2004] and [Meyer and Pe-
ters, 2003]. This is especially important in the screening for weakly binding
fragments, where NMR can outperform screening assays that require a min-
imal affinity which may not be reached in the first screening. In [Dalvit,
2009] NMR methods in fragment screening were compared to the biophysical
techniques surface plasmon resonance (SPR), fluorescence anisotropy (FA)
and fluorescence lifetime (FL) and lead to the conclusion that NMR has the
largest dynamic range. In Tab. 1.9, a comparison of the different NMR
techniques SAR-by-NMR, spin labeling, STD, trNOE and INPHARMA is
shown, which can be exploited to obtain informations upon ligand binding
to a target protein.
All of these are frequently used in pharmaceutical research. Discussed in
the following are the interesting methods i) SAR-by-NMR, which is based
on chemical shift perturbations and ii) SLAPSTIC, that uses a spin labeled
protein or ligand. These methods are especially interesting, because they are
applied for second site ligand screening, a technique highly desired for the
upcoming and often successful approach of fragment based drug discovery
(FBDD) [Rees et al., 2004]. Hereby medium binding ligands are linked to
create higly potent drugs. The NOE based methods STD, trNOE and IN-
PHARMA, which are the most important technical basis for this thesis, will
be discussed in detail after the introduction of the NOE concept.
Chemical shift perturbations and SAR-by-NMR
An important application of NMR is the mapping of ligand binding sites
on the protein, including the search for a second-site binder by SAR-NMR
[Shuker et al., 1996]. Therefore the protein target has to be labeled with
a heteronuclear NMR enabling stable isotope like 15N, or 13C labeling of
protein methyl groups. Then an HSCQ spectrum can be recorded to obtain
a chemical shift map of the protein residues. Upon ligand binding, chemical
shifts of residues in the close environment of the ligand will change. Given
that an assignment of the protein was done, the binding site of the ligand can
be determined by these shift perturbations. This methodology is also useful
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SAR by NMR Spin labeling              STD                                  trNOE INPHARMA
Large protein
(> 30 kDa)
limited yes                                yes                                    yes                                       yes
small protein
(< 10 kDa)
yes                             yes                                no                                     no no
Isotope-labeled
protein required
yes                             yes                                no                                     no no
Binding epitope
on protein
yes no                                 no                                     no no
Binding epitope
on ligand
no                              no                                  yes                                    yes                                      yes
Amount of protein
[μM] at 500 MHz
~25                             ~1 ~ 0.1 ~5 ~25
KD tight binding no limit 100 pM    100 pM ~10 μM ~ 10 μM
KD weak binding ~1 mM ~10 mM                     ~10mM ~ 10 mM ~10 mM
Identification of
ligand
no                              yes                                 yes                                    yes                                   yes
Comments robust method     sensitive method,
but results ambig-
uous if  lysine posi-
tions unknown
robust method 
to determine the 
bound  ligand 
conformation   
yields the relative
binding mode of two
ligands that target 
the same binding site
robust method    
Figure 1.9: Comparison of NMR spectroscopy techniques for the identification
and characterization of binding of ligands to proteins. The table is a modification
of [Meyer and Peters, 2003].
as a screening tool for a wide range of binding affinities from weak mM to
strong nM ligand binders. Especially interesting in this sense is the SAR-
by-NMR technique, where ligands are screened for binding in the presence
of a known binder. If additional shift perturbations occur for residues close
to the binding site of the first ligand, it can be concluded that both ligands
bind to a similar binding site. With the information of a second-site ligand
both molecules can be linked as is often done in FBDD approaches, which
can result in a binder that is orders of magnitudes stronger than the initial
binders. The methodology can be even improved together with the NMR
methodology ILOE [Becattini et al., 2006].
Spin-labeled protein/ligand and SLAPSTIC
The approach of spin labels attached to protein side chains as a tool to
identify interacting compounds (SLAPSTIC) was in the first place used as
a screening tool of ligands against a target protein [Jahnke, 2002]. There-
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fore a side chain of the protein is spin labeled with a paramagnetic organic
compounds such as TEMPO. The paramagnetic label leads to drastically in-
creased relaxation rates of neighboring protons, therefore a strong decrease
or even quenching of a ligand proton signal indicates a binding event of the
ligand to the labeled protein. This effect can be used as a screening tool for
binding ligands. The methodology can also be applied vice versa with a spin
labeled ligand, then used for second-site screening. When a second ligand
binds to a binding site close to the first ligand, the proton signals of this lig-
and will relax very fast due to the proximity of the paramagnetic spin label
of the first ligand. This effect can be measured in a 1D experiment or a T1ρ
relaxation experiment. When a second site ligand is found, it can be linked
via chemical synthesis to the first ligand and the best linked ligand chosen
for further development. There are several successful examples of this ap-
proach for FBDD [Jahnke et al., 2003,Poppe et al., 2007,Leone et al., 2010],
which can also be combined with SAR-by-NMR or ILNOE. SLAPSTIC is
very sensitive and robust against false positive detection. Yet, the limitation
is the need of a spin-labeled first ligand, which is often limited by chemical
resources.
1.2.2 The Nuclear Overhauser Effect (NOE)
Longitudinal and transverse relaxation
The term relaxation refers to the return of the spins to their equilibrium
states. This comprises i) longitudinal relaxation, which is the spin-lattice re-
laxation along the z-axis and ii) transverse relaxation, which is the spin-spin
relaxation within the xy-plane. Furthermore the cross-relaxation between
two dipoles leads to a unique and very useful NMR phenomenon: the Nu-
clear Overhauser Effect (NOE). The NOE crossrelaxation rate contains a
distance information that displays one of the most important properties of
NMR-based structure calculations. Moreover, the NOE can be used to study
dynamics as it also contains information on relaxation mechanisms. In the
following section a detailed description of the NOE is given and how it can
be back-calculated. This will be the theoretical basis for the largest part of
this thesis.
As stated above, relaxation contains longitudinal and transverse relaxation.
The first is the return of the spins to the equilibrium state along the z-axis
and is also termed spin-lattice relaxation. The longitudinal relaxation time
T1 can be easily measured with an inversion recovery experiment. A 90◦
pulse places the magnetization in the xy-plane and a 180◦ pulse inverts it.
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By variation of the time τ between the two pulses, a straight line of the re-
laxation time constant can be obtained. A quick estimate can be performed





The transverse relaxation is the return of the spins to the equilibrium
state in the xy-plane and is also termed spin-spin relaxation. The transverse









This is just a rough estimate and the linewidth contains also other con-
tributions such as chemical exchange or unresolved couplings. T2 can be
measured accurately with the CPMG (Carr-Purcell-Meiboom-Gill) experi-
ment, also called spin echo. Therefore a 90◦ pulse is followed by several 180◦
pulses. The magnetization in the xy-plane is constantly reduced and the
amplitude of the decay gives T2.
T2 is further dependent on the size of the molecule: during the brownian
rotation diffusion in solution, the correlation time τc is the time it takes for
the molecule to rotate by one radian and depends on the molecular size. τc






Hereby η is the viscosity, d the radius of the molecule (it is assumed that
the molecule is spherical), k the Boltzmann constant and T the temperature.
As can be seen, the larger the molecule, the higher the viscosity and the
lower the temperature, the larger is τc.
So far a description of the processes and motions occurring during dipole-
dipole relaxation was obtained. The next step is the connection of these
motions to the Larmor frequency. Therefore the amount of motion present
at the observed Larmor frequency has to be found. This is described by a
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correlation function G(t), which is frequently used in physics. For the present




Yet, the correlation function is a function of time. Fourier transformation






1 + ω2τ 2c
) (1.7)
This equation assumes a protein system with rigid side chains. Dynamics
of different amino acid types can be involved by using order parameters, as







1 + ω2τ 2c
(1− S2)τ
1 + ω2τ 2
) (1.8)
Hereby the order parameter S2 is an estimated or experimentally de-
termined descriptor of the internal motion. The values range from 0 to 1,
whereby 1 would represent a rigid system without internal dynamics.
The Solomon equations
The return of a two spin system to the equilibrium state can be described with
the Solomon equations [Solomon, 1955]. The origin of the NMR signal are
transitions of spins between the different energy levels of the α and β state.
In the case of dipole-dipole relaxation the interactions of the spins can be
understood, when taking a close look on the transitions. On the energy level
diagram in Fig. 1.10 the transitions of the spin states are shown. Hereby the
rate constants W of the transitions are given: i) W1(α or β) indicates single-
quantum transitions, ii)W2 indicates double-quantum transitions and iii)W0
zero-quantum transitions. There are eight single-quantum transitions, where
only one spin changes the state and these lead to autorelaxation. Additionally
there are two double- and two zero-quantum transitions, where both spins
change the state and these lead to auto- and crossrelaxation. The energy
levels of the αβ and βα states have the same energy level in the diagram,
because a homonuclear system is shown. In a heteronuclear system of e.g.
1H and 13C, these levels would have different heights. The diagram in Fig.
1.10 illustrates the probabilities of the transitions to occur:
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Figure 1.10: Energy level diagram of a homonuclear two spin system. Indicated
are the 12 possible transitions between the spin states.
The rate constants for the transitions between the energy levels are termed
W0,W1 andW2. From these the autorelaxation ρ and crossrelaxation σ terms
of the spins I and S can be derived:
ρI = W2 + 2W1 +W0
ρS = W2 + 2W1 +W0 (1.11)
σIS = W2 −W0
These lead to the Solmon equations of a two spin system:
d∆Iz(t)
dt
= −ρI∆Iz(t)− σIS∆Sz(t) (1.12)
d∆Sz(t)
dt
= −ρS∆Sz(t)− σIS∆Iz(t) (1.13)
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The motional regimes
The autorelaxation rate ρ of the dipole-dipole interaction is always a negative
term as can be seen in equations shown above. In comparison to this, the
crossrelaxation rate can be positive or negative, depending on the value of
the correlation time τc. Hence, if the molecule is small and τc is short, the
dominant transition will be double quantum and the rate constant is positive.
While, if the molecule is large and τc is long, the dominant transition is zero-
























Figure 1.11: Simulation of the crossrelaxation rate σ between two protons (distance
2 Å) at a Larmor frequency of 600 MHz. While the correlation time τc of the
molecule is increasing, the sign of the signal changes from positive to negative.




, extending out of the graph.
The turnover point between these two motional regimes is at a correlation




. At this point no NOE signal is observed. The different
motional regimes are a very useful phenomenon for drug discovery, as a small
molecule that binds to a big molecule will adopt the correlation time of the
latter.
The NOESY experiment
The phenomenon of cross-relaxation gives rise to a signal between spins close
in space, if the distance is less than approximately 5 Å [Cavanagh et al., 2007].
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The NOE effect can be measured in a 1D spectrum as a transient or steady-
state NOE experiment (described below). In this case it is designed as a
difference experiment, where two spectra are recorded (on- and off-resonance
irradiation) and subtracted. The extension to a 2-dimensional NOESY exper-
iment with diagonal peaks and cross-peaks can be easily achieved. Therefore
an initial 90◦ pulse is followed by the evolution time t1 and a second 90◦
pulse brings the magnetization to the z-axis. During the mixing time, the
magnetization is kept longitudinal and all magnetization except Iz is sup-
pressed by phase cycling or pulse field gradients. This is followed by a third








1 12 13 14 15 16
Figure 1.12: Pulse sequence of a standard NOESY experiment. Indicated are the
pulses and the coherence transfer pathway.
In the following the magnetization at the indicated numbers of Fig. 1.12
during the pulse sequence are described by the product operator formalism.
Product operators are a practical representation of the density matrix de-
scription of spin dynamics. The first two pulses are identical to the well
known COSY sequence:
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1) + Iz + Sz (1.14)
2)− Iy − Sy (1.15)
3)− IycosΩIt1cosπIISt1 + 2IxSzcosΩIt1sinπJISt1
+ IxsinΩIt1cosπJISt1 + 2IySzsinΩIt1sinπJISt1 (1.16)
4)− IzcosΩIt1cosπIISt1 − 2IxSycosΩIt1sinπJISt1
+ IxsinΩIt1cosπJISt1 − 2IzSysinΩIt1sinπJISt1 (1.17)
The interesting part starts here after the second 90◦ pulse. The NOESY
has the same pulses as e.g. the DFQ-COSY, yet the difference is the coher-
ence selection. During the mixing time τm only longitudinal magnetization
and zero-quantum (ZQ) coherence is accepted and allowed to evolve based
on the phase cycle:
5)− aIzcosΩIt1cosπJISt1 + ZQycosΩIt1sinπJISt1cos(ΩI − ΩS)τm (1.18)
− bSzcosΩIt1cosπJISt1 − ZQxcosΩIt1sinπJISt1sin(ΩI − ΩS)τm
The amplitudes a and b are matrices that describe the efficiency of the









R is in place the relaxation matrix for a two spin system. In the case of
a large molecule, R will increase tremendously and the multistep transfers
will lead to spin diffusion. The chemical exchange also contributes to a and
can be described with a kinetic matrix, as will be described later in the text.
The relaxation matrix consists of the elements of the autorelaxation rate ρ
and crossrelaxation rate σ, which are defined as:
Autorelaxation : ρI = b
2 1
r6IS
[6J(2ω) + 3J(ω) + J(0)] (1.20)
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Back to the NOESY experiment, the final 90◦ pulse leads to the signal
and gives:








(2IxSx + 2IzSz)cosΩIt1sinπJISt1sin(ΩI − ΩS)τm
The terms aIy and bSy lead to the desired diagonal peaks and cross-
peaks. They are in-phase and absorptive in both dimensions. The term
1
2
(2IzSx − 2IxSz) is anti-phase and dispersive in both dimensions. It repre-
sents the unwanted zero-quantum contribution to diagonal peaks and cross-
peaks. For large molecules it can be neglected, as the ZQ relaxation is fast
and the anti-phase contribution small. In the case of small molecules it can
be avoided, for example by using a ZQ-filter [Thrippleton and Keeler, 2003]
or reduced with a 180◦ refocusing pulse during the mixing time. The last
term −1
2
(2IxSx + 2IzSz) is double quantum coherence and not observable.
The presented description of the NOESY experiment is based on [Hore et al.,
2000,Cavanagh et al., 2007,Keeler, 2010].
The magnetization transfer can not only take place in the longitudinal, but
also in the transverse plane. This is done in a ROESY (rotating-frame nuclear
Overhauser spectroscopy) experiment, where the mixing time is substituted
by a spin-lock field to keep the magnetization in the transverse plane. As
seen in equation 1.24 the sign of the ROESY cross relaxation rate is always
positive (in comparison to the NOE cross relaxation rate as shown above), as
it is an addition and not a difference of two positive terms. Yet, ROE has the
disadvantages of a less favorable spin diffusion than NOE and artifacts from
J-coupling. Still, the ROE experiment is useful for molecules that display









[3J(2ω) + 2J(0)] (1.24)
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Back-calculation of the NOE
The NOE peak volumes V that evolve during the mixing time of a NOESY




= −(R + K) · (V(t)−Veq) (1.25)
V represents the volume matrix of all considered spins that evolve during
time t. The Boltzmann equilibrium magnetization is represented by Veq. R
is the relaxation matrix and K is the kinetic matrix of the chemical exchange.
K is derived from the chemical equilibrium rate constants for example from
a ligand to protein binding event. R and K can be united to the matrix D.




The dynamic matrix D = R+K is asymmetric and therefore not practi-
cable for computation. D has to be turned into a symmetric and diagonalized
matrix, which can be efficiently computed. For this operation D has to be
multiplied with a symmetrization matrix S and its inverse matrix S−1 to give
the symmetrical Ds matrix. The result has then to be multiplied with a diag-




= S · e−Ds·τm · S−1 ·V(0) (1.28)
= S ·X · e−λ·τm ·XT · S−1 ·V(0) (1.29)
Using the final equation 1.29, the NOE peak volumes can be efficiently
back-calculated for all relevant protein and ligand systems.
1.2.3 Transferred NOE (trNOE)
As was discussed in the section above, there are two motional regimes for the
NOE that depend on the size of the molecule. The consequence is, that large
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molecules display much larger signals in the spectrum than small molecules
due to their larger correlation time. If a small molecules binds to the large
molecule, there will be a magnetization transfer and the signals of the small
molecule will adopt the same strong, negative intensities as with the large
correlation time. This happens because these large intensities of the bound
form just overlay the small, positive signals of the free form. As a result one
sees the bound conformation of the small molecule in the NOESY spectrum
and not the free form. Especially if the molecule has many torsion angles,















Figure 1.13: Principle of transferred NOE magnetization, observable in an NMR
NOESY spectrum. Magnetization of the ligand protons spreads to the protein
protons and back.
The magnetization transfer of trNOE is shown in Fig. 1.13. The case for
long mixing times is shown, where the magnetization spreads by spin diffusion
all over the protein. Therefore the NOE peaks also contain information of
the protein surroundings. If one is just interested in the bound conformation,
it is feasible to record at very short mixing times to avoid spin diffusion or
even measure with a deuterated protein in order to see only the transfer
between ligand protons. First applications of the trNOE were done in the
1970s [Balaram et al., 1972,Balaram et al., 1973].
The theoretical description and back-calculation is derived from the approach
by [Clore and Gronenborn, 1982] and [Ni and Zhu, 1994]. In the kinetic model
it is assumed that ligand A binds to a target protein T to form a complex
TA. This reaction is reversible and described by the rate constants k12 and
k21. Due to the large excess of the ligand, it is assumed that the target is
never in the unbound state:





The relaxation matrix R can be set up as a block matrix. Diagonal ele-
ments represent the auto-relaxation terms and the others the cross-relaxation











Hereby the superindex of each R indicates the species and the subindex
indicates the protons of the species for which the relaxation is described. So
RAA represents the free ligand, RTAA is the relaxation of ligand protons in the
bound form, RTAT is the relaxation of protein protons in the ligand bound
protein form. Finally RTAT,A and RTAA,T represent the cross-relaxation between
the protons of the bound ligand and the target protons, respectively. The
kinetic matrix K represents the processes of the system at equilibrium. It
includes the rate constants k12 and k21 and the concentrations of [TA] and







The trNOE is a very useful technique to derive the bound conformation
of a ligand to a protein, given that several off-events take place during the
mixing time, i.e. the binding is not too strong. It can also be used to check
if a ligand binds to a protein, but this application is now mostly done with
the much faster STD method (see below).
Interligand NOE
In the case that the binding pocket of a protein is large enough that it can
accommodate two ligands at the same time, an interligand NOE (ILOE)
signal between these can be observed [Li et al., 1999]. Also it is possible that
a ligand binds outside of the binding pocket and an NOE is observed to the
ligand inside the binding pocket. As for the trNOE there is spin diffusion
enhancing the signal, but the original magnetization transfer takes place
28 CHAPTER 1. INTRODUCTION
between the two ligands. If the protein would be deuterated or the spectrum
would be recorded at very short mixing times, minimizing extremely the
effect of spin diffusion, there would still be the interligand NOE visible. This
has been theoretically described in detail [London, 1999]. The technique is
very useful for linking small fragments to a potent inhibitor and has already
been applied successfully in drug discovery [Becattini et al., 2006,Sledz et al.,
2010].
1.2.4 INPHARMA
The INPHARMA (Interligand NOE for PHARmacophore MApping) effect
was first observed when epothilone A and baccatin III were measured to-
gether with tubulin in one NMR sample [Sánchez-Pedregal et al., 2005]. It
was possible to observe a magnetization flow between the two ligands, which
was transferred via the protein by spin diffusion. The result are NOE sig-
nals between the binding molecules, yielding information about their relative
binding orientation. As the magnetization flow goes via the protein, the
information of protein density around the ligands is also given. If the pro-
tein would be deuterated, or very short mixing times would be chosen, no
spin diffusion would take place and the INPHARMA peaks would not be
observable. This has been shown with deuterated PKA samples [Orts et al.,
2008a]. Because the information of the protein environment is included in
the INPHARMA peaks, even the absolute binding mode of the ligands in
the binding pocket can potentially be derived. The magnetization transfer
of INPHARMA during a NOESY experiment is shown in Fig. 1.14. One
ligands binds to the protein and the magnetization spreads by spin diffusion
to the protein protons. When the second ligand binds, the magnetization is
transferred onto this ligand.
The magnetization transfer of INPHARMA can be described similar to
the trNOE, but the relaxation and kinetic matrix have to be adjusted to the
situation of two ligands. Such a description was done for the ILOE effect
by [London, 1999] and proposes five different states: Ligands A and B in the
free form, ligands A and B bound and both ligands bound. Transferring this
to the INPHARMA situation we end up with four different chemical species:
Ligands A and B in the free form and ligand A and B bound to the target
(in the on- and in the off-state). Setting up these equations was described in
detail [Reese et al., 2007,Orts et al., 2008b,Orts et al., 2009]. In this kinetic
model it is assumed that the target is never in the unbound state due to the
large excess of the two ligands and therefore the unbound target is negligible.
The complexes then form as follows:






















Figure 1.14: Principle of INPHARMA magnetization transfer, observable in an
NMR NOESY spectrum. Magnetization of the first ligand spreads to the protein
protons and is transferred to the second ligand upon binding. NOESY peaks




TB + A (1.33)
The relaxation matrix can be set up in the same way as for the trNOE,
just the ligand B has to be added:
R =

RAA 0 0 0 0 0
0 RBB 0 0 0 0
0 0 RTAA R
TA
A,T 0 0
0 0 RTAT,A R
TA
T 0 0
0 0 0 0 RTBB R
TB
B,T





Hereby RTXT (X = ligand A or B) represents relaxation between protons
of the target, while the ligand is in the bound state. RTXX represents the
relaxation of ligand protons in the bound form. RTXT,X and RTXX,T represent
the cross-relaxation between the protons of the bound ligand and the target
protons. The kinetic matrix can be derived from the trNOE in the same way:
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K =

k21[TB]I 0 −k12[B]I 0 0 0
0 k12[TA]I 0 0 −k21[A]I 0
−k21[TB]I 0 k12[B]I 0 0 0
0 0 0 k12[B]I 0 −k21[A]I
0 −k12[TA]I 0 0 k21[A]I 0
0 0 0 −k12[B]I 0 k21[A]I

(1.35)
Summarizing the relaxation and the kinetic matrix according to equa-
tion 1.26 results in an accurate description of the multi-step transfer which


































Superimposed crystal structures 
of ligand 3 and ligand 4.
Figure 1.15: Example of the INPHARMA method, demonstrating the ability to
give distance related superimpositions of bound ligands. These observations are
proven by the superimposed crystal structures, shown below.
An example of the INPHARMA method is shown in Fig. 1.15 for the
PKA binding ligands 3 and 4. The slice through the NOESY spectrum at
the resonance of the methyl group of ligand 3 in ω1 demonstrates that the
magnetization is transferred via protein protons (H) to ligand 4 and suggests
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e.g. a larger spatial proximity of 3-CH3 to 4-H8 than 4-H1-5. Below are the
crystal structures of ligand 3 (black) and ligand 4 (white) superimposed to
demonstrate the correct prediction of INPHARMA. The sample contained
0.045 mM PKA, 1.2 mM of ligand 3 and 0.9 mM of ligand 4 in PBS D2O
buffer.
1.2.5 Saturation transfer difference (STD)
The two-dimensional NOESY is very useful, but also requires long NMR
measurement time. The NOE can be measured also in a one-dimensional
fashion. For this purpose the signal of one specific protein proton frequency
will be saturated that does not overlap with proton frequencies of the lig-
and. This is done by RF irradiation onto this frequency. The single-quantum
transitions are significantly reduced and the same holds true for the signal.
In practice two different spectra are recorded. One spectrum with the RF ir-
radiation far away from any molecule signal (off-resonance) and one spectrum
with the RF irradiation on one specific molecule frequency (on-resonance).
The difference spectrum shows a strongly reduced signal at the saturated
frequency and also reduced signals of protons close in space to the saturated
proton. This one-dimensional NOE can be used in a fast and easy manner
to determine the constitution of small molecules.
The method also works in the case of chemical exchange, because the sat-
uration can be transferred by spin diffusion. The consequence is that the
saturation of one frequency of a big molecule will quickly spread over the
whole protons. If a small molecule binds weakly, it will also get saturated.
Given that there are several off-events during the saturation time, the bind-
ing event is visible by a change in the difference spectrum. The saturation is
normally set to a frequency where no ligand signals are to be found: around
0.5 ppm in the methyl group region of the protein, or around 11 ppm beyond
the aromatic region of the protein. The magnetization transfer is shown for
irradiation on methyl groups in Fig. 1.16. This technique is termed satura-
tion transfer difference (STD) and was first introduced by [Mayer and Meyer,
1999].
The back-calculation of STD peak volumes is done with the complete re-
laxation matrix approach similar to the NOESY spectra. Yet, the saturation
by RF irradiation has to be taken into account. The following description
of the back-calculation is based on the complete relaxation and conforma-
tional exchange matrix (CORCEMA) theory developed by [Jayalakshmi and
Krishna, 2002] and [Jayalakshmi et al., 2004]. Here an ideal case is assumed
with an infinite recovery delay and an instantaneous saturation by RF ir-
radiation of the saturated spins, e.g. methyl groups. The equation for the



















Figure 1.16: STD magnetization transfer. Protein protons of a specific frequency
(here methyl groups) are saturated by RF irradiation. Magnetization spreads to
all protein protons and the bound ligand.
back-calculation of peak volumes is set-up similar to equation 1.26, with an
additional matrix Q to describe the saturated protons:
V(t) = V(0) + (1− e−D·t) ·D−1 ·Q (1.36)
Q is a matrix that describes the cross-relaxation terms between the sat-
urated protein protons (e.g. from methyl groups) and the rest of protein
protons, as well as the transfer to the bound ligand. Q is build up like R of
the trNOE and STD shown above, yet it contains a new species: the protein
protons TRF that receive saturation by RF directly. As the free ligand does
not receive magnetization, the saturation its equal to 0.
Besides the detection of ligand binding and determination of the rate con-
stants of the same, STD can be used to obtain information on the ligand
binding mode. This was first demonstrated on oligosaccharides binding a
protein by group epitope mapping [Mayer and Meyer, 2001]. Oligosaccha-
rides are a feasible example: they are very large ligands and the parts that
are buried in the protein and exposed to the solvent are well separated in
space. Buried protons get stronger saturation from the protein, therefore
they can be distinguished easily from those exposed that receive less satura-
tion. The ability of STD to derive the binding epitope of even a small ligand
to a protein is demonstrated in Fig. 1.17: ligand protons in close contact to
the protein such as 4-H8 and 4-H9 suffer from stronger saturation via protein
protons than solvent exposed protons such as 4-H1-5.
The STD sample contained 0.045 mM PKA and 0.9 mM of ligand 4. On


























Figure 1.17: Example of the STD effect. The signal of the aromatic ring of the
ligand is stronger than those of the single protons. After subtracting the 1D from
an STD, it becomes clear that the single protons are deeper in the binding site and
receive more magnetization from the protein. This observation is proven by the
corresponding crystal structure.
the right side the crystal structure of ligand 4, demonstrating the exposition
of the aromatic ring to the solvent and the close contact of protons 4-H8 and
4-H9 to the protein protons.
Taking together the widely used screening capabilities of STD with the speed
of the experiment and the binding mode information obtainable, this tech-
nique is extremely useful for NMR and drug discovery. It is criticized that
the method depends too much on T1 and may give wrong results for some
spins [Yan et al., 2003, Mizukoshi et al., 2012]. But this problem can be
overcome with the accurate description delivered by the complete relaxation
matrix approach.
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WaterLOGSY
WaterLOGSY is an alternative to STD in NMR screening. The mechanism
is opposite of STD: instead of saturating the protein, the bulk water is sat-
urated. This is achieved by an 180◦ pulse on the water frequency, followed
by a strong water suppression block [Dalvit et al., 2001]. While the STD
represents the steady-state version of the one-dimensional NOE, the Water-
LOGSY is recorded in a transient state manner. The magnetization will
spread to protons exposed to the bulk water which affects the free and the
bound form of the ligand. Yet, the magnetization that spreads over the whole
protein and the bound ligand will change the sign of the NOE of the ligand
protons, due to the long correlation time of the macromolecule. This will not
happen to the free form of the ligand that will have a positive NOE. There-
fore WaterLOGSY can be used to identify ligand binding. Ligand protons
that are buried in a protein binding pocket do not get as strongly affected
by the magnetization transfer as protons directly exposed to the bulk water.
Therefore it is also possible to receive the binding epitope of a ligand. When
information on the binding epitope is desired, the method can be used com-
plementary to STD, as the difference spectrum should display the opposite
information of the STD spectrum, i.e. the protons exposed to water like in
the SALMON approach [Ludwig et al., 2008a,Ludwig et al., 2008b]. The Wa-
terLOGSY experiment has the advantage that no protein proton frequency
has to be saturated, which can be useful for ligands with many methyl groups
that overlap with protein methyl groups in the spectrum. Still, the Water-
LOGSY experiment is significantly longer than STD and is therefore not the




2.1.1 Protein kinases as drug targets
Protein kinases are a family of enzymes that modify and activate other pro-
teins by chemically adding a phosphate group. This phosphate group comes
from an ATP molecule that binds to the very conserved binding pocket of
the protein kinase. In the human genome 518 putative protein kinase genes
were identified [Manning et al., 2002], which would account for 1.7 % of the
human genes. Protein kinases can be divided in threonine/serine kinases
(e.g. PKA, CDK) and tyrosine kinases (e.g. ABL), depending on which
amino acid of the target protein they phosphorylate. Protein phosphoryla-
tion plays a key role in most aspects of the regulation in the cell, especially
signal transduction. Abnormal phosphorylation, e.g. caused by mutations
in the protein kinase can lead to unregulated cell growth, which is a crucial
step in the development of cancer. Therefore protein kinases have become
the second most important family of drug targets after G-protein coupled
receptors, accounting for 20-30 % of the drug discovery programmes [Cohen,
2002]. The history of kinase drug design started in the early eighties, when
it was found that tumour promoting phorbol esters are activators of protein
kinase C [Castagna et al., 1982]. The first drugs developed for kinase inhi-
bition were isoquinolinesulfonamides [Hidaka et al., 1984], which target the
ATP binding site and showed good cell permeability. These substances led
to the discovery of compounds like fasudil [Asano et al., 1998], which were
approved in Japan for the market to treat cerebral vasospasm. Yet, these
inhibitors showed a comparably low potency, which made it hard to com-
pete with the ATP concentration inside the cell (2-10 mM). The situation
changed when a natural, nanomolecular inhibitor was discovered [Tamaoki
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et al., 1986]: the antifungal agent staurosporine, produced by the bacterium
Streptomyces, inhibits most kinases and was used a a lead structure by several
companies (Fig. 2.2). But even with the discovery of a very strong inhibitor
a main problem still remained: the low selectivity, meaning that many differ-
ent kinases are targeted unspecifically. The first clinical success came from
another natural product, rapamycin, that showed strong effects in immuno-
suppression by inhibiting the protein kinase mTOR specifically [Davies et al.,
2000]. The greatest success of a specific protein kinase inhibitor and a land-
mark in structure-based drug design in general is imatinib. This compound
was developed by Novartis under the treading name Gleevec and targets
the Abelson tyrosine kinase (ABL). ABL fuses with the breakpoint cluster
region (BCR) and forms an enhanced kinase that is observed in nearly all
cases of chronic myelogenous leukemia (CML) [Druker et al., 1996]. Pa-
tients of CML can be cured successfully with imatinib and Gleevec was soon
approved to the market and a huge financial success. Today an interest-
ing drug target is epidermal growth factor receptor (EGFR) tyrosine kinase,
which is overexpressed in lung and breast cancer. The Astra-Zeneca com-
pound Iressa [Morin, 2000] was approved for the market. Another important
kinase family are the cyclin-dependent kinases (CDKs) which play essential
roles in cell proliferation. Hereby flavopiridol [Senderowicz, 2000] from Sanofi
is an interesting candidate. At the time of this thesis only 9 small molecule
drugs that target kinases are approved to the market, while nearly 30% of all
industrial drug discovery programs focus on protein kinases [Backes et al.,
2008].
2.1.2 ATP binding site
The first 3-dimensional structure of a protein kinase was obtained in 1991,
when the crystal structure of the catalytic subunit of the cAMP-dependent
protein kinase A (PKA) was solved [Knighton et al., 1991]. The mechanism
of action of the natural binder ATP is well understood [Bossemeyer et al.,
1993], as well the binding modes of many diverse inhibitors [Engh et al.,
1996]. In the physiological environment PKA is a tetramer that consists of
two catalytic and two regulatory units. Activation by four second messenger
cAMP molecules releases the two catalytic subunits. Generally the catalytic
subunit of a protein kinase is amenable for crystallization. For most im-
portant inhibitors and many fragment drugs crystal structures exist in the
public PDB as well as in the proprietary databases of pharmaceutical com-
panies. Protein kinase structures are not amenable to be solved by NMR,
as the catalytic subunit is already too large (42 kDa in the case of PKA).









Figure 2.1: Crystal structure of ATP bound to PKA (PDB entry code: 1ATP).
Indicated are the N-lobe and C-lobe, the binding site at the hinge region, and the
phosphorylated residues Thr197 and Ser338. On the right side there are the different
binding pockets indicated: the common binding motif at the hinge region and the
DFG motif of the backpocket, which is guarded by the gatekeeper residue.
different methods, including chemical shift calculation, paramagnetic tagging
and selective labeling. Investigations with TROSY revealed then conforma-
tional changes upon phosphorylation [Langer et al., 2004]. Phosphorylation
activates the kinase and induces a conserved, major conformational change.
In the case of protein kinase A, phosphorylation takes place on Thr197 and
Ser338. A new hydrogen bond between P-Thr197 and His87 is the key element
of activation and induces a cascade of new hydrogen bonds, also stabilizing
the conserved DFG motiv [Kornev et al., 2006]. This region of Asp-Phe-Gly
(DFG) forms the backpocket next to the ATP-binding site. The entrance
to this pocket is guarded by the gatekeeper, normally a bulky amino acid
like phenylalanine. In the case of PKA it is Met120. Some ligands have the
ability to re-orient the gatekeeper and penetrate into the backpocket. This
behavior is highly desirable in kinase drug design, as it opens the way for
higher selectivity. ATP is attached with a hydrogen bond to the Val123-NH
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and the Glu121-CO at the hinge region and covers the adenine pocket, the





















Figure 2.2: Constitution of the natural product staurosporine on the left side and on
the right the crystal structure of staurosporine bound to PKA (PDB code: 1STC).
Staurosporine forms hydrogen bonds to the hinge region (Val123 and Glu121 and
Leu172). It also moves aside the gatekeeper residue Met120 and Phe327 on the other
side and penetrates into both backpockets.
In the case of p38 MAP kinase an additional hydrophobic groove is formed
that allows the specific binding of the ligand SB203580, together with specific
amino acids in the backpocket like Thr106, [Tong et al., 1997]. NMR investi-
gations of the complex using RDCs showed that the inhibitor and the protein
are highly dynamic in comparison to the rigid crystal structure. So the inter-
pretation of ligand binding modes considering conformational changes profits
from being studied with NMR in addition to X-ray crystallography [Honndorf
et al., 2008,Honndorf et al., 2012]. As mentioned above it is generally easy to
obtain the crystal structure of a protein kinase with its bound ligand. Still,
this is not the case for all ligands and especially flexible molecules are some-
times difficult or impossible to co-crystallize. Therefore the application of an
NMR-based scoring function for docking and molecular dynamic simulations
of ligand binding modes is highly desirable. It was shown in 2008, that the
NMR method INPHARMA can be applied successfully to PKA [Orts et al.,
2008b,Orts et al., 2008a], which is a representative for all members of the
protein kinase family. Two ligand fragments targeting the ATP binding site
were investigated and the crystal structures of these ligands were correctly
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identified out of several artificial docking modes, if some ad-hoc assumptions
are taken. In the following part it will be demonstrated that the methodol-
ogy can be substantially improved by taking more NMR data into account.
Therefore no more assumptions have to be taken and the methodology is
expanded from the original ligand pair to a diverse ligand set.
2.2 Material & Methods
2.2.1 Protein expression and sample preparation
The chinese hamster Cα catalytic subunit of cyclic adenosine monophosphate
(cAMP) dependent protein kinase A (PKA) was expressed and purified ac-
cording to the published procedure [Langer et al., 2004].
0.38 mL D2O PBS-buffer with a PKA concentration of 0.045 mM and addi-
tional 150 mM NaCl were combined with 0.020 mL DMSO-d6 with appro-
priate ligand concentration (L1: 0.3 mM, L2: 0.9 mM, L3: 1.2 mM, L4: 0.9
mM). 2 mM TCEP were added as an anti-aggregation agent.
2.2.2 NMR spectroscopy
INPHARMA spectra were recorded using the standard NOESY pulse pro-
gram noesyphpr. Ligand combinations 1&2, 2&3 and 3&4 were recorded on
a 700 MHz spectrometer and combination 1&3 on a 900 MHz spectrome-
ter. Both spectrometers are equipped with cryogenically cooled probe heads
(Bruker, Karlsruhe). The mixing times 400 ms, 600 ms, 800 ms and 1 s were
recorded.
Combination B3&2 was recorded on an 700 MHz and B5&3 on an 800 MHz
spectrometer with a mixing time of 800 ms. Concentrations and conditions
are in the appendix.
STD spectra were recorded with a standard pulse sequence (stddiffesgp.2)
with 8 scans on a 400 MHz spectrometer. Saturation was achieved by a train
of shaped 90◦ pulses of 50 ms length. A number of 160 selective pulses was
applied, leading to a total length of saturation of 8 s. 8 s were used, since the
usually applied 2 s did not fully saturate the resonances. The on-resonance
irradiation was performed at +0.5 ppm and off-resonance irradiation was set
to +30 ppm.
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2.2.3 Docking and molecular dynamics simulations
For ligands 1-4, 1000 binding modes per ligand in the crystal structure 3DNE
were created using the docking software PLANTS [Korb et al., 2006]. These
were clustered with 2 Å RMSD similarity filter and the best scoring struc-
ture from every cluster was used as a representative structure.
For ligands B3 and B5, 10 docking modes within the crystal structure 3DNE
were created respectively. TrNOE data were used to restrain the docking of
ligand B3. Three-dimensional structures of the ligands were created using
CORINA [Sadowski and Gasteiger, 1994].
Energy minimizations and molecular dynamic simulations were done as im-
plemented in Gromacs [Hess et al., 2008], using the amber99sb force field
[Hornak et al., 2006] for the protein and the General Amber Force Field
[Wang et al., 2004] for the ligand. EM was done with conjugate gradient
integrator in 1000 steps. MD was done using steepest descent integrator
with a stepsize of 2 fs. Simulations were done for 1 ns in implicit solvent,
using the Generalized Born model augmented with the hydrophobic solvent
accessible Surface Area (GBSA). From every trajectory 100 or 500 snapshots
were saved, respectively.
2.2.4 Back-calculation of peak volumes
All INPHARMA, trNOE and STD peak volumes were back-calculated with
the software SpINPHARMA, using the complete-relaxation matrix approach
[London, 1999,Orts et al., 2009] as described in the introduction 1.2. Methyl-
groups were described using a 3-site jump model [Tropp, 1980]. STD satura-
tion was applied to all methyl groups. Protons within a distance of 8 Å from
any ligand proton were considered. The INPHARMA peaks were normalized
to the sum of all peaks in the direct dimensions [Koeck and Griesinger, 1994].
The correlation times were estimated to be 15 ns. Kd values were determined
by STD competition experiments (L1: 0.03 mM, L2: 0.09 mM, L3: 0.09 mM,
L4: 0.09 mM). On-rates (kon) were assumed to be in the diffusion limit 108
M−1s−1. The multiplexing approach was realized with an in-house written
Python program.
2.3 Results I - Method development
In the first part of the results it is described how the methodology was further
developed, starting from the reproduction of the [Orts et al., 2008b] data.
In the second part the application to several complicated ligand binding
modes, including conformational changes of the protein, will be shown. In the
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following the test set of ligands is described and their behavior in molecular
docking. Then the NMR spectroscopic data and their back-calculation is
discussed which finally leads to ligand binding mode identification. In the
end molecular dynamics simulations will be used to refine the structures.
2.3.1 Molecular docking
In the beginning the two ligands 1 and 2 from [Orts et al., 2008b] were used
and then accompanied by the new ligands 3 and 4. These are shown in
Fig. 2.3. The crystal structures of these ligands in complex with PKA are



























Figure 2.3: Four indazole-based PKA binding ligands. Indicated is the number of
representative structures after docking.
The crystal structure of PKA in complex with ligand 1 (PDB code 3DNE)
was applied to obtain the protein coordinates. This structure was chosen to
make the results comparable to previous INPHARMA studies, where it was
also used. 1000 docking structures were created for every ligand within the
crystal structure 3DNE by the ant colony algorithm based docking program
PLANTS [Korb et al., 2006]. This docking program was found to compare
well with the established program GOLD [Korb et al., 2009b]. Docking mod-
els were clustered by a 2 Å RMSD similarity filter and the best scoring dock-
ing mode from every cluster was taken as a representative structure for this
42 CHAPTER 2. PROTEIN KINASE A
cluster. The docking results were scored by the PLANTS scoring function
ChemPLP, and only for ligand 1 the correct binding mode received the best
score. Alternative scoring of the PLANTS docking modes with ChemScore
and ASP led to a comparable bad performance of docking scoring functions.
Only GOLDscore was able to identify correctly the binding modes of ligand
1, 2 and 4, but not for ligand 3. Scores of the docking scoring function can
be found in the appendix.
2.3.2 INPHARMA
In the first place, the experimental data from [Orts et al., 2008b] were re-
produced. Sample conditions were improved by the addition of TCEP to
stabilize the PKA sample against aggregation. Also the increase of protein
and ligand concentrations led to better resolved spectra. The NOESY spec-
tra of the ligand combinations 1&2 (Fig. 2.6) and 3&4 (Fig. 2.7) are shown
in the following and 2&3 and 1&3 are shown in the appendix. INPHARMA
signals were clearly observed for every combination. Several programs were
tested for peak integration, including Sparky, TopSpin, Cara and NMRView.
The box integration scheme of NMRView was the most effective tool to cor-
rectly integrate even very small and overlapping peaks, so it was used in all
following investigations.
In [Orts et al., 2008b], it was demonstrated that the linear correlation
coefficient RINPHARMA between the experimental and back-calculated IN-
PHARMA peak volumes is better for the crystal structures, than for syn-
thetic binding modes, as seen in Fig. 2.4.
In the present study, no synthetic binding modes were used, but real
docking modes as proposed by the state-of-the-art software PLANTS. The
peak volumes were back-calculated for all 70 possible double combinations of
the docking modes of ligand pair 1&2 and correlated with the experimental,
integrated peak volumes. The linear correlation coefficient RINPHARMA was
used to score the quality of the fit between experimental and back-calculated
peak volumes of every docking pair. The result can be seen in Fig. 2.5:
RINPHARMA is plotted against the RMSD of the two PKA/ligand structures
compared to the average crystal structures. The structure pair closest to the
crystal structures is considered to be the correct answer. Yet, RINPHARMA
places the correct answer amongst the 10% best structure pairs, but too
many false positives prevent the identification of the correct structures. The
identified binding mode includes the correct binding mode of ligand 2, but is
far off for ligand 1.
The similar problem was found for all other double combinations (1&2,
2.3. RESULTS I - METHOD DEVELOPMENT 43
Figure 2.4: Result from [Orts et al., 2008b]: The crystal structures (pair A) show
a better correlation between experimental and back-calculated INPHARMA data
than synthetic rotations of these (pairs B-D). Some ad-hoc criteria defined in this
publication also support this finding.
2&3, 1&3 and 3&4): The correct answer was scored approximately amongst
the 10% best scoring structures, but the identified binding modes were far
off the correct answer. An approach to use a higher number of docking
modes (one thousand structures per ligand, resulting in one million double
combinations), resulted just in higher numbers of false positives (data not
shown). The final conclusion is, that not the number of structures should
be increased, but the amount of data input, given that no additional NMR
work is necessary. From the INPHARMA NOESY spectra the trNOE can
be extracted, yielding information on the bound ligand conformation. Still,
this information is not very useful for small, rigid molecules as in the present
case.
Before the recording of an INPHARMA NOESY, the ligands are checked for
binding to the protein by STD. Remembering the introduction part, STD












Ligand 1 - Ligand 2
70 structure pairs







Figure 2.5: RINPHARMA plotted against the RMSD of the two PKA/ligand
structures compared to the crystal structures, the best structure according to
RINPHARMA has a red circle, the best answer has a green circle. RINPHARMA
does not pick the correct structure as there are too many false positives.
not only gives information on the binding behavior of a ligand, but also on
the ligand binding mode.
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Figure 2.6: NOESY spectrum of ligand 1 (0.3 mM) and ligand 2 (0.9 mM) in the
presence of PKA (0.045 mM). INPHARMA peaks chosen are marked in green. The
mixing time was 800 ms on a 700 MHz spectrometer, equipped with a cryogenically
cooled probe head. The spectrum was recorded at 293 K with 64 scans, 2048 points
in F2 and 580 points in F1.






















































Figure 2.7: NOESY spectrum of ligand 3 (0.9 mM) and ligand 4 (0.9 mM) in the
presence of PKA (0.045 mM). INPHARMA peaks chosen are marked in green. The
mixing time was 800 ms on a 700 MHz spectrometer, equipped with a cryogenically
cooled probe head. The spectrum was recorded at 293 K with 64 scans, 2048 points
in F2 and 580 points in F1.
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2.3.3 STD
In principle one could simply use the STD spectra that were recorded prior to
the INPHARMA NOESY measurements. In the present study, every ligand
was measured with PKA on its own, to avoid signal overlaps. When STD
is used to investigate if a ligand is binding to a protein, very small protein
concentrations are used. Now, that the binding epitope should be derived,
the protein was as high concentrated as for the INPHARMA measurements
(0.045 mM). In this manner the binding epitope was found to be derived in
the optimal way. Different saturation times (2 s, 4 s, 6 s and 8 s) were tested
for ligand 1 and a build-up series of the ligand signals was recorded. As can
be seen in Fig. 2.8, the signal increases up to 6 s and then stays at this
intensity level. Finally, 8 s were chosen as the optimum saturation time, to












Figure 2.8: STD build-up curve of ligand 1 (0.3 mM) in solution with PKA (0.045
mM). Saturation was done on methyl groups. Signal intensities increase to a sat-
uration time of 8 s.
One spectrum was recorded with on-resonance irradiation (0.5 ppm) and
a second spectrum with off-resonance irradiation (30 ppm). The STD spec-
trum was obtained by subtracting the first from the latter manually. In this
manner the 1D (off-resonance irradiation) and the STD spectrum are better
comparable than, if only an interleaved difference spectrum is recorded, as it
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is normally done. For all four ligands, the binding epitope could be derived
from the STD spectra. This is shown in Fig. 2.9.
For the back-calculation of STD, the experimental peak volumes (V) were





Back-calculated peak volumes were treated in the same way. Both, ex-
perimental and back-calculated volumes are multiplied by 100 as a scaling
factor for better representation.
For the graphical representation of STD in percent that was introduced
by [Mayer and Meyer, 2001] and is shown in the figures, the largest STD



















































































































Figure 2.9: Experimental STD data of the four PKA binding ligands. The normal
1D in the presence of 0.045 mM PKA is shown in black and the STD spectrum
in blue. Ligand concentrations were 1 (0.3 mM), 2 (0.9 mM), 3 (1.2 mM) and 4
(0.9 mM). Saturation was applied for 8 s on 0.5 ppm on a 400 MHz spectrometer
(number of scans = 8; temperature = 298 K; time domain = 16384 points). Proton
3 of ligand 3 was dismissed due to broadening, caused by an overlap with broadened
protein signals. The VMax.STD values are: L1: 13.75; L2: 28.6; L3: 16.91; L4:
32.66.
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2.3.4 INPHARMA-STD
In the following a new approach was tested to combine INPHARMA with
the STD data, also considering trNOE. The different data sets were com-
bined using a simple average of the correlation coefficients RSTD, RtrNOE













In the present case the software SpINPHARMA describes already the
combined trNOE for the ligand pair, so the last equation was not necessary.
The results for the double combination are shown in the following figures.
They are striking in three ways: i) the combination of INPHARMA and STD
finds the correct (or close to correct) binding mode in every example, ii) this
works even though INPHARMA and STD would fail respectively on their
own and iii) the NMR approach performs better than the docking scoring
functions ChemPLP and GOLDScore.
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Figure 2.10: RSTI plotted against the RMSD of the two ligand/PKA structures
compared to the crystal structures, the best structure according to RSTI has a black
circle. The best structures selected by different scoring are represented in blue
(INPHARMA), green (STD), red (ChemPLP) and yellow (GOLDScore). RSTI
selects the correct docking mode, i.e. the mode with the smallest RMSD to the
average crystal structure.



























Figure 2.11: RSTI plotted against the RMSD of the two ligand/PKA structures
compared to the crystal structures, the best structure according to RSTI has a black
circle. The best structures selected by different scoring are represented in blue
(INPHARMA), green (STD), red (ChemPLP) and yellow (GOLDScore). RSTI
selects the correct docking mode, i.e. the mode with the smallest RMSD to the
average crystal structure.
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average RMSD to crystal structure [A]




























Figure 2.12: RSTI plotted against the RMSD of the two ligand/PKA structures
compared to the crystal structures, the best structure according to RSTI has a black
circle. The best structures selected by different scoring are represented in blue
(INPHARMA), green (STD), red (ChemPLP) and yellow (GOLDScore). RSTI
selects the second best docking mode, i.e. the mode with the smallest RMSD to
the average crystal structure.
































Figure 2.13: RSTI plotted against the RMSD of the two ligand/PKA structures
compared to the crystal structures, the best structure according to RSTI has a black
circle. The best structures selected by different scoring are represented in blue
(INPHARMA), green (STD), red (ChemPLP) and yellow (GOLDScore). RSTI
selects the correct docking mode, i.e. the mode with the smallest RMSD to the
average crystal structure.
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2.3.5 Multiple ligands (Multiplexing)
In order to evaluate the impact of having more ligands than two (multiplex-













The ligand combinations 1&2, 1&3, 2&3 and 3&4 were chosen, as they
give well dispersed spectra, while the combinations 1&4 and 2&4 display
many overlaps and therefore not enough quantifiable INPHARMA peak. As
seen in Fig. 2.14, the differentiation between the correct structures and those
with larger RMSD is even more pronounced and the correct binding mode
can be identified with RMultiplexingSTI more easily. It is noteworthy that this
multiplexing of more than two ligands substantially improves INPHARMA
scoring, while STD, trNOE and the docking scoring functions do not im-
prove. In the example presented, the multiplexed INPHARMA scoring found
the correct binding mode, while it failed with only one pair. To minimize
INPHARMA measurement time and optimize INPHARMA cross peak inte-
grals each ligand should then be measured only twice in one pair with the
ligand that binds slightly weaker and in the other pair with the ligand that
binds slightly stronger: (n-1). Hereby n is the number of ligand pairs. This










and is shown in Fig. 2.15. RMultiplexingSTI finds again the correct structures,
but INPHARMA picks structures as the best scoring ones, which are far away
in RMSD (more than 5 Å) from the correct structures. This observation un-
derlines, that RMultiplexingSTI is a very robust scoring factor, while RINPHARMA
can perform very well, but does not show the same level of robustness as
RMultiplexingSTI and depends strongly on the number of structure pairs that are
taken into account.
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Figure 2.14: RMultiplexingSTI plotted against the RMSD of all four ligand/PKA
structures compared to the crystal structures, the best structure according to
RMultiplexingSTI has a black circle. The best structures selected by the different
scoring are represented in blue (INPHARMA), green (STD), purple (trNOE) red
(ChemPLP) and yellow (GOLDScore). RMultiplexingSTI and INPHARMA find the
correct docking mode, i. e. the mode with the smallest RMSD to the average
crystal structure.
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Figure 2.15: RMultiplexingSTI plotted against the RMSD of all four ligand/PKA
structures compared to the crystal structures, the best structure according to
RMultiplexingSTI has a black circle. The best structures selected by the different
scoring are represented in blue (INPHARMA), green (STD), purple (trNOE) red
(ChemPLP) and yellow (GOLDScore). RMultiplexingSTI finds the correct docking
mode, i. e. the mode with the smallest RMSD to the average crystal structure.
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2.3.6 Molecular dynamics simulations and refinement
In the previous studies a rigid system was assumed and the docking mode in
the crystal structure is an average of what is seen in solution. This is a very
simple approximation but useful to derive the correct binding orientation of
the ligand without using too many structural models. The question is now
arising, if the best docking mode is really the most faithful? In solution the
protein is a dynamic system and the ligand will be subjected to strong forces,
moving it in the binding pocket and modulating its conformation. Therefore
investigations with molecular dynamics simulations using a given force field
without experimental restraints were done, starting with the docking model
of each ligand, respectively. MD studies were done on all ligands presented



































Figure 2.16: Ten docking modes of ligand 1 to PKA were sent to a molecular
dynamics simulation of 1 ns. Snapshots were taken every 10 ps. Indicated is the
change in RMSD to the crystal structure. While some binding modes remain stable
in the binding pocket, others show strong dynamics or even move out of the binding
site.
The Pearson correlation coefficient R was used to score the fitting between
the experimental and back-calculated INPHARMA, trNOE and STD data.
R was not squared to take into account, that small ligands only display a few
proton peaks, and the differentiation of a positive or negative correlation is
the valuable information, as it reflects directly the buried and exposed parts



























Docking structure index 
Figure 2.17: Averages of the trajectories shown in Fig. 2.16.
of the bound ligand in the case of STD. R can differentiate this very well,






In order to cover a larger conformational space, docking structures with
good RSTI values can be run in an unrestrained MD simulation. By tak-
ing snapshots of the resulting trajectories many new structures close to the
starting structure are generated. These can then be cross-validated against
the experimental data in order to find the best one, respectively. For this
purpose every structure obtained from a snapshot was again scored by RSTI .
In this case the application of a quality factor (equation 2.7) is appropriate,
because small changes in the geometry are balanced by the high number of
calculated structures. Hereby the Q-Factor is the most important selection
criterion. In Fig. 2.18 and Fig. 2.19 the refinement is done against STD,
trNOE and INPHARMA data independently. All refinement methods end
up in a structure pair very close to the crystal structure reference and dis-
play very good correlations between experimental and back-calculated peak
volumes.





























































Figure 2.18: The ligand pair 1 and 2 with the best RSTI score was run in an unre-
strained MD simulation for 1 ns and resulting snapshot structures (500 per ligand)
were rescored against STD, trNOE and INPHARMA peak volumes, respectively.
Correlation of the experimental and back-calculated peak volumes are shown.




























































Figure 2.19: The ligand pair 3 and 4 with the best RSTI score was run in an unre-
strained MD simulation for 1 ns and resulting snapshot structures (500 per ligand)
were rescored against STD, trNOE and INPHARMA peak volumes, respectively.
Correlation of the experimental and back-calculated peak volumes are shown.
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2.4 Results II - Application and testing
2.4.1 Ligands and conformational changes
In the preceding chapter the methodology was developed and successfully
yielded the correct binding mode of ligands to PKA. It has to be mentioned
that the ligands could be docked correctly into the protein crystal structure
by the docking program PLANTS, which is very favorable. It is very impor-
tant for docking that the side chains of the protein crystal structure have an
orientation that allows the ligand to adopt the correct binding mode during
the docking process. In other words, the correct binding mode can obviously
not be selected, if it is not found during docking. This represents one of the
largest issues in molecular docking: to dock a ligand correctly into the protein
binding site, the side chains must be in an adequate conformation. When
the quality of docking programs is evaluated, the procedure is often as fol-
lows: The ligand is taken out of the protein-ligand complex crystal structure
and then docked back into the empty binding pocket, e.g. done in [Meiler
and Baker, 2006,Cross et al., 2009]. Around 80% of ligands can be docked
correctly this way with standard docking programs like GOLD [Korb et al.,
2009b]. Yet, this hit rate would be much lower, if the side chains would not
be in the adequate conformation. Approaches of using flexible side chains
or backbone motions via molecular dynamics simulations within the docking
process are normally very time consuming and it is not guaranteed, that the
correct solution will be found. In the following, the developed methodology
of NMR-based protein-ligand complex structure determination is applied to
three advanced binding modes, meaning that the correct binding mode is
more difficult to be found, as for example a conformational change of a side
chain is necessary.
2.4.2 Advanced binding mode I - Biased crystal struc-
ture
Ligand e (Fig. 2.21) is a small fragment termed chlor-indazole and binds
PKA with a very low affinity (Kd = 1.2 mM) and the binding mode could
not be derived from the crystal structure reliably. Even though the crystal
structure was obtained, two possible binding modes were found and these
could not be further distinguished. These two crystal structures are shown
in Fig. 2.20. Both make a hydrogen bond with the NH of Val123, but they
are flipped by 180◦ relative to each other. Now that the methodology was
established in the previous chapter, the ligand e was again investigated, using
INPHARMA and STD data.
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Ligand e crystal structure 1
Ligand e crystal structure 2
Figure 2.20: The two different crystal structures that were obtained for ligand e.





















Figure 2.21: Experimental STD data of PKA binding ligand e. The normal 1D
in the presence of 0.03 mM PKA is shown in black, and the STD spectrum in
blue (enlarged by a factor of 4). Ligand concentration was 1.2 mM. Saturation
was applied for 8 s on 0.5 ppm on a 400 MHz spectrometer (number of scans = 8;
temperature = 298 K; time domain = 16384 points).
An STD of ligand e with PKA was recorded as shown in Fig. 2.21. Due
to the low affinity, the difference spectrum only showed very low differences
between the peak volumes, when the binding epitope was derived, but they
were measurable.
The INPHARMA NOESY was recorded together with ligand 3, as this ligand
pairs did not show overlaps in the aromatic region. RSTI was calculated for
ten docking models of ligand e, including the two crystal structures and is
shown in Fig. 2.22. One structure is clearly favored with an RSTI of 0.73
and represents crystal structure 1. Crystal structure 2 received an RSTI of
only 0.42. Therefore it is concluded that crystal structure 1 is the favored
binding mode of ligand e in solution.
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Figure 2.22: RSTI plotted against the RMSD of the two ligand/PKA structures
compared to the crystal structures (in the case of ligand e crystal structure 1 is
shown), the best structure according to RSTI has a black circle.
2.4.3 Advanced binding mode II - Backpocket penetra-
tion
It was described in section 2.1.2 that the ATP binding site of PKA hosts
a backpocket, which is guarded by the gatekeeper residue Met120. Most ki-
nases display a similar motive, that a backpocket is blocked by a gatekeeper
residue. The ATP binding site of kinases is not very specific and therefore it
is crucial for the medicinal chemist to develop drugs, that are specific for the
ATP-binding site of the targeted kinase. For this purpose the penetration of
a ligand into the backpocket can highly improve selectivity. As was described
before, the kinase inhibitor staurosporine occupies both backpockets of PKA.
At this stage, the developed NMR method can only deal with ligands that
bind to the PKA structure with a closed backpocket. To get the correct
binding mode of a backpocket penetrating ligand, the gatekeeper residue has
to change its conformation. How can this be realized for the NMR method?
In the following, it will be shown that the methodology can actually already
handle this issue. Therefore ligand B5 was chosen, where it is known from
the crystal structure, that a penetration into the backpocket takes place, a
2.4. RESULTS II - APPLICATION AND TESTING 63



































Figure 2.23: Experimental STD data of PKA binding ligand B5. The normal 1D in
the presence of 0.03 mM PKA is shown in black, the difference spectrum between
1D and STD in blue. Ligand concentration was 0.5 mM. Saturation was applied
for 8 s on 0.5 ppm on a 400 MHz spectrometer (number of scans = 8; temperature
= 298 K; time domain = 16384 points). The VMax.STD value is 30.97.
In the first place, an STD spectrum was recorded, as seen in Fig. 2.23. Vi-
sual inspection already gives a clear proposal: Protons H1-H4 will be buried
in the protein, while the sugar group is exposed to the solvent. The ligand
recalls partially to ligand 1, yet the binding mode seems to be different, as
the protons H6 and H7 receive unexpected strong magnetization in compar-
ison to protons H5 and H8.
Second, an INPHARMA NOESY was recorded. Ligand 3 was chosen as the
competitive ligand, as there were least overlaps in the 1D spectrum with this
ligand in comparison to others. Visual inspection of the spectrum (shown
in the appendix) confirms the STD observations: The protein buried methyl
group of ligand 3 is very close to protons H1-H4, but far from the sugar group
and the other protons of ligand B5. 10 docking modes of ligand B5 were cre-
ated and STD, trNOE and INPHARMA were back-calculated for all docking
modes. The result can be seen in Fig. 2.24: Two docking modes, very close
in RMSD, score better than the other structure pairs. If it is assumed that
the correct binding mode of ligand 3 is already known, the selection gets even
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Figure 2.24: The 100 pairwise combinations of ligand B5 (black) and ligand 3
(red) scored against RSTI on the left side. On the right side only the pairs with
the correct structure of ligand 3 are shown. Therefore only the RMSD of ligand







Figure 2.25: Best docking model of ligand B5 by RSTI in black and the crystal
structure in red. The gatekeeper residue Met120 normally closes the backpocket in
PKA. But for ligand B5 in the bound state, the backpocket is open as seen in the
crystal structure.
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Crystal structure
Best MD structureGatekeeper Met120
Backpocket open
Backpocket open
Figure 2.26: Best MD structure of ligand B5 by RSTI in green and the crystal
structure in red. The gatekeeper residue Met120 is in the open position in both
structures.
If the obtained binding mode is inspected and compared with the crystal
structure (Fig. 2.25), it can be seen that they are very close in RMSD. Yet,
the backpocket can not be entered, as the gatekeeper residue Met120 is in the
closed and not in the open conformation. Therefore it would not be noticed,
that this ligand penetrates into the backpocket and has the potential to be
optimized to a highly specific binder.
Now the obtained ligand binding mode was run in an unrestrained MD sim-
ulation for 1 ns, as was done in the MD refinement described above. In-
deed, during the MD simulation the gatekeeper immediately opens (Fig.
2.27) and ligand B5 penetrates into the backpocket. And most interestingly,
these structures with the backpocket penetration score (best RINPHARMA :
0.94) better than the initial docking model with the closed backpocket (best
RINPHARMA : 0.86. The structure with the best score is shown in Fig. 2.26.
The RMSD is only slightly closer to the crystal structure in comparison to
the best docking mode but the interesting observation, the backpocket pen-
etration, is obtained.




























Figure 2.27: RMSD of the gatekeeper residue Met120 during an MD simulation of
1 ns with bound ligand B5. The gatekeeper immediately opens, as can be seen by
the large RMSD change in the first step. Around 280 ps the gatekeeper closes, but
most of the time it is forced to the open position by ligand B5. A general trend
is observable, that the gatekeeper keeps on opening. Still, it can be assumed that
the gatekeeper would not move away further in a simulation that last longer than
1 ns.
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2.4.4 Advanced binding mode III - Docking failure
The third example presents ligand B3 and treats two problems that occur
within the docking process of this ligand, when compared with the crystal
structure of the complex PKA:B3: i) the ligand has two rotatable bonds
which are not correctly rotated (wrong by 180◦) and ii) a side chain (Asp184)
blocks the correct orientation of the solvent exposed part of the ligand. In
the first place, an STD spectrum was recorded, as seen in Fig. 2.28. The
binding epitope of the ligand could be clearly identified. Protons H1 and H2
are buried in the protein, while the methyl group is exposed to the solvent.
Strong differences in intensities between protons H1 and H3, as well as H4
and H5, indicate that the binding mode is not balanced in the middle of the
binding pocket, but protons H1 and H4 are closer to the protein side than
the others.





























Figure 2.28: Experimental STD data of PKA binding ligand B3. The normal 1D
in the presence of 0.045 mM PKA is shown in black and the STD spectrum in blue.
Ligand concentration was 1 mM. Saturation was applied for 8 s on 0.5 ppm on a
400 MHz spectrometer (number of scans = 8; temperature = 298 K; time domain
= 16384 points). The VMax.STD value is 15.71.
In comparison to the other PKA ligands, B3 has torsion angles from which
the bound conformation can be characterized by trNOE. A trNOE spectrum
was recorded as seen in Fig. 2.29. The spectrum clearly indicates that the
protons i) H1 and H4, ii) H3 and H5, iii) H5 and the methyl group, are close
in space in the bound conformation. A NOESY spectrum of ligand B3 in
solution without PKA (not shown) confirms that the two bonds freely rotate
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Figure 2.29: NOESY spectrum of ligand B3 (1 mM) in the presence of PKA (0.045
mM). The bound conformation of B3 can be derived from trNOE. The mixing
time was 800 ms on a 700 MHz spectrometer, equipped with a cryogenically cooled
probe head. The spectrum was recorded at 293 K with 64 scans, 2048 points in F2
and 388 points in F1.
10 docking modes of B3 in PKA were created and visually inspected.
Surprisingly, non of the docked structures displayed the bound conformation
known from trNOE. This indicates that trNOE have to be applied whenever
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Figure 2.30: The 100 pairwise combinations of ligand B3 and ligand 2 scored against
RSTI . The identified structure pair is close, but not the closest selection to the
crystal structure. It should be noticed that none of the structure pairs correctly
reproduced the binding orientation of the crystal structure.
possible. Now two solutions are on hand: i) using a rigid docking with the
correct conformation of ligand B3 or ii) restrain the torsion angles during
docking. The first approach is not the ideal solution, because the trNOE
gives a good estimation, but not an exact description of the torsion angle.
And a small distinction from the correct angle might have a negative influence
on the docking, as the ligand might not fit with the restrained conformation.
The second approach gives the docking program a range in which the distance
between two protons has to be placed. The distances between the protons
close in space, as interpreted based on the trNOE spectrum shown in Fig.
2.29, were restraint to the following ranges: H1-H4: 1-3 Å, H3-H5: 1-3 Å,
and H5-CH3: 1-5 Å. These distances were chosen, as a rotation of the torsion
angle around 180◦ from the expected conformation resulted in a distance
larger than 3 Å or 5 Å, respectively. It has to be mentioned here, that
PLANTS is the only docking program at the moment that allows such a
distance restraint. This approach turned out to be successful, as most of the






Figure 2.31: Best docking model of ligand B3 by RSTI in black and the crystal
structure in red. Ligand orientation and torsion angles are correct, but the solvent
exposed part of the ligand does not well reproduce the crystal structure. It can
be seen that the residue Asp184 is rotated in the crystal structure and allows the
ligand to adopt a binding mode which is restricted in the rigid protein structure
that is used during the docking
docked structures now display the correct bound conformation.
Finally an INPHARMA NOESY was recorded with ligand 2 as the competing
ligand. The spectrum is shown in the appendix and displays more than 12
INPHARMA peaks. These were back-calculated for all 10 docking models
and the result of RSTI is shown in Fig. 2.30. One structure pair is favored
over the others and shown in Fig. 2.31, together with the crystal structure
of B3. It can be seen that the torsion angles and the orientation of the
ligand are correct. Yet, the structure is 3.49 Å RMSD away from the crystal
structure. The problem hereby is, that the methyl-group bearing ring of
ligand B3 can not rotate into its correct position, because it is hindered by
the conformation of side chain Asp184. It can be seen in the crystal structure,
that such a conformational change has to take place to allow the ligand to
adopt the correct binding mode. A refinement of the docking structure with
MD was applied, but the side chain did only slightly rotate. The RMSD to
the crystal structure is now 3.02 Å for the best scoring MD structure, and
the RSTI improved from 0.54 to 0.74.
An alternative approach is presented in the following, which exploits the
information of trNOE first and will therefore be termed TSI instead of STI.
Following the argument that this ligand displays very informative trNOE
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data, which were necessary to get the torsion angles right during the docking
process, these data should be used as a first selection criterion. As can be
seen in Fig. 2.32, the docking structure with index 8 clearly has the best
trNOE correlation. It also scores very good for STD. For the ligand 2, it
is already known from the previous chapter, that only one binding mode
has a convincing STD correlation. When the INPHARMA correlation of
structure 8 with the correct binding mode of ligand 2 is investigated, the
score is only 0.19. On the other hand, structures with better INPHARMA
scores display very bad STD or trNOE scores. When structure 8 was run
in an unrestrained MD simulation for 1 ns, the residue Asp184 immediately
changed its conformation and ligand B3 was allowed to adopt the correct
orientation as can be seen in Fig. 2.33. The best scoring binding mode



























Figure 2.32: Selection of the binding mode starting by trNOE and STD (TSI
guided): From the ten docking structures (1-10), structure 8 clearly has the best
trNOE correlation (circled red) and the second best STD score as seen below.
This optimization is very impressive when one takes into account that the
RSTI was only 0.29 in the starting structure. With the original procedure
STI applied, a structure of 3.02 Å RMSD to the crystal structure would have





Figure 2.33: Best MD structure of ligand B3 by RTSI in green and the crystal
structure in red. The residue Asp184 opens during the MD simulations and gives
way for the correct binding mode, which score significantly higher than the original
docking structure.
been selected. But with the second approach TSI, the selected structure had
an RMSD of only 1.12 Å after optimization. It has to be concluded, that
the correct binding mode can not always be found in a linear manner, but
sometimes different approaches have to be tested and compared. For the
presented case, the trNOE data were essential. The docking program would
have failed in the first step, and the NMR-based ligand binding mode deter-
mination method would have failed in the second step without trNOE data.
This issue underlines again the importance of taking all available data into
account and scale them in comparison to each other, if necessary. The con-
clusion is, that a ligand with torsion angles can be guided by trNOE during
the docking and the trNOE should be scored first to take only structures into
account, that fulfill the trNOE restraints. In the case of a ligand with several
torsion angles, it is therefore advisable to apply the methodology STI devel-
oped in the previous chapters and the TSI method of the present chapter and
then compare the scores. In the present case of B3, the structure obtained
by the TSI guided method led to a better score (RSTI : 0.85; RMSD: 1.12 Å)
than the STI guided method (RSTI : 0.74; RMSD: 3.02 Å).
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2.5 Discussion & Conclusion
Summary
A methodology was developed to find the correct ligand binding mode out
of many diverse docking models by the application of fast obtainable exper-
imental NMR data. A flowchart of the methodology, termed NMR-based
ligand binding mode determination, can be seen in Fig. 2.34.
EM and MD refinement
Protein structure
Back-calculation







Figure 2.34: The flowchart gives an overview of the NMR-based binding mode
determination methodology. Starting with a crystal structure or homology model
docking models are created. INPHARMA, trNOE and STD peak volumes for
every docking model are back-calculated. Then the back-calculated volumes are
correlated with the experimental NMR data and the best scoring model is chosen.
In the case of a ligand with many torsion angles, it is advisable to do the TSI
methodology in parallel.
INPHARMA was shown to be very useful for the relative binding mode
determination, yet it lacked efficiency in the determination of the absolute
binding mode. TrNOE is very useful for the bound conformation, but per-
forms not very well, when applied to find the absolute binding mode by
including the protein environment. Finally STD finds very efficiently the
protein buried and solvent exposed part of the ligand, but this information is
often not sufficient to find the absolute binding mode. The main point of this
thesis is, that the combination of all three methods results in a powerful tool
to decipher the correct binding mode. Additionally, the multiplexing of many
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ligands strongly improves INPHARMA and therefore the overall correlation
approach. Even for difficult docking cases, where conformations of amino
acids have to change to enable the correct binding mode, the method can be
successfully applied. Furthermore the refinement with molecular dynamics
simulations was found to be an optimal tool. The amount of structures that
have to be calculated for the MD approach is high, therefore the software
SpINPHARMA is speed-optimized to fit this purpose. The Pearson corre-
lation coefficient R is used in a first stage, where the correct binding mode
has to be found out of diverse docking structures. In a second step a ge-
ometry optimization can be done using energy minimization and molecular
dynamic simulations, which is then scored together by R and a quality factor
Q, which is more sensitive to small changes in the geometry. In the following
some issues are critically discussed, which may lead to difficulties or even
wrong results. Afterwards an outlook is given.
Consideration of the experimental error
For the INPHARMA peaks, random areas of the background within the
NOESY spectrum were integrated and an S/N ratio of 10 was found. There-
fore the error is estimated to be between 10 % and 20 %. For the intraligand
(trNOE) peaks 5% were estimated and for the diagonal peak volumes 2%.
For the STD spectra the same was done and results in a similar error esti-
mation between 10% and 20%. The intraligand peaks have the lowest error,
but also contain the least information, especially with rigid small molecules.
Therefore it is justified to apply a 1:1:1 weighting, when the three parameters
are combined. If the spectra of either the INPHARMA NOESY or STD have
a low S/N ratio (e.g. 5), it is probably advisable to use another weighting
scheme and to put more weight on the parameter with the best S/N ratio.
Yet, this approach was not applied within this thesis.
Hidden binding site for INPHARMA
RSTD, RtrNOE and RINPHARMA are combined to RSTI as described in the
equation 2.3 with a simple average. Yet, STD has different requirements to
off-rates than INPHARMA. Indeed, STD requires only one off-event during
the saturation lasting several seconds, while INPHARMA requiring at least
two off-events in the mixing time of a few 100 ms. When STD is recorded,
the Kd values of the ligands can be estimated. Given that the Kd value of a
ligand is lower than 10 µM and still shows INPHARMA signals, it is advis-
able to be careful that INPHARMA and STD really emerge from the same
binding site. One can imagine that the STD signals show a strong ligand
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binding event and the INPHARMA signals a weaker binding event to an-
other binding site, for example the protein glycogen phosphorylase has four
different ligand binding sites. However, no such effect was observed so far.
To make sure that an effect of a strong binding site for STD does not occur,
we recommend to determine the Kd values of every ligand. This can be done
with STD if a reference ligand exists. A reference ligand has a known Kd
value and can be removed from the binding site by titration with another
ligand. If no reference ligand is available, other biophysical methods like
isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR)
could be used. Given that there are ligands with a binding affinity below 10
µM, it can be assumed that they are strong binders and potentially invisible
to INPHARMA. One option to handle ligands with binding affinities below
10 µM is to titrate them with weaker binding ligands (typically in the 100-
1000 µM range) during an STD experiment. When the signal intensity of
the ligand goes down, it binds the same binding pocket as the weaker binder
and the INPHARMA signal can be trusted.
Unspecific binding
It is not uncommon that i) different binding modes of one ligand exist, ii)
unspecific binding of the ligand to the surface or subpockets of the protein
occurs or iii) long channels on the way to the binding pocket are present,
where the ligand has to go through. All of these issues contribute to the NMR
signal, additionally to the time that the ligand resides at the principal binding
site. STD and trNOE signals are especially affected by the contribution of
unspecific surface and subpocket binding or long channel pathways. The
same holds true for INPHARMA, even tough one could imagine that hereby
the unspecific contribution is lower, as both ligands would have to reside at
the same unspecific binding site for a certain time and this would then rather
be the case for subpockets and channels, than for diffusion controlled surface
binding events. Such unspecific binding effects are yet not characterized well
enough. An STD study was done on human serum albumin (HSA) with L-
tryptophan as the ligand, while the principal binding site was blocked by the
very strong binder naxopren. The result was a strong remaining STD signal
for the ligand, caused by unspecific binding [Ji et al., 2008]. This approach
is very interesting and could also be applied to INPHARMA. Therefore the
binding pocket of PKA could be blocked by staurosporine, and two other
PKA binding ligands could be measured for their unspecific INPHARMA
signals. On the other hand, it is not clear if the remaining STD signals are
really unspecific binding, or if the strong binder does indeed block all binding
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events to the specific binding pocket.
Aggregation of the protein
If one takes a closer look on the molecular weights of the systems used for IN-
PHARMA so far: i) PKA (40 kDa plus dimer- and tetramerization), GPR40
(30 kDa plus membrane fragment), tubulin (50 kDa plus aggregate forma-
tion) and iv) glycogen phosphorylase (100 kDa plus dimerization), it is clear
that they are very large molecules with a very efficient magnetization transfer.
In the case of PKA, it was observed that the signal-to-noise ratio strongly
increases, if no anti-aggregation agent is added to the sample. When the
protein aggregates, the complexes become very huge and the magnetization
transfer most efficient. The quality of the correlation between experimental
data and back-calculated data will also strongly increase (Luca Codutti and
Steffen Grimm, oral communication). Nevertheless, in the presented study,
there was always TCEP as an anti-aggregation agent added. The logic be-
hind this is, that the sample is stable for weeks instead of days and that
possible changes in the binding pocket, that could putatively occur during
the aggregation process, can be neglected. Also the aim of this study is the
monomeric PKA and not an aggregated state.
Outlook
Following studies should be done on soluble proteins like other kinases or
phosphatases, where the crystal structure is known, to undertake a proof-
of-concept study and further develop the methodology and the MD refine-
ment strategy. The methodology could also be used on whole cells to better
simulate the physiological environment. It is also imaginable to use even
more NMR parameters in a more elaborate strategy, namely chemical shift
changes upon ligand binding. These could be back-calculated in the case of
very strong binders and in the case of weak binders, it would be possible to
back-calculate the chemical shifts of the protein signals, that change upon
ligand binding in an HSQC spectrum. Such an approach is currently in the
focus of a group in Lyon. But these approaches would then require labeling
of the ligand in the strong binding scenario and labeling of the protein in
the weak binding scenario, which is time consuming and not always possible.
Still, these approaches are much faster than the classical NMR approach of a
full assignment of the protein signals and the following structure calculation
of the protein-ligand complex.
Chapter 3
G-protein coupled receptor 40
3.1 Introduction
3.1.1 G-protein coupled receptors
G-protein coupled receptors (GPCRs) are the largest family of membrane
proteins. GPCRs play the most important role in hormone and neurotrans-
mitter response, followed by ion channels. Therefore GPCRs are responsible
for signal transduction inside the whole organism, control of nerves, muscles
and senses like vision, olfaction and taste. Within the neurotransmitter re-
sponse for example, up and down regulation of body functions is controlled
by i) the adrenergic receptor controlled (via adrenaline) sympathtic and ii)
the muscarinic receptor controlled (via acetylcholine) parasympathic system.
Both receptor families comprise different GPCR subtypes.
The human genome contains around 800 GPCRs which can be further di-
vided in five classes, with the rhodopsin-like family being by far the largest
with 670 members. All GPCRs share the common motif of seven α-helices
that wind through the membrane and face the extracellular space with a
ligand binding site. The ligand binding site is buried deep in the GPCR’s
hydrophobic pocket and the intracellular facing site of the GPCR binds a
specific heterotrimeric G-protein. Generally the mechanisms of a GPCR
can be demonstrated with the β2-adrenergic receptor: adrenaline (or nora-
drenaline) binds to the GPCR ligand binding site and activates the release
of Gα-protein. This stimulates adenylate cyclase, turning then AMP into
cAMP. Increase of cAMP will in turn activate cAMP-dependent protein ki-
nase A (PKA) to phosphorylate proteins involved in cell-specific modes of
action, e.g. muscle-cell contraction [Rosenbaum et al., 2009]. Yet the sig-
naling behavior of GPCRs can be much more complex, as seen in Fig. 3.1,
where the β2-adrenergic receptor can also trigger another pathway, when the
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G-protein binding site is phosphorylated. A molecule which binds and acti-
vates the GPCR is termed agonist, while a molecule that binds, but does not
activate the GPCR is called antagonist. It is observed that GPCRs tend to
have certain noise levels, where they are signaling without being activated.
This behavior can be turned off by an inverse agonist, a molecule that binds


































































Figure 3.1: Schematic presentation of the complex signaling pathway of the β2-
adrenergic receptor GPCR [Rosenbaum et al., 2009].
Groundbreaking work in the field of GPCR research was done by Robert
Lefkowitz and Brian Kobilka and was rewarded with the Nobel price in chem-
istry 2012. The first being responsible for major achievements in the under-
standing of the signaling pathways and the latter for the structure determina-
tion, especially of the β2-adrenergic receptor. Detailed understanding of the
GPCR signaling mechanism on an atomic level was obtained with the crystal
structure of rhodopsin [Palczewski et al., 2000]. Retinal is bound to opsin and
the absorption of light changes its configuration, activating a signal pathway
that finally leads to vision. It could be understood that the configuration
change activates a tryptophan conformation change, the so called rotamer
toggle switch, leading to a global conformational change of the GPCR that
results in the release of G-protein [Hofmann et al., 2009].
The crystal structure of the β2-adrenergic receptor [Rasmussen et al., 2007]
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with the bound inverse agonist carazolol was of high interest, as the substrate
of this receptor are neurotransmitters and therefore more relevant for drug
discovery than rhodopsin. The conclusion is, that the binding of an agonist
leads to the activation of the rotamer toggle switch as in rhodopsin and the
separation of the transmembrane helices TM3 and TM6. The ionic lock be-
tween ECL2 and ECl3 will break during the movement of TM6 [Audet and
Bouvier, 2008]. It seems that the ionic lock can break even in the absence
of an agonist. This does not happen when the inverse agonist binds, so it is
thought that the inverse agonist stabilizes TM6 and therefore the ionic lock.
G-protein coupled receptors are membrane proteins and very difficult to crys-
tallize due to the lack of exposed polar surfaces, a generally low expression
level and poor thermal stability. In pharmaceutical industry they are often
represented by homology models [Hillisch et al., 2004]. The seven transmem-
brane helices are a conserved motif and can easily be modeled, even though
the sequence similarity between different GPCRs is often only around 10%.
More problematic for example is the extracellular loop 2 (ECL2), which can
occur in very different conformations (Fig. 3.2) and works like a lid over
the binding pocket. It was even proposed that in some cases the results
of GPCR homology modeling would be better, if the ECL2 loop is excluded
from the structure [Costanzi, 2008]. For a long time the only available crystal
structure and therefore a template for homology modeling was rhodopsin.
Figure 3.2: Homology model of the β-adrenergic receptor with bound ligand and
coupled G-protein. It is noteworthy that the extracellular loop 2 has the form of a
helix.
Nowadays the technique of GPCR crystallization improved substantially
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and more crystal structures become available, e.g. recently the M2 muscarinic
receptor [Haga et al., 2012] bound to a ligand. Even the ligand free form of
a GPCR was now found for the GPCR opsin, without bound retinal [Park
et al., 2008]. Such models can be a very useful starting point for drug discov-
ery with the virtual screening approach. Yet, in a virtual screening approach
for the β2-adrenergic receptor several strong binders were identified, but most
of them turned out to be inverse agonists [Kolb et al., 2009]. This indicates
that stabilizers of the inactive, ligand bound form of the GPCR were identi-
fied. The conclusion would be, that it is also very useful to obtain the active,
ligand free form of a GPCR, in order to develop agonists instead of inverse
agonists or antagonists. It depends on the desired result, if a GPCR should
be up- or down-regulated, i.e. if an agonist or an antagonist has to be found.
Next to the described orthosteric ligand that binds at the binding pocket,
there are allosteric ligands that do not bind at the binding site, but still trig-
ger a reaction on the GPCR. Recently it was possible to design a dualsteric
ligand, that combined both properties [Mohr et al., 2013]. The application
of other methods such as NMR spectroscopy to understand the complex dy-
namics of the highly flexible GPCR molecules and the binding of ligands to
the same are very promising. Hereby, not the whole structure is in the focus,
but smaller areas of specific interest are investigated. It was demonstrated
that the dynamics of the ionic lock of the β2-adrenergic receptor could be
accurately described for an agonist, an antagonist and an inverse agonist
using NMR spectroscopy [Bokoch et al., 2010] in conjunction with solved
X-ray structures. The action of these different ligands on the ionic lock and
therefore on the extracellular surface of the GPCR could not be seen in the
corresponding crystal structure of the GPCR. After successful labeling, the
dynamics of the rhodopsin C-terminus were investigated [Werner et al., 2008].
Furthermore it was possible with NMR to reveal the bound conformation of
the peptides PACAP [Inooka et al., 2001] and neurotensin [Luca et al., 2003]
in its specific GPCR. Drug design for GPCRs is a challenge that takes into
account all available information of the few existing crystal structures, homol-
ogy models, ligand-based pharmacophore search and libraries with privileged
GPCR binding building blocks. Nearly 50% of recently launched drugs tar-
get GPCRs, making them the most important drug target and also the most
beneficial one, with around 30 billion $ sales in 2001 [Klabunde and Hessler,
2002].
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3.1.2 GPR40: Homology models and proposed ligand
binding modes
The G-protein coupled receptor 40 (GPR40), also known as the free fatty
acid receptor 1 (FFAR1), is an interesting drug target in diabetes research.
For a long time it was an orphan receptor, which natural binder and function
was unknown. This suddenly changed in 2003, when it was found that long-
chain fatty acids, especially linoleic acid, bind to GPR40 and activate a signal
cascade, taking part in the regulating of insulin secretion [Itoh et al., 2003].
GPR40 is preferentially expressed by the gene FFAR1 in the β-cells in the
pancreas. Activation of GPR40 by fatty acids induces a signaling pathway
which leads to a higher Ca2+ concentration in the cells. This ultimately
stimulates the release of insulin from the β-cells, a mechanism which does
not work properly in type 2 diabetes patients.
Today several pharmaceutical companies are developing drugs as GPR40
agonists. At the time this thesis is written, Takeda has a compound [Negoro
et al., 2010] in phase III of clinical trials and other companies have presented
interesting candidates, e.g. Amgen [Lin et al., 2011] or Merck [Zhou et al.,
2010]. Yet, these compounds were identified during high-throughput screen-
ing and chemically optimized on a trial-and-error base, as there is no crystal
structure of GPR40 available.
A homology model for GPR40 based on rhodopsin (Fig. 3.3) was made by
the Costanzi group [Tikhonova et al., 2007]. The group is very experienced
in the modeling of G-protein coupled receptors. In the GPCR dock contest
2008, which takes place every two years, the group submitted a homology
model of the adenosine receptor A2A with the bound ligand ZM241385 and
reached the closest RMSD to the newly obtained crystal structure [Michino
et al., 2009].
The binding of ligand GW9508 to GPR40 was investigated in detail by
docking to the homology model and experimental SAR data by amino acid
exchange [Sum et al., 2007]. In Fig. 3.3 the SAR supported binding mode
of GW9508 to GPR40 is seen in detail. The carboxylic moiety is anchored
between Arg183, Arg258 and Asn244. The hydrophobic tail is placed in the
hydrophobic pocket, the linker stabilized by His86 and the last aromatic ring
of GW9508 is stabilized by an NH-π interaction with His137.
This homology model turned out to be very useful and was applied as a
basis for docking studies [Lu et al., 2010], QM/MM studies [Lu et al., 2011]
and to successful virtual screening [Tikhonova et al., 2008] for new binders.
Another homology model was made based on the β-adrenergic receptor,
that displayed similar binding modes of ligand GW9508 and linoleic acid as
for the previous homology model. Yet, the new model seemed to describe















Figure 3.3: Homology model of GPR40 with bound ligand GW9508 in a detailed
view. The binding mode reproduced best the site-directed mutagenesis data, a
hydrogen bonding between the carboxylic group and the arginine residues, as well
as a stabilizing contact to His137 [Tikhonova et al., 2007,Sum et al., 2009].
the structure of the ECL2 loop more accurately and a mechanism for the
activation of GPR40 could be proposed [Sum et al., 2009]. An ionic lock
between two arginine (Arg183 and Arg258) and two glutamic acid (Glu145 and
Glu172) residues is proposed to be released by linoleic acid binding to the
arginines with its carboxylic group, while the hydrophobic tail is stabilized
in the hydrophobic pocket. This mechanism explains well the SAR data,
that the two arginines are crucial for binding and every ligand that binds to
GPR40 has a carboxylic moiety or at least a comparable chemical structure.
The most interesting GPR40 binding ligand at the moment is TAK-875
from Takeda, which reached phase III of clinical trials and binds with an
EC50 of 50 nM. A binding mode was proposed by Takeda [Negoro et al.,
2010] by docking of TAK-875 to an internal homology model. The anchoring
of the carboxylic moiety of TAK-875 to the arginines is in common with the
GW9508 model, but the rest of the ligand does not enter the hydrophobic
pocket and the sulfate group forms a hydrogen bond to Lys259. There is no
amino acid exchange data to prove this interaction, and it has to be said
that the homology model was done without the ECL2 loop, resulting in an
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Figure 3.4: Homology model of GPR40 with ligand TAK-875 docked to the binding
site. Proposed is a hydrogen bonding between the carboxylic group of TAK-875
to the arginine residues and between the sulfate group and Lys259 [Negoro et al.,
2010].
unrealistic representation of GPR40.
Figure 3.5: Homology model of GPR40 with compound 37 manually docked to the
binding site. Proposed is a hydrogen bond to the arginine residues and a stabilizing
contact between the nitrogen of ligand 37 and His86 [Christiansen et al., 2011].
A third binding mode was proposed for compound 37 by [Christiansen
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et al., 2011] to an internal homology model (Fig. 3.5). This model again
shares the anchoring of the head group to the arginines, but makes the sta-
bilizing contact to His86. The ligand was docked manually, as there is no
homology model available with a binding site that allows a docking pose
to this amino acid. This assumption is realistic, as the ligand is very rigid,














Figure 3.6: Alignment of ligands 5 and 6 based on INPHARMA signals (simplified
for clarity) observed between the indicated regions. From the four proposals by
Catalyst, only one fits the experimental data.
In 2010, it was shown that a simple GPR40 sample in solution can be pro-
duced by the lysation of cells that over-express GPR40. The buffer solution
contains membranes including GPR40 and is amenable for NMR studies. It
could be shown that EC50 values could be accurately reproduced with STD
experiments and that INPHARMA peaks between two competing ligands
are observable. Using the NMR data it was possible to align the ligands in
a realistic manner and choose between different proposals, obtained by the
alignment program Catalyst (Fig 3.6) [Bartoschek et al., 2010].
3.2 Materials & Methods
3.2.1 Sample preparation
GPR40 was overexpressed by the pharmaceutical company Sanofi as de-
scribed [Bartoschek et al., 2010]. Before sample preparation the membranes
were thawed and dialyzed with D2O buffer containing DSS as an internal
reference, deuterated Tris buffer and deuterated EDTA. Sample preparation
was done in Shigemi tubes with a total volume of 250 µM.
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3.2.2 NMR spectroscopy
INPHARMA spectra were recorded using the standard NOESY pulse pro-
gram noesyphpr. Ligand combinations 5&6 and 5&7 were recorded on a 700
MHz spectrometer, equipped with a cryogenically cooled probe head (Bruker,
Karlsruhe). STD spectra were recorded with a standard pulse sequence (std-
diffesgp.2) with 16 scans on a 400 MHz spectrometer Saturation was achieved
by a train of shaped 90◦ pulses of 50 ms length. A number of 160 selective
pulses was applied, leading to a total length of saturation of 8 s. The on-
resonance irradiation was performed at -2 ppm and off-resonance irradiation
was set to +30 ppm.
3.2.3 Docking and alignment
10 binding modes per ligand were created in the homology model of GPR40
[Tikhonova et al., 2007] using the docking software PLANTS [Korb et al.,
2006]. The ligands were kept flexible and the protein rigid. Three-dimensional
structures of the ligands were created using CORINA [Sadowski and Gasteiger,
1994].
3.2.4 Energy minimization and molecular dynamic sim-
ulations
Energy minimization and molecular dynamic simulations were done as imple-
mented in Gromacs [Hess et al., 2008], using the amber99sb force field [Hor-
nak et al., 2006] for the protein and the General Amber Force Field [Wang
et al., 2004] for the ligand. EM was done with conjugate gradient integra-
tor in 1000 steps. MD was done using steepest descent integrator with a
stepsize of 2 fs. Simulations were done for 1 ns for every docking mode re-
spectively in implicit solvent, using the Generalized Born model augmented
with the hydrophobic solvent accessible Surface Area (GBSA). From every
trajectory 100 snapshots were saved and the RMSD to the starting structure
was calculated.
3.2.5 Back-calculation of peak volumes
All INPHARMA, trNOE and STD peak volumes were back-calculated with
the software SpINPHARMA, using the complete-relaxation matrix approach
[London, 1999,Orts et al., 2009]. Methyl-groups were described using a 3-site
jump model [Tropp, 1980]. STD saturation was applied to all methyl groups.
Protons within a distance of 8 Å from any ligand proton were considered.
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The correlation time was estimated to be 100 ns. Kd values were determined
by STD competition experiments (L5: 340 nM, L6: 160 nM). On-rates (kon)
were assumed to be in the diffusion limit 108 M−1s−1.
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3.3 Results
3.3.1 Docking, STD and INPHARMA Ligands 5 and 6
The ligands 5 and 6 (Fig. 3.7) were identified from high-throughput screen-
ing by Sanofi and an alignment based on experimental NMR data, i.e. the
relative binding mode, is known. To get the absolute binding mode, dock-
ing models were created in the public, SAR data supported homology model
of GPR40 [Tikhonova et al., 2007]. 10 binding modes per ligand were ob-
tained and manually investigated. As seen in Figs. 3.8 and 3.9, these binding
modes are diverse and display different orientations in the binding pocket.
The docking modes obtain good ChemPLP scores, indicating that they fit
well to the binding site. In Fig. 3.10, the docking modes of ligand 5 are shown
together with the SAR-supported ligand GW9508, indicating that the ligand
fits well the binding site and the best scoring docking mode is very close to













Figure 3.7: Ligands 5 (EC50 = 340 nM) and 6 (EC50 = 280 nM) identified during
high-throughput screening by Sanofi.
Extensive INPHARMA NOESY measurements were done with the ligand
pair 5 and 6 [Bartoschek et al., 2010] and used as a basis for the experimen-
tal data. For every docking model obtained the STD peak volumes were
back-calculated, as well as for every pair of docking models the trNOE and
INPHARMA peak volumes. The correlation coefficients R between experi-
mental and back-calculated peak volumes of STD, trNOE and INPHARMA
were combined to RSTI . The best scoring model is shown in Fig. 3.11 with
important amino acids and hydrogen bonds indicated. The carboxylic group
of both ligands is anchored between the arginines Arg183, Arg258 and Asn244
and Ser247. The rest of the ligands is placed in the hydrophobic pocket deeper
buried in the GPR40 structure. In Fig. 3.12 all 100 combinations of the 10
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1. RMSD to 1 = 0 A
    ChemPLP score = -128.4
2. RMSD to 1 = 1.72 A
    ChemPLP score = -121.6
3. RMSD to 1 = 2.03 A
    ChemPLP score = -115.2
4. RMSD to 1 = 2.78 A
    ChemPLP score = -113.9
5. RMSD to 1 = 5.82 A
    ChemPLP score = -110.1
6. RMSD to 1 = 6.79 A
    ChemPLP score = -109.5
7. RMSD to 1 = 6.82 A
    ChemPLP score = -106.4
8. RMSD to 1 = 7.8 A
    ChemPLP score = -106.1
9. RMSD to 1 = 7.24 A
    ChemPLP score = -105.6
10. RMSD to 1 = 2.07 A
      ChemPLP score = -104.5
Figure 3.8: Docking modes of ligand 5 in the homology model of GPR40. Indicated
is the RMSD to the first docking model and the ranking by the docking scoring
function ChemPLP.
1. RMSD to 1 = 0 A
    ChemPLP score = -100.8
2. RMSD to 1 = 3.3 A
    ChemPLP score = -100.5
3. RMSD to 1 = 3.9 A
    ChemPLP score = -100.4
4. RMSD to 1 = 2.12 A
    ChemPLP score = -94.8
5. RMSD to 1 = 3.58 A
    ChemPLP score = -90.2
6. RMSD to 1 = 2.58 A
    ChemPLP score = -85.7
7. RMSD to 1 = 3.57 A
    ChemPLP score = -85.6
8. RMSD to 1 = 6.62 A
    ChemPLP score = -81.7
9. RMSD to 1 = 3.96 A
    ChemPLP score = -81.0
10. RMSD to 1 = 2.03 A
      ChemPLP score = -79.7
Figure 3.9: Docking modes of ligand 6 in the homology model of GPR40. Indicated
is the RMSD to the first docking model and the ranking by the docking scoring
function ChemPLP.
docking models per ligand are shown, sorted by their RSTI values. On the
right side of the diagram, the RMSD to the best scoring structure is indi-
cated. For the calculation of the RMSD only the carboxylic moieties, the
chinoline moiety of ligand 5 and ring I of ligand 6 were used, as the connec-
tor part of the ligand is very flexible and not the crucial part for the binding.
A general trend can be observed: the closer the RMSD is to the best scoring
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Figure 3.10: 10 docking modes of ligand 5 in the homology model of GPR40. Indi-
cated is the best scoring structure in red and the SAR-supported ligand GW9508
[Tikhonova et al., 2007] in blue.









Best scoring structure pair
Figure 3.11: Detail of the binding mode of the two ligands (5 black, 6 red) in
the pocket. The best scoring pair is shown schematically superimposed with the
important amino acids and hydrogen bonds at the binding site indicated.
















































Figure 3.12: RSTI scores for the 100 pairwise combinations, including the RMSDs
to the best scoring structure pair. Structure pairs (on top) with the best scores
display the same motif of an overlap of the ligand 6 ring II and the chinoline
moiety of ligand 5. Indicated in red the best scoring pair using the scoring function
ChemPLP.
3.3.2 Modeling and molecular dynamics simulations
Molecular dynamics simulations of the ligands 5 and 6 within the binding
pocket of the GPR40 homology model were performed to obtain a better
understanding of the ligand dynamics in the binding site, as well as to refine
the obtained binding modes from INPHARMA. An MD simulation was done
for 1 ns in implicit solvent for every of the 10 docking models per ligand,
resulting in 20 MD trajectories. In Figs. 3.13 and 3.14 the RMSD of the final
structure to the starting structure (obtained from docking) of each trajectory
is shown. It was visually inspected that around 5 Å RMSD from the starting
structure, the ligand starts to leave the binding pocket with the hydrophilic
tail.
It can be seen that some structures are stable at the binding site, while
others are moving far off and even leave the binding pocket. Generally it can
be said that the ligands are very dynamic at the binding site and also those
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Figure 3.13: RMSD value between the final structure to the initial binding mode
during an MD simulation of 1 ns of ligand 5. Not all ligand binding modes stay
in a stable position in the binding pocket. The higher the RMSD value, the more






















1 2 3 4 5 6 7 8 9 10
Figure 3.14: RMSD value between the final structure to the initial binding mode
during an MD simulation of 1 ns of ligand 5. Not all ligand binding modes stay
in a stable position in the binding pocket. The higher the RMSD value, the more
unstable is the binding mode.
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a) b)
Figure 3.15: The superimposition of the PLANTS structures with the best score
(a) and the superimposition of the MD structures with the best score (b) after
refinement against RSTI . It is noteworthy that ring II of ligand 6 performs a flip
during the MD simulation of 1 ns.
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3.3.3 STD Ligand 7
Ligand 7 (Fig. 3.16), termed 9-43 in the literature, binds GPR40 with an











Figure 3.16: Ligand 7, agonist of GPR40 with EC50 = 69 nM.
Ligand 7 is soluble up to 0.05 mM and displayed a strong STD signal
in solution with GPR40 membranes. A binding group epitope could be ex-
tracted as seen in Fig. 3.17 and nearly no STD effect was observed in solution
with empty membranes. Yet, the binding affinity is too strong to expect IN-
PHARMA peaks.
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Figure 3.17: STD spectrum and binding epitope of ligand 7, binding to GPR40
membranes. Nearly no binding is observed to membranes without GPR40.
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3.4 Discussion & Conclusion
Here it is shown that the absolute binding mode of ligands to the membrane
protein and GPCR GPR40 can be determined based on a published homol-
ogy model [Tikhonova et al., 2007]. Ten docking models for each of the two
ligands 5 and 6 in the homology model were created using PLANTS and sub-
sequently energy minimized using the Amber force field. The INPHARMA,
trNOE and STD integrals necessary for RSTI scoring were back-calculated
for every model.
Correlation of these back-calculated values with the experimental data
results in a clear proposal for the optimal binding mode. It is also observed
that the next RSTI scoring structure pairs have a small RMSD. Yet, there are
some structure pairs (e.g. the 8th structure), which have a large RMSD but
still score very well (RSTI = 0.62 compared to 0.75 of the best scoring pair).
This structure, however, can be excluded on the basis of mutant analysis
data (see below). The best scoring structure in terms of RSTI is in good
agreement with the previously determined relative binding mode [Bartoschek
et al., 2010], which was confirmed by the observation that the presence of
the aromatic ring II of ligand 6 does not strongly affect the binding affinity,
while the aromatic ring I is crucial for binding. Site directed mutagenesis
experiments with the ligand GW9508 [Sum et al., 2007], which is very similar
in structure to ligands 5 and 6, supports the concept that the carboxyl moiety
is anchored between Arg183, Arg258 and Asn244, as the mutation of each of
these residues to Ala almost abolishes binding. Additionally, the mutation
of His137 to Ala lowered the binding affinity, which is compatible with a
polarized NH-π-interaction of the 3-phenoxy moiety with His137 [Tikhonova
et al., 2007]. These data are in excellent agreement with our model. We
observe the carboxyl moieties anchored between Arg183, Arg258, Asn244 and
Ser247, while the chinoline group of ligand 5 as well as the aromatic ring I of
ligand 6 are in close contact to His137. This binding mode explains well why
the aromatic ring I of ligand 6 is necessary for binding, while the aromatic
ring II is not; ring II is in fact too far to contact His137. The 8th structure with
a good RSTI but large RMSD displays an overlay of the rings as expected,
but both ligands are oriented completely differently in the binding site and
no contact with the crucial arginines is formed; this binding mode would not
explain the mutation data, which indicate that the arginines are essential for
ligand binding. A comparison between the GW9508 and the received binding
modes of ligand 5 and ligand 6, together with the SAR data indicated can
be seen in Fig. 3.18.
To get a better understanding of the obtained binding modes, each was
taken as the initial structure for a molecular dynamics simulation of 1 ns.
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Figure 3.18: Comparison of the binding mode of ligand GW9508, obtained by
docking and SAR data [Tikhonova et al., 2007] and the RSTI derived binding modes
of ligands 5 and 6 superimposed. Both share an anchoring of the carboxylic moiety
to charged amino acids and a close contact of an aromatic ring to His137, proposing
a NH- π stabilization. Below a comparison of the relative binding mode of the two
ligands derived by INPHARMA [Bartoschek et al., 2010] and the absolute binding
modes derived from the combined scoring. Both share an overlap of ring I of ligand
6 with the chinoline moiety on ligand 5.
It was shown that the chosen binding mode and those close in RMSD to
it, remain at the initial binding side with a fluctuation less than 5 Å, while
those with a larger RMSD display a less stable binding mode. Generally it
can be said, that the ligand starts to penetrate deeper in the binding pocket
and that the ligands behave very flexible with several flips occurring in the
hydrophobic tail, the chinoline moiety in ligand 5 and the aromatic rings I
and II in ligand 6. These simulations explain well how flexible the ligands
bind. The hydrophobic part is able to flip, so it can be assumed that all
docking structures close in RMSD to the chosen one, represent a correct
conformation observed during the binding event. The new ligand 7 is not a
fatty acid derivative as the ligands 5 and 6 and displays therefore a possibly
different binding mode. The binding of ligand 7 to GPR40 membranes was
confirmed and investigated with STD. The carboxylic group of ligand 7 seems
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to bind to the same site as the thiazolidinedione head group of ligands 5 and
6. The linker part also aligns, while the tails seem to have different binding
sites. This is reasonable, as ligand 5 is longer and more flexible and is thought
to interact with His137. Ligand 7 instead is shorter and less flexible and is
potentially stabilized by His86 as proposed for the binding mode of compound
37 [Christiansen et al., 2011]. Such a stabilization was also found in docking
of the short and rigid ligand TUG-424 to the homology model [Lu et al.,
2010].
The results are promising, especially in view of the fact that the determi-
nation of ligand binding modes in GPCRs remains a difficult task, as can be
regularly seen in docking competitions [Michino et al., 2009,Kufareva et al.,
2011].
The GPR40 membrane preparations in the light of new experimen-
tal data
In the preceding text the situation was described in the context that the
experimental data from [Bartoschek et al., 2010] result from specific binding
of the ligands to GPR40. This was supported in the paper by the removal
of the ligand 5 STD signal by the titration with the natural binder linoleic
acid. This is a robust argument, as the probability that linoleic acid blocks
the membranes and therefore lowers the STD binding signal of ligand 5 is
very unlikely. On the other hand, the paper did not present a NOESY ex-
periment, of the ligands within a sample of normal membranes that do not
over-express GPR40. Such experiments were recently done on mammalian
CHO and human HEK cells that do not over-express GPR40. According
to these experiments, there is no difference in the NMR data between the
membranes that over-express GPR40, and those that do not. STD and IN-
PHARMA peaks are in principle the same for the GPR40 over-expressing
cells and the normal cells. This would imply that the STD, trNOE and
INPHARMA peaks result from unspecific binding of the ligands in the mem-
branes or to unidentified lipid binding membrane proteins.
Additionally it was observed that linoleic acid forms micelles at a certain
concentration (0.5 mM) and it is very probable that the fatty acid derived
ligands 5 and 6 do the same. Indeed, if the concentration of ligand 5 is
increased in solution an STD signal rises in the absence of membranes. It
could be assumed that a titration of ligand 6 with ligand 5 would lead to a
decrease in the STD signal of the first. Instead, the signal of ligand 6 stays
the same and strongly increases at a concentration of 200 µM ligand 5, as
can be seen in Fig. 3.19. This supports the idea that ligand 5 forms micelles
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at high concentrations where other ligands can bind to.
7.07.58.08.5
100 µM ligand 6
+ GPR40 membrane
+50 µM ligand 5
+100 µM ligand 5
+200 µM ligand 5
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Figure 3.19: Titration of a sample containing GPR40 membranes (HEK) and 100
µM of ligand 6 with ligand 5. While the concentration of ligand 5 is increased, the
STD signal of ligand 6 stays constant. At a concentration of 200 µM ligand 5, both
STD signals strongly increase. The spectra were recorded by Bettina Elshorst at
298 K with on-resonance irradiation at -0.5 ppm.
The ligands applied are very lipophilic and tend to micelle formation and
membrane binding. Probably the presence of the membranes even triggers
the formation of micelles. With these new data given it seems possible that
STD and INPHARMA can arise from i) micelle formation, ii) membrane
binding or iii) unidentified membrane protein binding or a combination of
these. It is therefore imaginable that the specific interaction with GPR40 is
not the main source of the STD and INPHARMA signals. These observations
also question the results and the modeled structures that were shown above
and imply that they have to be treated with care.
When the HEK cells were investigated with GPR40-specific antibodies (4093
TEA, Fig. 3.20), it became clear that the over-expression level is not much
higher than in the normal membrane. Also it is shown that GPR40 is present
in the normal HEK membrane. This led to the question, if there is at all
a difference between the membranes that over-express GPR40, and those
that do not. This is in turn an argument for the specific interaction of the
ligands with GPR40. In the publication [Bartoschek et al., 2010] there were
most likely membranes from High Five insect cells applied. These gave, in
comparison to HEK and CHO cells, a high over-expression level of GPR40
which is magnitudes higher than in normal membranes. There were no High
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Five insect cells without GPR40 over-expression available, but Sf9 insect cells
that also originate from a lepidopteran cell line. The experiment was repeated
with these membranes, which definitely do not contain human GPR40, and
binding signals from STD and INPHARMA were observed. Still, it could




M33 111 1031 1031 103M
































GPR40 over-expression membrane HEK Control membrane HEK
1D
STD
Figure 3.20: Comparison of GPR40 over-expressing membranes and control mem-
branes. The STD signal of both HEK membranes is the same as seen above. This
is confirmed by the SDS-Page and Western Plots shown below. GPR40 concentra-
tion is nearly equal. CHO cells give no signal at all, but High Five insect cells show
a very high over-expression level. These experiments were done within Sanofi.
The question is further complicated by the nature of the ligands, which
are very easy to be aligned with their carboxylic moieties and the hydrophobic
aromatic tails. It is very probable that their relative binding mode is the same
in i) GPR40, ii) the membranes, iii) other membrane proteins or iv) micelles.
It can well be that the binding mode which was modeled above based on
NMR data is present in GPR40 and at other binding sites. Therefore one
would not see a difference whether the ligand is binding specific to GPR40
or not.
The ligands 5 and 6 were measured with liposomes to see if unspecific binding
is taking place rather to the membrane or to membrane proteins. The 1D
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and STD spectra showed a very strong broadening of the signals (Fig. 3.21),
which was not observed in the presence of membranes. This indicates that
the ligands go to the liposomes and bind there. Yet, in the presence of cell
membranes the signal line shapes look very different. The NOESY spectrum
of the ligands/liposome sample showed trNOE, but also broadened and no
INPHARMA. This is in agreement with the argumentation in [Bartoschek
et al., 2010], that the ligands do not exchange enough in the vast space of the
membranes to give rise to INPHARMA signals. It can be concluded that the
membrane binding is contributing to the NMR signal of ligand/membrane
samples, but is not the main contribution to the signal. Therefore in turn
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Figure 3.21: Comparison of the ligands 5 and 6 aromatic region together with
liposomes (red) and with cell membranes (black). In the case of liposomes an
enormous line broadening can be observed. Spectra were recorded on a 400 MHz
spectrometer by Adam Mazur.
The putative conclusion is, that there are off-target binding events con-
tributing to the signal and therefore the spectra of GPR40 over-expressing
membranes and normal membranes look very similar. This would also be in
agreement with the observation of [Bartoschek et al., 2010], that linoleic acid
can remove a ligand from its binding site. The difference is just, that the lig-
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and is not removed from GPR40 only, but also from other fatty acid binding
membrane proteins. In turn, a titration with ligand 5 can not be successful,
as this ligand starts to form micelles at concentrations approximately higher
than 0.2 mM.
It is possible that these issues are specific for the ligands of the GPR40
system and do not turn up with other protein systems. Investigations of
GPCR and ion channel membrane preparations are at the moment done
within proprietary projects at the pharmaceutical company Sanofi to ad-
dress these questions. It is very important to finally answer these issues to
decide if STD, trNOE and INPHARMA are amenable for membrane proteins
with the presented sample preparation. First results on the cannabinoid re-
ceptor 1 (CB1) showed similar issues to the GPR40 system, i.e. STD and
INPHARMA signals in the presence of membranes that do not over-express
CB1. On the other hand, STD investigations on whole cells with a CB1
binder were shown to work only with CB1 over-expressing cells and not with
others [Pereira et al., 2009]. In this case the ligand was hydrophilic and a
large steroid derivative, so there was most probably neither membrane bind-
ing, nor unspecific membrane protein binding, nor micelle formation taking
place.
In conclusion, it was found that the NMR-based protein-ligand complex
structure determination methodology should be applicable to membrane pro-
tein preparations if the following issues do not occur: i) micelle formation
(can be regulated with ligand concentration), ii) membrane binding (can be
regulated with ligand lipophilicity), iii) low target over-expression levels (can
be tested with antibodies) and iv) specific or unspecific binding to other
membrane proteins (can be tested with normal cell membrane preparations).
The fourth point excludes many fragment-like ligands and also the ligands
5 and 6. The modeled binding mode of these ligands can therefore be seen
as a general binding motif of these ligands to GPR40 and other fatty acid
binding membrane proteins.




4.1.1 Tubulin and antimitotic drugs
The protein tubulin is the building block for the microtubules, a cytoskeletal
assembly which reaches out from the centrosome into all directions inside the
cell. The functions of the microtubules include the stabilization of the cell,
the transport of organelles and cell division. During the latter the mitotic
spindle is formed by the microtubules, which is the driving force for the









Figure 4.1: Polymerization mechanism of microtubules [Jordan and Wilson, 2004].
In the nucleation phase of the microtubule assembly there are heterodimers
of the α- and β-subunits of tubulin formed. These heterodimers have a
molecular weight of 100 kDa and range over a distance of 8 nm. Once these
103
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heterodimers accumulate with other tubulin heterodimers to a certain size,
the elongation of the microtubules starts. The final microtubule assembly
structure consists of closed ring made out of 13 protofilaments of head-to-tail
assembled heterodimers with a diameter of 24 nm. At the β-tubulin expos-
ing (+) end the microtubule is then further elongated. This procedure of


















Figure 4.2: Binding sites of antimitotic drugs to microtubules [Jordan and Wil-
son, 2004]. a) vinblastine binds to the (+) end and suppresses MT assembly. b)
colchicine binds to tubulin heterodimers fixing the conformation to suppress MT
dynamics. c) paclitaxel binds to the interior surface and stabilizes the MT.
Amodulation of the tubulin polymerization (and depolymerization) mech-
anism has a direct influence on the mitotic spindle that is responsible for cell
division, and if mitosis does not function properly, the cell will die or undergo
apoptosis. The consequence is, that antimitotic drugs aiming to destroy the
mitotic spindle will especially harm cells that tend to divide very often. This
holds true for cancer cells and therefore antimitotic drugs are of highest im-
portance for chemotherapy as cytostatica. Three different mechanisms of
tubulin modulators have been found within natural products. They differ by
their binding site to tubulin or the microtubule: i) the first group comprises
the vinca alkaloids from the periwinkle, e.g. vinblastine. They bind to the
(+) end of the microtubule, between α and β tubulin, as seen in crystal
structure 1Z2B and inhibit polymerization, ii) colchicine from the autumn
crocus binds at a distinct site of the β subunit, stabilizing a conformation
that inhibits straightening of the microtubule. It is used to cure gout and
related inflammatory disorders and iii) paclitaxel, epothilones and related
substances bind to the taxane binding site of β-tubulin, which is at the in-
terior of the microtubule and stabilize the microtubule or affect the number
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of protofilaments. Hereby they inhibit depolymerization or produce a mi-
crotubule without proper function. These three different binding sites are
illustrated in Fig. 4.2. For cyclostreptin, a covalent binding to Thr220 very
close to the taxane binding site was observed and proposes a weak binding
site en route to the taxane binding site [Buey et al., 2007]. These presented
molecules display only a small selection of tubulin binding drugs and many
more are under investigation [Dumontet and Jordan, 2010,Amos, 2011]. The
most frequently applied antimitotic drug is paclitaxel (trading name: Taxol),
originally extracted from the pacific yew tree, that binds microtubules with
high affinity and stabilizes them. The binding mode of paclitaxel to Zn-
stabilized tubulin sheets is known from the electron crystallography derived
structure [Löwe et al., 2001] and it is assumed that the binding mode in
tubulin monomers or heterodimers is the same. The binding is stabilized
by two phenyl-rings of paclitaxel, that penetrate into grooves on the tubulin
surface and stabilize the conformation of the highly flexible M-loop. Pacli-
taxel is poorly soluble in water and therefore is sometimes replaced in studies
by its baccatin III (bacIII) core. First, bacIII was believed to be an inac-
tive derivative of paclitaxel, but then bacIII was found to be a stabilizer of
microtubules like paclitaxel with an activity around ten times lower than pa-
clitaxel [Chatterjee et al., 2001,Andreu and Barasoain, 2001]. This indicates
that bacIII also specifically targets the taxane site and stabilizes the M-loop
in a similar manner to paclitaxel. Yet, there is no data on the binding mode
of bacIII published, and it is unknown if the bacIII binding mode is similar
or different to the one of paclitaxel.
4.1.2 The binding mode of epothilone
Extensive studies using NMR spectroscopy were done on the binding modes
of drug molecules binding to the taxane-binding site of β-tubulin. The bound
conformation of discodermolide [Sanchez-Pedregal et al., 2006], dictyostatin
[Canales et al., 2008], docetaxel [Canales et al., 2011] and tubulysin [Kubicek
et al., 2010] were derived using trNOE and INPHARMA data. The natural
product epothilone A (epoA, Fig. 4.4) is also in the group of anticancer
agents that target the taxane-binding site of β-tubulin. Epothilone showed
activity in cancer cells that were resistant against Taxol and the epothilone
derivative ixabepilone was released in the United States under the trading
name Ixempra. An electron crystallography (EC) derived binding mode of
epothilone to Zn-stabilized tubulin sheets is known [Nettles et al., 2004].
There is a severe disagreement between the bound conformation in solu-
tion found by the NMR methods trNOE and CCR [Carlomagno et al., 2003]
and the EC-derived structure. An NMR model of the binding mode, based
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Figure 4.3: Binding mode of epothilone A to tubulin heterodimers as determined
by NMR spectroscopy (left) and to Zn-stabilized tubulin sheets as determined by
electron crystallography (right).
on molecular modeling with HADDOCK and scoring by INPHARMA was
published [Reese et al., 2007] and shows a very different binding mode of
epoA to β-tubulin compared to the EC-derived structure. An investigation
by solid state NMR of epothilone B (patupilone) bound to microtubules re-
vealed details about the pharmacophore. Still, it was not possible to decide

































Figure 4.4: Constitution and configuration of epothilone A.
The binding site of cyclostreptin was discovered to be in the pore site,
which is situated between the two β units of two tubulin dimers. Follow-
ing this observation, some authors ( [Canales et al., 2008], [Magnani et al.,
2009], [Canales et al., 2011]) proposed that the pore site is also the binding
site in solution of paclitaxel-like antimitotic drugs that bind the taxane site
inside the microtubule. The logic behind this was, that STD data showed
differences in the binding mode between the tubulin and the microtubule
samples. Additionally it was observed that the binding affinities are not
as strong as expected in the tubulin samples. Therefore these drugs would











































Figure 4.5: Constitution and configuration of the baccatin III core, derived from
paclitaxel.
quently the drugs only bind to the taxane site, if a microtubule is either
in the growing phase or already present. An exception could be the Zn-
stabilized sheets, that were used to determine the crystal structures of pa-
clitaxel and epothilone and which show that the drugs bind to the taxane
site. As there are INPHARMA signals between the taxane binding drugs like
baccatin, epothilone and discodermolide; epothilone would also be affected.
Indeed, there were also INPHARMA peaks observed between epothilone and
tubulysin. Tubulysin is a peptide with a structure very similar to soblidotin,
a dolastatin derivative. Dolastatin is known from X-ray crystallography to
bind close to the vinblastine and cyclostreptin (pore) binding site [Cormier
et al., 2008]. Therefore it had to be concluded that the possibility of another
binding site on tubulin in solution is probable [Kubicek et al., 2010].
On the other hand, experimental data obtained by H/D exchange (HDX)
followed by mass spectrometry measurements give another picture. Based
on these data, the taxane binding site is stabilized and therefore protected
against deuteration, if the taxane binding site drugs are in solution [Khrapunovich-
Baine et al., 2009]. Furthermore three new binding modes of epothilone A
are proposed, which are supported by the H/D data [Khrapunovich-Baine
et al., 2011]. These are shown in Fig. 4.6 and are closer to the NMR-, than
to the EC-derived structure.
At the final stage of this thesis, a new crystal structure of epothilone bound
to tubulin was published [Prota et al., 2013]. The structure is deposited in
the PDB under the entry code 4I50 and shows a complex between αβ tubu-
lin, the stathmin-like protein RB3, tubulin tyrosine ligase and epoA. The
structure is shown later in the text in Fig. 4.19 and epoA is contrary orien-
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tated at the binding site to all above mentioned structures. This new crystal
structure shows epothilone bound to tubulin with four hydrogen bonds and
fixes the M-loop of tubulin as a structured alpha-helix. The hydrogen bonds
are induced by OH3, OH7, O1 and the N of the thiazole ring of epoA and
are in good agreement with SAR data [Nicolaou et al., 1997,Regueiro-Ren
et al., 2002,Buey et al., 2004]. The crystal structure also explains well, why
an addition of a methyl group to C12 results in a much stronger binding
affinity, as in this structure there is a cavity to fill by the methyl group.
Figure 4.6: Binding mode proposals of epothilone A (shown in magenta) to tubulin,
supported by HDX data [Khrapunovich-Baine et al., 2011].
To further investigate the tubulin/epoA system, new STD data were
recorded and applied in the following section as a selection criterion to choose
between the ambiguous binding modes. As the INPHARMAmethod depends
on two different molecules that target competitively the same binding site,
baccatin III (bacIII) was used complementary to epothilone A. BacIII is the
core element of paclitaxel (Fig. 4.5, lacking the rest that bears two phenyl
rings. The logic behind this is, that bacIII is much better soluble than pa-
clitaxel. Interestingly, INPHARMA found for bacIII another binding mode
than it would have been expected from the EC structure of paclitaxel. Thus,
for bacIII there were also new STD data obtained.
4.2 Material & Methods
4.2.1 STD experiments
The epoA sample was prepared with 0.5 mM epothilone A and 0.012 mM
tubulin (Cytoskeleton Inc., Denver (USA)) in D2O containing phosphate (3
mM), calcium (1.5 mM) and sodium (0.7 mM). Saturation was applied for 1
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s on -3.5 ppm on 298 Kelvin a 900 MHz spectrometer equipped with a cryo-
genically cooled probe head (ns: 16, TD: 8K). The epoA sample preparation
and measurement was done by Karel Kubicek.
The bacIII sample was prepared with 2 mM baccatin III and 0.020 mM
tubulin in D2O PIPES buffer containing sodium phosphate (50 mM), EGTA
(1mM), DTT (1mM) and calcium chloride (2mM). Saturation was applied
for 1.5 s on -1.5 ppm at 278 Kelvin on a 900 MHz spectrometer equipped
with a cryogenically cooled probe head (ns: 512, TD: 8K)
4.2.2 Back-calculation of peak volumes
All INPHARMA, trNOE and STD peak volumes were back-calculated with
the software SpINPHARMA, using the complete-relaxation matrix approach
[London, 1999, Orts et al., 2009] as described in the introduction part 1.2.
Methyl-groups were described using a 3-site jump model [Tropp, 1980]. STD
saturation was applied to all methyl groups. Protons within a distance of 8
Å from any ligand proton were considered. The INPHARMA and intraligand
peaks were normalized to the sum of all peaks in the direct dimensions [Koeck
and Griesinger, 1994]. The correlation time was estimated to be 100 ns. Kd
values were estimated to be 0.001 mM or 0.01 mM for epoA and 0.05 mM for
bacIII. On-rates (kon) were assumed to be in the diffusion limit 108 M−1s−1.
4.2.3 Molecular dynamics simulations
The INPHARMA derived HADDOCK model of the epothilone-tubulin com-
plex [Reese et al., 2007] and the EC derived structure [Nettles et al., 2004]
were used as starting structures for energy minimization and molecular dy-
namics simulations. Additionally the same was done for bacIII. There-
fore the INPHARMA derived HADDOCK model of the tubulin/bacIII com-
plex [Reese et al., 2007] was used for the NMR model. For the EC structure
of bacIII, the EC-derived and refined structure of paclitaxel bound to the
tubulin dimer (PDB code 1JFF) was used [Löwe et al., 2001] and paclitaxel
was computationally modified to bacIII, followed by energy minimization.
For the crystal structure the epothilone binding monomer (chain D) of PDB
structure 4I50 was used. Energy minimizations and molecular dynamic sim-
ulations were done as implemented in Gromacs [Hess et al., 2008], using the
amber99sb force field [Hornak et al., 2006] for the protein and the General
Amber Force Field [Wang et al., 2004] for the ligand. EM was done with
conjugate gradient integrator in 1000 steps. MD was done using steepest
descent integrator with a stepsize of 2 fs. Simulations were run for 1 ns at
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300 K and 1 atm in implicit solvent, using the Generalized Born model aug-
mented with the hydrophobic solvent accessible Surface Area (GBSA). From
every trajectory 100 snapshots were saved, respectively. RMSD changes of
the ligands were calculated within Gromacs using least square fit method to
reference to the whole system and to obtain RMSD values, which are not
influenced by spatial motions of the protein.
4.3 Results
4.3.1 STD experiments
STD spectra were recorded for epoA and bacIII as described in the method-
ology section. STD effects were clearly visible and the group binding epitopes
could be derived from the spectra, as is shown in Figs. 4.7 and 4.8.
STD data epothilone A
For epoA, the protons H17, H19 and H15 get the strongest saturation. These
protons are situated at the linker between the macrocycle and close to the
thiazole ring. The methyl group H21, that is also situated at this ring gets
the strongest saturation of the epothilone methyl groups. In comparison,
the methyl groups H22, H23, H24 and H25, which are close in space, all get
much lower saturated than H21. The protons of the hydrophobic stretch
get comparably highly saturated, while the protons of the other side of the
macrocycle with the three oxygen groups are weakly saturated. These values
already result in a rough picture of the binding epitope: The thiazole ring and
the linker are very close to the protein, as well as the hydrophobic stretch of
the macrocycle. Farther away from the protein and more exposed to the sol-
vent are the methyl groups H22-H25 and the oxygen bearing stretch. These
observations are supported and complemented by the WaterLOGSY spec-
tra (not shown). When one inspects the electron crystallography structure
of epothilone (PDB code 1TVK), it becomes clear that this group epitope
might not fit very well. As seen in the crystal structure, the binding mode
is mainly supported here with the oxygen bearing stretch being close to the
protein, forming hydrogen bonds with the same. To test this observation,
the RSTD values for the EC-derived structure and the NMR-derived struc-
ture were back-calculated and compared with the experimental data. The
result was an RSTD for the NMR structure with 0.55 and -0.025 for the EC
structure, whereas the NMR structure is clearly favored. An energy mini-
mization improved the NMR structure to 0.56 and the EC structure to 0.11.












































































Figure 4.7: Comparison of the 1D and STD spectra of epothilone A in solution
with tubulin heterodimers. The VMax.STD value is 96.18.
STD data baccatin III
A comparable study was done for bacIII. Hereby the NMR derived structure
was used and for the EC-derived structure the binding mode from paclitaxel
to tubulin (PDB code 1JFF) was applied. Therefore the structure of pacli-
taxel was computationally changed to bacIII and the resulting structure was
energy minimized. Accordingly, the NMR structure was also energy mini-
mized with the same (Amber) force field. The group epitope was not as clear
as in the case of epothilone. Yet, it can be said that the phenyl ring must be
buried in a protein cavity. Calculation of RSTD resulted in 0.65 for the NMR
structure and 0.67 for the EC structure. The STD values were then combined
with experimental trNOE and INPHARMA data of epoA and bacIII from
the literature [Reese et al., 2007] to yield RSTI values. Back-calculation and
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Figure 4.8: Comparison of the 1D and STD spectra of baccatin III in solution with
tubulin heterodimers. The VMax.STD value is 14.68.
combination of the parameters was done as described before. For the energy
minimized NMR structures of epoA and bacIII, the RSTI is 0.63 and for the
energy minimized EC structures of epoA and bacIII, the RSTI is 0.44. This
implies that the NMR structure of epoA is clearly favored, but the bacIII
structures are both very similar in their scores. The crystal structure 4I50
obtained an RSTI of 0.69 with the NMR structure of bacIII and an RSTI of
0.59 with the EC structure of bacIII.
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4.3.2 Molecular dynamics simulations
MD epothilone A
To investigate whether scoring against RSTD and finally against RSTI can be
further optimized, an unrestrained molecular dynamics simulation was run
for 1 ns in implicit solvent, starting from the EC and the NMR structures,
respectively. In Fig. 4.9 and Fig. 4.10, it can be seen how much the binding
modes of epoA changed from the starting structure during the MD simula-
tion. It is remarkable, that the flexible M-loop of tubulin, which is oriented
differently in the NMR structure than in the EC structure, moves closer to
the latter during the simulation of the NMR structure. This can be seen later
in Fig. 4.15. 100 snapshots from the MD trajectories were taken respectively
and the peak volumes were back-calculated to yield the RSTD values. The
best scoring NMR MD structure gained an RSTD of 0.75. The best EC MD
structure gained an RSTD of 0.61. The final structure of the MD trajectory
gave an RSTD of 0.65 for the NMR structure and an RSTD of 0.45 for the EC
structure. Still, the NMR structure scores better, but the EC structure was
significantly improved. As can be seen in the trajectory 4.10, the position of
epoA in the EC structure changes immediately, which also supports that the
starting structure is energetically not very favorable.
An additional MD trajectory lasting 10 ns was recorded for the epoA bound
monomer of the crystal structure 4I50 and is shown in Fig. 4.11. The MD
was recorded for 10 ns, as after 1 ns a sudden change in RMSD happened.
In the end it turned out to be an outlier, caused by a sudden movement of
the M-loop towards the solvent. EpoA in this structure stays stable and the
final structure changed only 1.9 Å in RMSD from the starting structure.
100 snapshots from the MD trajectories were taken respectively and the fi-
nal structure of the MD trajectory got an RSTD of 0.76 and best scoring
structure an RSTD of 0.84.



























Figure 4.9: MD simulation starting from the NMR-derived tubulin/epoA complex
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Figure 4.10: MD simulation starting from the EC-derived tubulin/epoA complex




























Figure 4.11: MD simulation starting from the crystal structure 4I50 of the tubu-
lin/epoA complex structure for 10 ns. RMSD changes of epoA relative to the
starting structure are indicated. Outliers are caused by sudden movements of the
M-loop towards the solvent.
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MD baccatin III
A similar MD simulation as for epoA was done for bacIII. The trajectories
of the EC and NMR structure are shown in Fig. 4.12 and Fig. 4.13. The
best scoring NMR MD structure by RSTD got 0.75 and the best EC MD
structure gained a comparable RSTD of 0.83. The final structure of the MD
trajectory gave an RSTD of 0.66 for the NMR structure and an RSTD of 0.43
for the EC structure. As can be seen in the RMSD values of the figures,
is the NMR derived structure more stable, i.e. does change less from the
original structure than the EC derived model. The latter changes around
5 Å RMSD compared to the starting structure, while the NMR structure
changes only around 2.5 Å. To evaluate how representative this stability is,
another unrestrained MD simulation of the original EC-derived structure of
paclitaxel bound to tubulin was run. This structure is generally considered
to be correct and reproducible. It can be seen in Fig. 4.14, that paclitaxel is
more stable, changing only around 2.5 Å RMSD from the starting structure,
compared to the derived baccatin III binding mode. These simulations prefer



























Figure 4.12: MD simulation starting from the NMR-derived baccatinIII/tubulin





























Figure 4.13: MD simulation starting from the EC-derived (derived from paclitaxel)
tubulin/bacIII complex structure for 1 ns. RMSD changes of bacIII relative to the
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Figure 4.14: MD simulation starting from the EC-derived tubulin/paclitaxel com-
plex structure for 1 ns. RMSD changes of paclitaxel relative to the starting struc-
ture are indicated.
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Scoring by RSTI
The new MD structures for epoA and bacIII, can be combined pairwise to
RSTI and scored accordingly. The best NMR structure pair of epoA and
bacIII by RSTI is 0.76 and the best EC structure pair obtained an RSTI of
0.7. The NMR structures are seen in Figs. 4.15 and 4.17; the EC structures in
Figs. 4.16 and 4.18 in comparison with the starting structures that obtained
0.63 for the NMR, and 0.44 for the EC structure pair. At the end of the
simulation, the NMR pair obtained an RSTI of 0.5 and the EC pair 0.53.
The crystal structure 4I50 of epoA in combination with the EC structure
of bacIII got as best RSTI 0.69 and 0.55 for the final MD structure pair.
Together with the NMR structure of bacIII, the crystal structure of epoA
obtained a best RSTI value 0.79, and 0.73 for the final MD structure pair.
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Figure 4.15: Tubulin/epothilone A complex structure derived from NMR [Reese
et al., 2007] in black (RSTI : 0.63) and in green the structure that obtained the
best RSTI value (0.76) during an MD simulation of 1 ns. It can be seen, that the
thiazole ring moves to the left, as the flexible M-loop does the same.
Figure 4.16: Tubulin/epothilone A complex structure derived from EC [Nettles
et al., 2004] in black (RSTI : 0.44) and in green the structure that obtained the
best RSTI value (0.7) during an MD simulation of 1 ns. The macrocycle moves
into another position, while the orientation of the M-loop does not change.
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Figure 4.17: Tubulin/baccatin III complex structure derived from NMR [Reese
et al., 2007] in black and in green the structure that obtained the best RSTI value
during an MD simulation of 1 ns. The position of baccatin III does not change
very much and the position of the phenyl ring does not change at all. Also the
orientation of the M-loop does not change much.
Figure 4.18: Tubulin/baccatin III complex structure derived from the EC structure
of paclitaxel [Löwe et al., 2001] in black and in green the structure that obtained
the best RSTI value during an MD simulation of 1 ns. Baccatin III begins to leave
the binding site and the M-loop changes its orientation.
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4.4 Discussion & Conclusion
The ambiguous binding mode of epothilone to tubulin in solution was rein-
vestigated based on new data. Therefore the existing structures were run
in an unrestrained MD simulations to create a large ensemble of conforma-
tions. These were then evaluated by new experimental STD data measured
for epothilone A and baccatin III. Finally they were compared by their re-
spective RSTD and RSTI values at the start and end of an MD simulation of
1 ns, as well as by the best scoring structure within this simulation. Accord-
ing to these data, the INPHARMA derived binding mode of epothilone is
favored. It scores much better than the EC derived binding mode by RSTD
at the start and at the end of the MD simulation. Also the RSTI values
of the NMR structure are better. The new crystal structure 4I50 of epoA
displays the best RSTD and RSTI values, whereas the combination with the
NMR structure bacIII is favored over the EC structure of bacIII.
In the case of baccatin III, the situation is more difficult. The NMR struc-
tures display RSTD and RSTI values very close to those for the EC structure.
Yet, the NMR structure is stable during the MD simulation, as the pacli-
taxel structure is, while the EC structure is changing much more in RMSD.
It can not be said for sure in which protein cavity the phenyl ring penetrates
and which of the structures is closer to the actual binding mode. On the
other hand, it is possible that the phenyl ring of bacIII could penetrate into
both cavities respectively and therefore bacIII possesses two distinct binding
modes. The NMR signal would then include the information of both binding
modes and both would obtain very similar scores, as it is observed.
So far trNOE, INPHARMA and STD data were applied from the NMR
side to reveal the binding mode of epothilone to tubulin. Until now it was
not possible to express tubulin in bacteria, meaning that no labeling with
stable isotopes for heteronuclear NMR is possible. Therefore nothing more
can be done from the NMR side. Yet, there are chemical shift data from
the solid state investigations of epothilone and microtubules. These can
be back-calculated and compared with different binding modes. Such an
approach could yield new informations on the binding mode of epothilone in
the future.
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NMR structure 
RSTD = 0.56
RSTI  = 0.63 (with bacIII NMR)
RMSD change during MD of 1 ns:  3.9 A
EC structure (PDB code 1TVK)
RSTD = 0.11
RSTI  = 0.44 (with bacIII EC)
RMSD change during MD of 1 ns:  4 A
Crystal structure (PDB code 4I50)
RSTD = 0.81
RSTI  = 0.69 (with bacIII NMR)
RSTI  = 0.59 (with bacIII EC)
RMSD change during MD of 10 ns: 1.9 A
Figure 4.19: Comparison of the three binding modes of epothilone to tubulin that
were mentioned in the text from left to right: NMR structure, EC structure and
crystal structure. The individual RSTD and RSTI values are indicated, as well as
the change in RMSD change from the starting structure during an MD simulation.
Chapter 5
Drug metabolism of anle138b
5.1 Introduction
5.1.1 Toxic protein aggregates in neurodegenerative dis-
eases
The hallmark feature of neurodegenerative diseases such as Alzheimer’s dis-
ease (AD), Parkinson’s disease (PD) and prion diseases is the ability of par-
ticular proteins to fold into stable alternative conformations and to form
neurotoxic aggregates that accumulate in the brain [Soto and Estrada, 2008].
These deposits share similar morphological, structural and staining charac-
teristics, although the main protein component is disease-specific.
Alzheimer’s disease is the most common form of dementia and is charac-
terized by extracellular plaques of β-amyloid and intracellular tangles, con-
sisting of paired helical filaments of the microtubule-associated protein tau.
PD affects about 1% of the population beyond 65 years of age. Patho-
logically, PD is characterized by depositions of α-synuclein aggregates and
degeneration of dopaminergic neurons in the substantia nigra, resulting in
impaired motor functions [Forman et al., 2005]. Prion diseases are invari-
ably fatal neurodegenerative diseases that include Creutzfeldt-Jakob disease
(CJD) and bovine spongiform encephalopathy (BSE). They are caused by
an unconventional infectious agent which consists primarily of the misfolded,
aggregated and beta-sheet rich PrPSc isoform of the membrane glycoprotein
PrPC . The available evidence suggests that PrPSc acts both as a template
for this conversion and as a neurotoxic agent causing neuronal dysfunction
and cell death [Giese and Kretzschmar, 2001]. Recently it was shown that
the drug bexarotene promotes expression level of ApoE, leading to the clear-
ance of β-amyloid from the brain [Cramer et al., 2012]. Nevertheless it is
123
124 CHAPTER 5. DRUG METABOLISM OF ANLE138B
more straight forward and potentially more effective to develop drugs that
destabilize the pathological protein aggregates in the case of β-amyloid, tau,
α-synuclein and the prion protein. No such drugs exist at the moment on the
market, but the need to find a cure for neurodegenerative diseases beyond
the symptomatic level is essential in a society constantly growing in age.
5.1.2 Anle138b - a novel aggregation modulator
In 2000, the first method for the detection of pathological prion protein
(PrPSc) in cerebrospinal fluid was developed. This was achieved by us-
ing a set-up for confocal dual-color fluorescence correlation spectroscopy.
The methodology was especially useful to get a definitive diagnosis for the
human form of the prion disease Creutzfeld-Jakob. As there is no drug
available to cure this disease, the set-up was applied for a high-throughput
screening of a chemical library against the aggregation of the prion protein.
The results of the antiprion drug discovery were presented in 2005 and re-
vealed a new class of substances as potential lead structure: N-benzylidene-
benzohydrazide derivatives [Bertsch et al., 2005]. Indeed, these substances
showed anti-aggregation effects on the prion protein in cell cultures, but in-
terestingly also against the aggregation of α-synuclein (Parkinson’s disease)
and PolyQ (Huntington’s disease). Based on these results, the stability of
the molecular structure was improved by a ring closure, leading to di-phenyl-
pyrazoles. A library of 150 compounds based on this lead structure were
tested simultaneously against the prion protein and α-synuclein in SIFT as-
says, as well as in vivo, e.g. with prion-infected or MPTP mice. The best
results for both targets (prion protein and α-synuclein), together with the
best performance in penetrating the blood-brain-barrier led to the selection
of anle138b as the drug candidate. An overview of this drug discovery pro-
cess is given in Fig. 5.1. At this point the pharmacokinetics, including drug
metabolism and toxicity of anle138b were unknown. The motivation of this




library of 20,000 chemically diverse drug-like compounds
SIFT and cell culture screening
(anit-prion)
























Bieschke et al, 2000
Bertsch et al, 2005
SAR-analysis
Focussed DPP library (~150 compounds)
Figure 5.1: Summary of the anle138b drug discovery process and the emerging
question concerning the drug metabolism.
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5.2 Material & Methods
5.2.1 HPLC analysis
Treated mice were sacrified, dissected, and samples were frozen at -80◦C. The
tissues were de-frozen at 4◦C prior to use. Tissues were homogenized twice
in 5 mL of acetonitrile at maximum speed for 3 minutes using a homoge-
nizer (IKA ULTRA-TURRAX Tube drive workstation, Germany). The ho-
mogenate was ultrasonicated at 30◦C for 5 minutes and centrifuged at 5000 g
for 10 min. An aliquot (0.1 mL) of supernatant was injected into the HPLC
system. Analytical high performance liquid chromatography (HPLC) was
performed using a Waters HPLC system with a Waters 996 Photodiode Ar-
ray Detector. All separations involved a mobile phase of 0.1% trifluoroacetic
acid (TFA) (v/v) in water (solvent A) and 0.1 % TFA in acetonitrile (solvent
B). HPLC was performed using reversed-phase (RP) column Eurospher RP
18, 100 Å, 5 µm, 250 x 4.6 mm at flow rates of 1 mL/min with a gradient of
solvent B from 0% to 100% in 50 minutes. The effluent was monitored for
UV absorption at 260 nm. Samples were quantified using the peak area ratio
of the measured compound to synthesized anle138b as external standard.
5.2.2 Mass spectrometric analysis
Peaks were collected and injected into an LTQ Orbitrap FT-mass spectrom-
eter. Measurement was done in ESI positive ion mode with and without
collision-induced fragmentation. Due to the nearly equal natural abundances
of the two bromine isotopes in anle138b, double peaks with the mass differ-
ence m/z 2 were manually selected and separated by the LTQ quadrupole
for ion scan. These were then fragmentated by the collision induced decay
(CID) at different energy levels and the specific fragments were measured in
the FT-MS.
5.2.3 NMR analysis
Anle138b and anle138c were dissolved in DMSO-d6 and were measured on
a 400 MHz spectrometer. For the metabolites, peaks were collected from
HPLC and the samples were frozen in liquid nitrogen. Then, the samples
were lyophilized to yield a white powder, which was dissolved in DMSO-d6.
0.2 mL of the sample solution were taken for NMR measurements. These
were carried out on a 600 MHz or 900 MHz spectrometer, both equipped
with a cyrogenically cooled probehead. Detailed sample conditions are in
the appendix.
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3.HPLC separation4.Injection to mass spectrometer
Figure 5.2: Investigation of drug metabolism: 1) the drug is fed to an animal, which
is afterwards 2) sacrificed to deliver organ samples or blood samples are taken. 3)
Homogenized organs or blood is run over an HPLC column to separate the organic
substances and 4) these are then further investigated by mass spectrometry.
5.3 Results
5.3.1 Anle138b analysis
In the first place a chemical analysis of anle138b was done to develop and test
the applicability of the method. In further studies the same methodology was
used to determine concentrations of anle138b in blood and tissue samples.
The molecule was clearly identified by mass spectrometry and displayed the
bromine natural isotope twin peak as seen in Fig. 5.5. After anle138b was
identified with mass spectrometry, it was measured using induced fragmen-
tation within the orbitrap mass spectrometer to obtain the fragmentation
pattern. During fragmentation, anle138b undergoes two major rearrange-
ments of the methylenedioxy group or a release of the bromine atom. The
pattern is interpreted in Fig. 5.3.
Anle138b was measured with NMR spectroscopy and was also clearly
identified (see appendix). Here the tautomeric constitution is expressed as
equally distributed twin peaks in the spectrum. The compound is soluble in








































Figure 5.3: The mass spectrum of anle138b, after selection of the m/z 343 isotope
during induced fragmentation. In addition to the original mass, three masses are
visible. m/z 285 and m/z 318 can be created during a rearrangement as described
in [Yan et al., 2007]. m/z 264 originates from a deletion of the bromine.
acetonitrile and can be quantified with HPLC diode array, using a standard.
In Fig. 5.4 the concentration of anle138b in rat plasma is visible at different
time points.
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Figure 5.4: Concentration of anle138b in rat plasma at different timepoints. The
maximum concentration is reached after 2-3 hours and then constantly declines
until it is gone after 12 hours.
Different extraction protocols of anle138b from mouse tissues were tested,
including methanol, ethanol, dichlormethane, trichlormethane and acetoni-
trile. Acetonitrile turned out to extract and dissolve anle138b the best, so
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it was used in further applications. As described in the methods section,
the extraction was supported by ultrasonication. Cell debris was removed
by centrifugation. After the methodology was validated, it was applied on
mouse brains to search for metabolites in the brain. As can be seen in Fig.
5.5, the HPLC chromatogram of a mouse brain homogenate clearly displays
anle138b (confirmed by mass spectrometry), but no additional metabolite.
This observation was confirmed by other mouse brains (with and without
MPTP) and rat brain samples. The reason for the background free detec-
tion of anle138b in the HPLC chromatogram is the following: i) the level
of anle138b in the brain is high and anle138b has a high solubility in ace-
tonitrile, ii) many other small organic molecules (e.g. amino acids, lipids,
dopamine) that are present in the brain have a lower concentration and/or a
lower solubility in acetonitrile and/or a low extinction coefficient at 260 nm.
Therefore several small peaks observed in the chromatogram could reflect the
presence of other UV-active endogenous compounds from the brain and iii)
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Calc. Mol. weight: 343.0082
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Figure 5.5: HPLC chromatogram of an MPTP mouse brain homogenate. The high
resolution mass spectrum (ESI+ mode) identifies the present compound clearly as
anle138b from the mass and the two equally populated isotopes 79Br and 81Br and
the two additional small peaks shifted by one mass unit originating from the 13C
isotope for 16 carbons in the molecule.
No metabolites were found in the brain. It has to be determined clearly
if they were absent or just not extractable with the applied methodology. So
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following the brain analysis, organs that are heavily involved in metabolism
like liver and kidney were also investigated. And indeed, in liver and kidney
(not in other organs) more metabolites were detected. This can be seen in
Fig. 5.6. These additional HPLC peaks were collected and investigated for
their masses. As anle138b contains a bromine atom, all metabolites also
display the same bromine double mass peak. It would be very unlikely that
a bromine atom gets removed during metabolism, but the other peaks were











































Figure 5.6: Representative HPLC chromatogram of a rat liver. The parent drug
anle138b (P) is highly concentrated. Minor concentrated are the four metabolites
(M). Also present is an unknown impurity (I) and a relict from the compound
synthesis (S).
5.3.2 Metabolite analysis
The metabolites identified during HPLC analysis were collected after sepa-
ration and intensively studied with high resolution mass spectrometry and
NMR spectroscopy and are described in the following section. The mass
spectra that follow induced fragmentation together with their interpretation
and NMR spectra can be found in the appendix. As seen in Fig. 5.7, the
structures of all four metabolites were elucidated.
M1 - Sulfurylated anle138c
In the first place the double peak at m/z 410/412 was identified. Induced
fragmentation resulted in the mass peaks m/z 331/333. This product was
clearly identified with further fragmentation as anle138c. So a functional







observed masses: 331.0082, 333.0061
calculated molecular weights: 331.0082, 333.0062 
M1
observed masses: 410.9646, 412.9619 
calculated molecular weights: 410.965, 412.963 
M3
observed masses: 359.0028, 361.0011
calculated molecular weights: 359.0031, 361.0011 
M4
observed masses: 345.0239, 347.0218 




























Figure 5.7: The observed masses were compared with probable metabolic structures
of anle138b. Due to the highly accurate observed masses, the chemical formulas of
the metabolites could be determined.
of a sulfate group. Sulfurylation is a typical phase II reaction, normally
done by the enzyme SULT1A3. Further investigations with NMR confirmed
the structure that yields two different molecules, depending which hydroxy
group is sulfurylated. As both hydroxy groups of anle138c are possible to
get sulfurylated, there are two metabolites: M1a and M1b.
M2 - Demethylenated anle138b (anle138c)
The double peak m/z 331/333 was identified, which corresponds to the com-
pound anle138c. Anle138c was synthesized as part of the DPP compound
library and can therefore easily be analyzed. It is identical with metabolite
M2. From the metabolism of the amphetamine drug MDMA (ecstasy) it is
known that a demethylenation of the methylenedioxy group to a catechol
group occurs [Tucker et al., 1994]. A similar reaction could be expected for
anle138b and the catechol derivative is then anle138c.
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M3 - Hydroxylated anle138b
The double peak m/z 359/361 was identified. This mass corresponds to
an addition of two methyl groups to anle138c. Yet, the observed mass
m/z 359,0028 does not correspond well with the calculated mass 359.02 of
this dimethylated molecule. Another interpretation is a demethylenation
of anle138b, followed by two rearrangements, as observed for the anle138b
fragmentation. This is supported by the two other mass fragments at m/z
301/303 and the anle138b fragment with the bromine atom released at m/z
280. The mass difference to anle138b for all fragments is 16, correspond-
ing well to an additional hydroxy group (in exchange to a hydrogen). Some
CYP450 enzymes are known to transfer hydroxy groups to drug molecules.
Yet, the position of the hydroxy group at M3 can not be determined by mass
spectrometry, as it does not go off during induced fragmentation.

















































Figure 5.8: Comparison of the 1D spectra of M3 and beneath of anle138b. M3
lacks the signal of H2, so this is the most probable hydroxylation site.
Analysis with NMR was done and similar signals to anle138b were ob-
served, but not proton H2, as seen in Fig. 5.8. hence, it is assumed that the
hydroxy group is placed to the aromatic ring at the position of H2. This is
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supported by empirical chemical shift predictions, that would expect an up-
field shift of the resonances, when a hydroxy group is added to the bromine
bearing aromatic ring.
M4 - Methylated anle138c
The double peakm/z 345/347 was identified. Induced fragmentation resulted
in the mass peak m/z 330/332 and further fragmentation into the mass m/z
313/315. The first change comprises a functional group of m/z 15, which
corresponds well to a methyl group. This methyl group was also observed
in an NMR spectrum and suggests that M4 is a methylated derivative of
anle138c, whereas one hydroxy group gets methylated (done by the enzyme
COMT), respectively. The second mass m/z 313/315 also confirms that M4
is a derivative of anle138c. As both hydroxy groups of anle138c are possible
to get methylated, there are two metabolites: M4a and M4b.
5.3.3 Pharmakokinetic studies
In the following the distribution properties of anle138b are investigated. So
far it is known that anle138b is efficiently absorbed and reaches the brain
after a short time. In the following study done with rats, the concentration of
anle138b within liver, kidney, spleen, thymus and fat tissue at the timepoints
4, 8 and 24 hours post application was investigated. It can be seen in Fig.
5.9 that anle138b reaches very similar concentration levels in brain, liver,
kidney, thymus and spleen; then the concentration declines constantly. Only
in liver, where the main metabolism takes place, the maximum is reached at
8 hours before it decreases. It is a striking observation how strong anle138b
accumulates in the fat tissue. The concentration in the fat is very high
and increases until it reaches a putative saturation that was not further
investigated here.
To test the behavior of the metabolite anle138c (M2) over time and to
compare its concentration in blood plasma with anle138b, time points during
24 hours were measured from mouse blood plasma. In comparison to the
other metabolites, the concentration of anle138c in the liver is not very high.
But if seen on a longer timescale of 24 hours, it becomes clear that the
concentration of anle138c is constantly increasing while it is metabolized
from anle138b. Anle138b is in turn decreasing in concentration. This can be
seen in Fig. 5.10.
























Figure 5.9: Concentration of anle138b in different rat tissue homogenates after 4,
8 and 24 hours. The compound leaves the organs after 4 hours, but accumulates
in the fat tissue.

























Figure 5.10: Concentration of anle138b and the metabolite anle138c in rat blood
plasma at different timepoints during 24 hours. Parallel to the decrease of anle138b,
the concentration of anle138c increases.
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5.4 Discussion & Conclusion
The metabolism of the toxic protein aggregate modulator anle138b was inten-
sively investigated. During this pharmacokinetic studies many informations
on the ADME properties were determined. Anle138b was found to be ab-
sorbed efficiently and is distributed to all organs. It passes the blood-brain-
barrier and is highly concentrated in the brain. Metabolism takes place in
the liver and kidney, where four metabolites were identified and their chem-
ical structures were elucidated. Anle138b gets demethylenated during or
hydroxylated during phase I metabolism by CYP450 enzymes. During phase
II metabolism the demethylenated metabolite, anle138c, gets sulfurylated or
methylated. Anle138b is metabolized and excreted from the body and no
anle138b is detected in blood and organs after 24 hours. An exception is the
fat tissue, were anle138b reaches high concentrations (Fig. 5.9) and a puta-
tive saturation level, which was not further investigated here. A summary of
the elucidated metabolism pathway in shown in Fig. 5.11.
There are several possibilities how the studies on anle138b pharmacokinet-
ics could continue. First it should be investigated with CYP450 assays,
which CYP450 is active in which transformation. Based on data for MDMA
metabolism it is assumed that CYP2D6 is doing the demethylenation [Tucker
et al., 1994, Kreth et al., 2000], but this should be further investigated.
Metabolite M3 should be synthesized to compare the NMR spectra and
HPLC chromatogram of the synthetic compound with the metabolite to make
sure in which position the bromine ring gets hydroxylated. If all metabolites
could be synthesized, it would be advantageous to test them in animal ex-
periments for their toxicity. In the end, anle138b has to be tested on humans
and one would have to see, if the human body produces the same metabolites
as rats and mice or different ones which could be toxic. An interesting topic
would be the combination of the metabolic investigations with the NMR-
based ligand binding mode determination. It could be possible to decipher
the binding mode of anle138b to its demethylenation enzyme, e.g. CYP2D6.
A docking model of anle138b to the crystal structure of CYP2D6 (PDB
code: 2F9Q) [Rowland et al., 2006] done with PLANTS is shown in Fig.
5.12. It proposes two distinct binding modes, that offer an explanation for
the demethylenation process, as well as for the hydroxylation site.
Such a model could be refined with NMR data like STD. It would be neces-
sary to investigate how the paramagnetic effects of the iron in the heme group
influences the result. It should be mentioned here, that the binding mode
of MPTP to its metabolizing enzyme (CYP2D6) was determined with NMR
spectroscopy by using T1 relaxation measurements as distance informations
of protons to the heme iron [Modi et al., 1997].
















































Figure 5.11: Metabolism and biotransformation pathway of anle138b, as revealed
by the presented study. In phase I, anle138b is hydroxylized and demethylenated
to anle138c by a CYP450 enzyme. Anle138c gets further sulfurylated by SULT1A3
and methylated by COMT.
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Figure 5.12: Best scoring docking models of anle138b into the crystal structure of
CYP2D6. This metabolic enzyme possesses a tunnel-like pathway to the reaction
center at the heme group. On the left side the methylene group of anle138b is
closest to the reaction center at the heme group. On the right side, the aromatic
ring of anle138b is closest to the reaction center with proton H2. This position is
thought to become hydroxylated.
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Chapter 6
Structure revision of arthrofactin
6.1 Introduction
Biosurfactants are surface active substances, derived from living organisms
[Cooper and Zajic, 1980]. Besides numerous industrial applications, biosur-
factants are also of high relevance for medical applications. In this respect,
particularly the multiple roles of biosurfactants on biofilm formation are of
high interest because of the emerging problem of biofilm formation in medical
devices and instruments. Knowledge about the underlying mode of action,
but also the exact molecular structure of the involved molecules are essential
for deeper insights and progress in this research field.
In 1993 arthrofactin was isolated from the bacterium Pseudomonas sp. MIS38
(at that time identified as Arthrobacter sp.) [Morikawa et al., 1993]. This
new cyclic lipopeptide (CLP) showed a capability to lower the surface ten-
sion of water from 72 to 24 mN
m
, making it the most effective biosurfactant
today, being 5-7 times more effective than surfactin. Arthrofactin belongs
to the family of lipoundecapeptides, together with amphisin, lokisin, tensin
and pholipeptin. The biosynthetic gene cluster of arthrofactin encodes the
three nonribosomal peptide synthetase (NRPS) subunits ArfA, ArfB and
ArfC, in which 11 modules and a terminal tandem thioesterase (TE) are ob-
served [Roongsawang et al., 2003]. In a last step, the terminal thioesterases
mediate the cyclization and release of the completed arthrofactin. Almost
typical for Pseudomonas-CLP-biosynthesis gene cluster, at the C-terminal
end of the NRPS a tandem of two distinct TE domains can be observed [Raai-
jmakers et al., 2006,Gross and Loper, 2009].
It is crucial to know the configuration and conformation of a potential drug
molecule. Unfortunately there are three different configurations and ring
closures of arthrofactin in the literature. All of them lack spectroscopic ev-
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idence and there was no crystallization of arthrofactin achieved. The first
structure was presented together with the identification of arthrofactin and
the ring closure was proposed to be between the 11-Asp and a CH atom of
the fatty acid part, as in surfactin [Morikawa et al., 1993]. The structure of
a very similar CLP, pholipeptin, was solved by NMR and the ring closure
was determined to be between the residues Asp-11 and Thr-3, as a Asp-11
β peptide linkage [Ui et al., 1997]. In 2002, the crystal structure of lok-
isin was solved [Sorensen et al., 2002] and confirmed a ring closure between
Asp-11 and Thr-3, but via a Asp-11 α peptide linkage to the allo-isomer
of threonine. A similar structure was then proposed for arthrofactin during
a study of the thioesterase of arthrofactin synthetase [Roongsawang et al.,
2007,Washio et al., 2010]. Nevertheless in the meantime a study on the non-
ribosomal peptide synthetase (NRPS) assembly line proposed a ring closure
between Asp-11 α and the H3 hydroxy group of the decanoic fatty acid side













































Figure 6.1: Constitution and configuration of arthrofactin proposed by [Balibar
et al., 2005]
A structural revision of arthofactin is done with three independent ap-
proaches: i) an intensive NMR investigation, comprising the complete assign-
ment and configurationa and ring closure determination, ii) a phylogenetic
tree of peptide synthetase domains of bacteria was done, with a special fo-
cus on the thioesterase domain. Placing the Pseudomonas strain then into
this tree should reveal the nature of the ring closure mechanism and iii) the
nature of the amino acids was clarified with HPLC and mass spectrometry.
















































Figure 6.2: Constitution and configuration of arthrofactin proposed by [Roong-
sawang et al., 2007]
6.2 Materials & Methods
6.2.1 Sample production and bioinformatics
Pseudomonas sp. MIS38 was cultivated in 7.5 L of Davis minimal broth. Af-
ter acidification to pH = 2, the broth was repetitively extracted with EtOAc.
The crude extract (1.1 g) was further fractionated via reversed-phase SPE
chromatography and followed by reversed-phase HPLC to afford 11.5 mg of
pure arthrofactin and minute amounts of its derivatives.
The amino acid sequences of TE proteins of all currently available cyclic
lipopeptides were retrieved from publicly accessible databases (http://www.
ncbi.nlm.nih.gov/entrez/). For phylogenetic analyses, alignments were made
with ClustalW2, available at http://www.ebi.ac.uk/Tools/msa/clustalw2/.
Trees were inferred by Neighbour Joining in ClustalW2.A phylogenetic tree
was constructed with all currently published amino acid sequences of 35 TE
domains identified in known bacterial and NRPS-derived CLP biosynthesis
clusters. Sample production and bioinformatics were done by Anna Lange
and Prof. Harald Gross.
6.2.2 NMR spectroscopy
10 mg of arthrofactin were dissolved in 0.5 mL of DMSO-d6. All NMR
spectra of arthrofactin were recorded at 25◦C in DMSO-d6 and referenced to
the residual solvent signals with resonances at δH/C 2.51/40.2. The internal
referencing of Bruker was used for 15N chemical shifts.
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Figure 6.3: 1D spectrum of arthrofactin in DMSO. Indicated are the main func-
tional groups from the peptide and the fatty acid (FA) part.
To allow for correct ordering chemical shifts are listed with ± 0.01 ppm
for 13C and 15N and ± 0.001 ppm for 1H, respectively. 1D 1H, 2D 1H-1H-
COSY, 1H-1H-NOESY, 1H-1H-TOCSY, 1H-13C-HSQC, 1H-15-HSQC and 1H-
13C-HMBC have been recorded using a Bruker 700 MHz spectrometer, and
1H-15N-HMBC with a Bruker 600 MHz spectrometer. Both spectrometers
are equipped with a cryogenically cooled triple-resonances probe head. The
1H spectrum was acquired using 16K data points at a spectral width of 7 kHz,
with 1 scan and a 2.0 s delay between transients. The data matrix was zero-
filled to 32K points and processed with an exponential window function. All
homonuclear 2D spectra were measured over 4K complex points in F2, 1024
increments in F1 for TOCSY, 800 for COSY and 600 for NOESY, collecting 8
(TOCSY) or 160 (COSY and NOESY) scans per increment with a relaxation
delay of 2.0 s. The spectral widths in the F2 and F1 dimensions were both 6.3
kHz for all homonuclear spectra. The mixing time of TOCSY and NOESY
experiments was set to 80 ms and 150 ms, respectively. The spectra width
of the heteronuclear spectra in the F2 and F1 dimensions were 4.2 kHz and
3.6 kHz for 1H-13C-HSQC, 1.4 kHz and 1.6 kHz for 1H-15N-HSQC, 6.3 kHz
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and 35.2 kHz for 1H-13C-HMBC, 6.3 kHz and 1.6 kHz for 1H-15N-HMBC
respectively. 4K x 1K data points were acquired with 16 scans per increment
for the 1H-13C-HSQC experiment, 4K x 320 data points with 64 scans for
the 1H-15N-HSQC experiment, 8K x 1K data points with 48 scans for the
1H-13C-HMBC experiment and 4K x 114 data points with 1000 scans for
the 1H-15N-HMBC experiment. In the 1H-13C-HMBC and 1H-15N-HMBC
sequence, the delay for the evolution of long-range couplings was set to 8.0
Hz and 6.0 Hz, respectively.
6.3 Results
6.3.1 Bioinformatic studies
The first TE domain encoded by the arthrofactin biosynthesis gene cluster
clearly groups with subclass II (Fig. 6.4) as determined by the phylogenetic
analysis. Therefore the structure of arthrofactin should be cyclized between
Asp-11 and Thr-3, instead of lactone ring formation between Asp-11 and
the H3 hydroxy group of the decanoic fatty acid side chain as originally
suggested. This is the clear proposal from bioinformatics that will be tested
in the following against experimental data.
Figure 6.4: Phylogenetic tree of the tandem thioesterase domain gene cluster of 35
amino acid sequences from literature. AF-TE2 that encodes for arthrofactin plots
in the group TE2 with a macrocyclisation via amino acids, unlike TE1, where the
macrocyclisation takes place via the fatty acid. Therefore a macrocyclisation via
amino acids is proposed by bioinformatics. This tree was simplified for clarity.
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6.3.2 NMR assignment
The assignment was started from the Hβ protons of serine, because they
have very characteristic chemical shifts and appear in pairs in the 1H-13C-
HSQC spectrum. In arthrofactin two serine residues are present, which are
separated by one leucine. With the help of 1H-1H-COSY and 1H-1H-TOCSY
experiments, the Hα and NH protons of each serine can be assigned with the
knowledge of the chemical shifts of the Hβ protons. However, which serine
belongs to which serine in the structure formula still remained unknown.
We started at the Hα proton with the chemical shift of 4.536 ppm. In the
1H-1H-NOESY spectrum it shows two cross-peaks with the protons in the
amide region. One cross-peak belongs to the intra-residue connection of the
NH and Hα protons. Since the NH of serine was assigned, the other proton
could be immediately assigned as the NH proton of the neighbored residue.
Subsequently, we assigned the corresponding Hα from the COSY spectrum
and this Hα proton shows a very strong peak with the NH proton of the
second serine residue in the NOESY spectrum. With this procedure we
identified the serine that we have started with: it is Ser-6 and the second one
is Ser-8. The assignment of the backbone protons of the remaining residues
was performed in the same way using a combination of TOCSY, NOESY
and COSY spectra. The chemical shifts of the carbonyl- and nitrogen-atoms
were assigned with HMBC experiments, and the chemical shifts of carbons






















































Figure 6.5: Key correlations used for the NMR assignment of arthrofactin.
The closure of the cyclic peptide between Thr-3 and Asp-11 was proven
by the following two evidences: (i) the Asp-11 Hα proton shows a HMBC
cross-peak with the carbonyl carbon of Asp-11 as well as the Thr-3 Hβ proton
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(Fig. 6.6), ii) the Asp-11 Hα and Thr-3 Hβ show NOESY crosspeaks (Fig.
6.7) and (iii) the Thr-3 Hγ shows a NOESY peak with the Asp-11 Hα (Fig.
6.9). Therefore, the closure of the ring must be situated here, between the
Asp-11 carbonyl group and the Thr-3 hydroxyl group. The sequence was
further verified using 1H-15N HMBC derived connectivities. The closure of
the lactone ring in the old formula was disproven by the absence of decisive
cross peaks: H-3 of the fatty acid to Asp-11 CO (1H-13C HMBC) and H-3 to
Asp-11 Hα (NOESY). The presence of a NOESY crosspeak of Asp-11 Hα to
Thr-3 Hβ and the absence of a crosspeak of the Hβ methylene group protons
of Asp-11 with Thr-3 Hβ indicated that no isoaspartyl linkage is present.










Asp-11 CO - Asp-11 Hα
Ile-10 CO - Asp-11 Hα
Thr-3 CO - Thr-3 Hβ
Asp-11 CO - Thr-3 Hβ
Asp-11 COOH - Asp-11 Hα
Figure 6.6: 1H-13C-HMBC spectrum of arthrofactin in DMSO. It can be seen that
the Asp-11 CO carbon atom is coupled with the Asp-11 Hα, as well as Thr-3 Hβ,
indicating a ring closure between Asp-11 and Thr-3.
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Asp-11 Hα
Thr-3 Hβ
Asp-11 Hα  -  Thr-3 Hβ









Figure 6.7: NOESY spectrum of arthrofactin in DMSO. The NOESY peaks be-
tween Thr-3 Hβ and Asp-11 Hα indicate a ring closure between Asp-11 and Thr-3.
[ppm] 5.0 4.9
Asp-11 Hα  -  Thr-3 Hβ
Thr-3 Hβ  -  Asp-11 HαAsp-11 Hα
Thr-3 Hβ
Figure 6.8: Slices from the NOESY spectrum shown above to illustrate that the




Thr-3 Hγ - Asp-11 Hα






Figure 6.9: NOESY spectrum of arthrofactin in DMSO. The NOESY peak between
Thr-3 Hγ and Asp-11 Hα indicates a ring closure between Asp-11 and Thr-3.
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6.4 Discussion & Conclusion
In summary, using a bioinformatics approach in combination with spectral
experiments, the revised structure of arthrofactin has been determined, as
depicted in figure 6.2. Arthrofactin has been shown to possess a cyclization
scheme between an D-allo-Thr and an Asp, as determined by the NMR ex-
periments HMBC and NOESY. The presence of D-allo-Thr was confirmed by
chiral HPLC and mass spectrometry. All TE domains of available CLP gene
cluster were systematized and propose a phylogenetic model which allows
the prediction of the regioselectivity regarding the macrocyclization process
during CLP biosynthesis. The data presented here show also the progress of
genetic sequence-based prediction of NRPS-derived natural products, which
reached already a significant level of accuracy and reliability. This bioin-
formatic prediction is verified by intensive NMR studies, including the full
assignment of arthrofactin and comprising clear evidence for the regioselec-
tivity of the ring closure. To further optimize the methodology other natural
product structures should be predicted by bioinformatics in the future. These
have to be validated with NMR spectroscopy and mass spectrometry. Still,
it is imaginable that the methodology can be optimized to a degree, where
experimental support can be reduced to a minimum. This is comparable
to the de novo determination of protein structures, just based on sequence
alignment. The data and interpretation described in this chapter is pub-
lished [Lange et al., 2012].
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A.1 Rescoring of docking poses with GOLD
Name RMSD to X-ray ChemPLP ChemScore ASP GOLDScore
Ligand 1
1 0.41 -84.5 33.8 28.27 45.78
2 5.1 -73.1 26.89 26 32.09
3 5.53 -63.3 25.8 26.87 34.22
4 2.62 -62.9 25.26 22.97 24.5
5 5.5 -59.8 25.56 21.21 32.66
6 6.33 -58.6 20.48 20.03 29.99
7 7.83 -57.6 18.15 15.36 26.02
8 3.94 -54.6 18.97 20.49 25.24
9 7.34 -53.7 17.69 15.73 24.37
10 5.24 -52.7 19.62 14.65 24.44
11 2.56 -52.6 21 19.56 28.58
12 7.38 -54.5 19.63 20.66 21.07
13 5.59 -54.3 23.8 19.31 30.93
14 7.25 -54 20.26 16.15 17.66
15 6.18 -53.5 19.78 19.69 29.4
16 6.99 -52.4 17.01 15.37 21.84
171
172 APPENDIX A. PROTEIN KINASE A
Name RMSD to X-ray ChemPLP ChemScore ASP GOLDScore
Ligand 2
1 5.2 -70.9 27.91 26.24 36.22
2 5.26 -69.4 25.02 24.19 35.66
3 1.41 -66.3 24.53 26.06 39.99
4 7.68 -61.5 17.33 13.16 30.25
5 3.14 -58.3 16.96 16.57 32.47
6 5.8 -58 17.12 17.47 31.92
7 6.78 -55.8 15.42 14.04 24.9
Name RMSD to X-ray ChemPLP ChemScore ASP GOLDScore
Ligand 3
1 3.36 -60.5 25.53 20.42 31.26
2 3.78 -57.9 22.29 20.61 29.33
3 4.4 -57.5 23.8 17.02 29.45
4 2.86 -55.4 24.25 21.5 35.89
5 2.85 -51.6 22.28 16.08 30.81
6 4.59 -51.5 21.45 15.52 28.51
7 5.54 -49.3 18.55 15.61 25.17
8 6.57 -47.7 16.76 11.53 21.5
9 3.74 -47.7 18.16 16.33 25.66
10 0.96 -47 18.97 14.35 27.32
11 2.47 -44.7 18.21 16.11 23.25
12 7.26 -44.5 13.63 13.1 20.69
13 5.44 -44.5 15.82 13.1 18.01
14 5.74 -44.1 16.21 12.41 12.73
15 4.55 -43.4 16.99 14.55 19.32
16 7.83 -43.1 14.61 11.05 18.7
17 4.55 -43 18.01 14.36 -13.62
18 7.5 -43 14.36 12.56 20.65
19 3.42 -42.8 16.78 15.12 28.7
A.2. NOESY SPECTRA OF LIGAND COMBINATIONS 173
Name RMSD to X-ray ChemPLP ChemScore ASP GOLDScore
Ligand 4
1 4 -66.7 10.36 23.8 29.1
2 3.85 -66 11.97 23.66 36.58
3 0.15 -64.3 16.7 27.5 40.39
4 6.1 -63.8 17.09 25.5 34.44
5 7.6 -62.6 12.18 19.4 33.01
6 5.99 -62.5 17.25 24.3 29.35
7 7.22 -61.4 17.43 22.66 35.46
8 7.43 -60.6 11.61 20.45 33.37
9 7.4 -59.7 16.58 22.82 32.46
10 6.29 -59.1 17.76 25.94 37.76
11 2.92 -58.8 14.4 25.6 37
12 5.92 -58.7 18.32 22.29 33.03
13 6.94 -58.7 15.1 23.05 35.51
14 5.96 -58.3 12.66 21.58 33.41
15 2.26 -57.8 11.11 23.94 28.63
16 7.14 -57.4 16.67 24.11 29.15
17 3.02 -56.4 11.19 22.12 38.04
18 6.44 -55.9 15.94 26.62 35.21
19 7.46 -55.5 10.89 20.05 29.37
20 6.01 -54.7 12.51 21.35 28.46
21 7.93 -54.5 13.71 18.14 26.73
22 7.18 -54.5 18.55 20.38 31.15
23 2.81 -54.8 10.95 21.98 20.48
24 4.57 -58.5 10.68 21.59 34.51
25 7.26 -56.1 16.32 19.17 28.91
26 2.07 -56.1 11 24.43 30.65
27 7.34 -56 12.65 20.05 28.97
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Figure A.1: NOESY spectrum of ligand 1 (0.3 mM) and ligand 3 (0.9 mM) in the
presence of PKA (0.045 mM). INPHARMA peaks chosen are marked in green. The
mixing time was 800 ms on a 900 MHz spectrometer, equipped with a cryogenically
cooled probe head. The spectrum was recorded at 293 K with 64 scans, 2048 points
in F2 and 580 points in F1.























































Figure A.2: NOESY spectrum of ligand 2 (0.9 mM) and ligand 3 (1.2 mM) in the
presence of PKA (0.045 mM). INPHARMA peaks chosen are marked in green. The
mixing time was 800 ms on a 700 MHz spectrometer, equipped with a cryogenically
cooled probe head. The spectrum was recorded at 293 K with 64 scans, 2048 points
in F2 and 580 points in F1.
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Figure A.3: NOESY spectrum of ligand B3 (1 mM) and ligand 2 (0.3 mM) in the
presence of PKA (0.045 mM). INPHARMA peaks chosen are marked in green. The
mixing time was 800 ms on a 700 MHz spectrometer, equipped with a cryogenically
cooled probe head. The spectrum was recorded at 293 K with 64 scans, 2048 points
in F2 and 388 points in F1.
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Figure A.4: NOESY spectrum of ligand B5 (0.5 mM) and ligand 3 (1 mM) in the
presence of PKA (0.045 mM). INPHARMA peaks chosen are marked in green. The
mixing time was 800 ms on a 800 MHz spectrometer, equipped with a cryogenically
cooled probe head. The spectrum was recorded at 293 K with 64 scans, 4096 points
in F2 and 512 points in F1.
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Figure B.1: Experimental STD data of the GPR40 binding ligands 5 and 6. The
normal 1D spectrum in the presence of GPR40 membranes is shown in black,
the STD spectrum in blue. For back-calculation only ligand 5 was considered, as
ligand 6 had too many overlapping signals in the aromatic region. The sample
contains 0.2 mM ligand 5, 0.1 mM ligand 6, 25% (v/v) GPR40 membranes, 10 mM
perdeuterated Tris and 1 mM perdeuterated EDTA. Saturation was done for 8 s
on -2 ppm on a 400 MHz spectrometer (number of scans = 16; temperature = 310
K; time domain = 32768 points).
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Figure B.2: NOESY spectrum of ligand 5 (0.2 mM) and ligand 6 (0.1 mM) in the
presence of 25% (v/v) GPR40 membranes in D2O (10 mM Tris, 1 mM EDTA).
INPHARMA peaks chosen are marked in green. The mixing time was 300 ms on
a 700 MHz spectrometer, equipped with a cryogenically cooled probe head. The
spectrum was recorded at 310 K with 128 scans and 8192 points in F2 and 256
points in F1.
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Appendix C
Anle138b




ESI-MS m/z (acetonitrile, positive mode): C16H11BrN2O2 [M + H+]: cal-
culated molecular weights: 343.0082, 345.0062; observed masses: 343.0085,
345.0063.
1H NMR (DMSO, 400 MHz): δ = 8.00 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H),
7.5 (d, J = 8.0 Hz, 1H), 7.4 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 1.5 Hz, 1H),
7.32 (d, J = 8.0 Hz, 1H), 7.19 (s, 1H), 7.0 (d, J = 8.0 Hz, 1H), 6.06 (s, 2H).
M1 - sulfurylated anle138c
5-(5-(3-bromophenyl)-1H-pyrazol-3-yl)-2-hydroxyphenyl hydrogen sulfate
4-(5-(3-bromophenyl)-1H-pyrazol-3-yl)-2-hydroxyphenyl hydrogen sulfate
ESI-MS m/z (acetonitrile, positive mode): C15H11BrN2O5S[M + H+]: cal-
culated molecular weights: 410.965, 412.963; observed masses: 410.9646,
412.9619.
1H NMR (DMSO, 600 MHz): δ = 8.04 (s, 1H), 7.87 (d, J = 7.8 Hz), 7.59
(d, J = 1.9 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.42 (dd, J = 8.2 Hz, 1.9 Hz,
1H), 7.38 (t, J = 7.8, 1H), 7.12 (s, 1H), 6.93 (d, J = 8.2, 1H).
1H NMR (DMSO, 600 MHz): δ = 8.04 (s, 1H), 7.82 (d, J = 7.8 Hz), 7.59
(d,J = 1.9 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.46 (dd, J = 8.2 Hz, 1.9 Hz,
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ESI-MS m/z (acetonitrile, positive mode): C15H11BrN2O2[M + H+]: cal-
culated molecular weights: 331.0082, 345.0062; observed masses: 331.0082,
333.0061.
1H NMR (DMSO, 400 MHz): δ = 8.02 (s, 1H), 7.83 (d, J = 8.1 Hz, 1H),
7.5 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 1.9 Hz, 1H),
7.08 (dd, J = 8.2 Hz, 1.9 Hz, 1H), 7.02 (s, 1H), 6.8 (d, J = 8.2 Hz, 1H).
M3 - Hydroxylated anle138b
4-(3-(benzo[d][1,3]dioxol-6-yl)-1H-pyrazol-5-yl)-2-bromophenol
3-(3-(benzo[d][1,3]dioxol-6-yl)-1H-pyrazol-5-yl)-5-bromophenol
ESI-MS m/z (acetonitrile, positive mode): C16H11BrN2O3 [M + H+] : cal-
culated molecular weights: 359.0031, 361.0011; observed masses: 359.0028,
361.0011.
1H NMR (DMSO, 900 MHz): δ = 7.92 (s, 1H), 7.65 (d, J = 8.1 Hz, 1H),
7.4 (d, J = 7.9 Hz, 1H), 7.36 (m, 2H), 7.34 (d, J = 8.0 Hz, 1H), 7.21 (s, 1H),
7.04 (d, J = 8.0 Hz, 1H), 6.07 (s, 2H).
1H NMR (DMSO, 900 MHz): δ = 7.92 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H),
7.4 (d, J = 7.9 Hz, 1H), 7.36 (m, 2H), 7.34 (d, J = 8.0 Hz, 1H), 7.18 (s, 1H),
6.96 (d, J = 8.0 Hz, 1H), 6.07 (s, 2H).
M4 - Methylated anle138c
5-(5-(3-bromophenyl)-1H-pyrazol-3-yl)-2-methoxyphenol
4-(5-(3-bromophenyl)-1H-pyrazol-3-yl)-2-methoxyphenol
ESI-MS m/z (acetonitrile, positive mode): C16H11BrN2O3 [M + H+] : cal-
culated molecular weights: 345.0239, 347.0218; observed masses: 345.0239,
347.0218.
1H NMR (DMSO, 600 MHz): δ = 8.03 (s, 1H), 7.86 (d, J = 8.1 Hz, 1H),
7.55 (d, J = 7.8 Hz, 1H), 7.39 (m, 1H), 7.23 (s, 1H), 7.22 (m, 1H), 7.03 (s,
1H), 6.86 (d, J = 8.2 Hz, 1H), 3.86 (s, 3H).
1H NMR (DMSO, 600 MHz): δ = 8.03 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H),
7.5 (d, J = 7.8 Hz, 1H), 7.39 (m, 1H), 7.23 (s, 1H), 7.14 (m, 1H), 6.97 (s,
1H), 6.82 (d, J = 8.2 Hz, 1H), 3.86 (s, 3H).
C.2 NMR spectra of anle138b and its metabo-
lites













Figure C.1: 1D spectrum of anle138b in DMSO-d6. Anle138b is present as a
tautomer, as the proton switches between the two nitrogen atoms.












Figure C.2: 1D spectrum of metabolite M1 in DMSO-d6.





























Figure C.3: DQF-COSY spectrum of metabolite M1 in DMSO-d6.












Figure C.4: 1D spectrum of metabolite M4 in DMSO-d6, recorded on a 600 MHz
spectrometer.























Figure C.5: DQF-COSY spectrum of metabolite M4 in DMSO-d6, recorded on a
600 MHz spectrometer.
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Figure C.6: Interpretation of the fragmentation pattern of M1, based on the mass
spectrometric fragmentation data. The sulfate group is released and M1 is degraded
































Figure C.7: Interpretation of the fragmentation pattern of M2, based on the mass
spectrometric fragmentation data. Either the aromatic ring is broken, leading to
the fragment m/z 303/305, or the bromine is released, resulting in the product
m/z 252.









































Figure C.8: Interpretation of the fragmentation pattern of M3, based on the mass
spectrometric fragmentation data. M3 behaves similar to anle138b with a rear-
rangement of the aromatic ring to m/z 313/315 or m/z 301/303. Release of the














































Figure C.9: Interpretation of the fragmentation pattern of M4, based on the mass
spectrometric fragmentation data. Demethylation results in the M2 (anle138c)-like
product m/z 330/332. Rearrangement of the aromatic ring leads to the product
m/z 313/315. Finally release of the bromine results in product m/z 266.
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Appendix D
Arthrofactin
D.1 Assignment of arthrofactin
ESI-MS m/z (acetonitrile, positive mode): C64H111N11O20Na [M + Na+]:
calculated molecular weights: 1376.79; observed masses: 1376.7907.
1H NMR (DMSO, 700 MHz): δ = 8.28; 8.16; 8.11; 8.078; 8.05; 8.04; 8.03;
7.99; 7.9; 7.82; 7.75; 5.004; 4.86; 4.52; 4.48; 4.47; 4.397; 4.342; 4.29; 4.236;
4.23; 4.186; 4.171; 3.79; 3.61; 3.6; 3.52; 3.46; 2.87; 2.64; 2.49; 2.42; 2.23; 1.88;
1.86; 1.6; 1.579; 1.56; 1.549; 1.52; 1.465; 1.439; 1.43; 1.37; 1.34; 1.24; 1.13;
1.08; 1.06; 0.86; 0.79;
13C NMR (DMSO, 700 MHz): δ = 172.8; 172.3; 172.3; 172.11; 171.9; 171.7;
171.4; 171.1; 170.6; 170.3; 170.28; 170; 168.8; 71; 68; 62.7; 61.15; 57.6; 56.59;
56.5; 55.66; 54.5; 51.91; 51.52; 51.07; 49.95; 48.38; 43.9 41; 40.82; 40.8; 40.16;
37; 36.9; 36.72; 35.71; 35.6; 25.2; 24.7; 24.51; 24.48; 24.4; 24.3; 23.52; 23.4;
23.03; 22.66; 21.9; 21.8; 16.81; 14.44; 14.37; 11.85; 11.7; 10.6;
15N NMR (DMSO, 700 MHz): δ = 124.17; 123. 87; 121.02; 120.35; 119.62;
116.83; 116.53; 116.41; 115.49; 112.83;
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Leu1-CH3 0.878 + 0.836 23.4 + 21.8
Leu1-O - 172.8
Asp2-NH 8.28 - 116.83
Asp2-a 4.48 49.95
Asp2-b 2.64 + 2.49 35.71
Asp2-COOH - 171.9
Asp2-O - 170.6









Leu4-CH3 0.867 + 0.815 23.52 + 21.9
Leu4-O - 172.3




Leu5-CH3 0.868 + 0.783 23.03 + 22.66
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Leu5-O - 171.7
Ser6-NH 8.078 - 115.49
Ser6-a 4.52 54.5
Ser6-b 3.6 + 3.46 62.7
Ser6-O - 170.6
Leu7-NH 8.05 - 120.35
Leu7-a 4.171 51.91
Leu7-b 1.56 40.16
Leu7-CH3 0.866 + 0.8 14.44
Leu7-O - 172.11
Ser8-NH 8.16 - 116.41
Ser8-a 4.236 56.59
Ser8-b 3.61 + 3.52 61.15
Ser8-O - 170.3














Asp11-NH 7.99 - 121.02
Asp11-a 5.004 48.38
Asp11-b 2.87 + 2.42 37
Asp11-COOH - 172.3
Asp11-O - 170
D.2 NMR spectra of arthrofactin
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Figure D.1: NOESY spectrum of arthrofactin in DMSO. The mixing time was 150
ms on a 700 MHz spectrometer, equipped with a cryogenically cooled probe head.
The spectrum was recorded at 298 K with 16 scans.
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Figure D.2: TOCSY spectrum of arthrofactin in DMSO. The spectrum was
recorded at 298 K with 8 scans, on a 700 MHz spectrometer, equipped with a
cryogenically cooled probe head. Spin lock (DIPSI) was applied for 80 ms.












Figure D.3: Detail of the 1D spectrum of arthrofactin in DMSO. With 1H-15N-
HMBC an assignment of all NH signals was possible.












Figure D.4: 1H-15N-HMBC spectrum of arthrofactin in DMSO. The spectrum was
recorded at 298 K with 1000 scans, on a 600 MHz spectrometer, equipped with a
cryogenically cooled probe head.
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